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SOMMAIRE 
 
 
 
 
 
 
Le virus de l’immunodéficience humaine de type 1 (VIH-1), l’agent étiologique 
du SIDA, est un rétrovirus complexe arborant plusieurs protéines accessoires : Nef, Vif, 
Vpr, et Vpu.  Celles-ci sont impliquées dans la modulation de la réplication virale, dans 
l’évasion immunitaire et dans la progression de la pathogenèse du SIDA.  Dans ce 
contexte, il a été démontré que la protéine virale R (Vpr) induit un arrêt de cycle 
cellulaire en phase G2.  Le mécanisme par lequel Vpr exerce cette fonction est 
l’activation, ATR (Ataxia telangiectasia and Rad3 related)-dépendante, du point de 
contrôle de dommage à l’ADN, mais les facteurs et mécanismes moléculaires 
directement impliqués dans cette activité demeurent inconnus.   
 
Afin d’identifier de nouveaux facteurs cellulaires interagissant avec Vpr, nous 
avons utilisé une purification d’affinité en tandem (TAP) pour isoler des complexes 
protéiques natifs contenant Vpr.  Nous avons découvert que Vpr s’associait avec 
CRL4A(VprBP), un complexe cellulaire d’E3 ubiquitine ligase, comprenant les 
protéines Cullin 4A, DDB1 (DNA damage-binding protein 1) et VprBP (Vpr-binding 
protein).  Nos études ont mis en évidence que le recrutement de la E3 ligase par Vpr 
était nécessaire mais non suffisant pour l’induction de l’arrêt de cycle cellulaire en G2, 
suggérant ainsi que des événements additionnels seraient impliqués dans ce processus.  
À cet égard, nous apportons des preuves directes que Vpr détourne les fonctions de 
CRL4A(VprBP) pour induire la polyubiquitination de type K48 et la dégradation 
protéosomale de protéines cellulaires encore inconnues.  Ces événements 
d’ubiquitination induits par Vpr ont été démontrés comme étant nécessaire à l’activation 
d’ATR.  Finalement, nous montrons que Vpr forme des foyers ancrés à la chromatine 
co-localisant avec VprBP ainsi qu’avec des facteurs impliqués dans la réparation de 
l’ADN.  La formation de ces foyers représente un événement essentiel et précoce dans 
l’induction de l’arrêt de cycle cellulaire en G2.  Enfin, nous démontrons que Vpr est 
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capable de recruter CRL4A(VprBP) au niveau de la chromatine et nous apportons des 
preuves indiquant que le substrat inconnu ciblé par Vpr est une protéine associée à la 
chromatine.   
 
Globalement, nos résultats révèlent certains des ménanismes par lesquels Vpr 
induit des perturbations du cycle cellulaire.  En outre, cette étude contribue à notre 
compréhension de la modulation du système ubiquitine-protéasome par le VIH-1 et son 
implication fonctionnelle dans la manipulation de l’environnement cellulaire de l’hôte. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mots clés: Virus, protéines accessoires, ATR, Point de contrôle de domage à l’ADN, 
cycle cellulaire, ubiquitination, ubiquitine ligase. 
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ABSTRACT 
 
 
 
 
 
 
Human immunodeficiency virus 1 (HIV-1), the etiologic agent of AIDS, is a 
complex retrovirus with several accessory proteins.  HIV-1 accessory proteins Nef, Vif, 
Vpr, and Vpu have been implicated in the modulation of viral replication, enhancement 
of viral fitness, immune evasion, and progression of AIDS pathogenesis.  In that regard, 
viral protein R (Vpr) induces a cell cycle arrest in the G2 phase by activating the 
canonical ATR (Ataxia telangiectasia and Rad3 related)-mediated DNA damage 
checkpoint, but cellular factors and mechanisms directly engaged in this process remain 
unknown. 
 
To identify novel Vpr-interacting cellular factors, we used tandem affinity 
purification (TAP) to isolate native Vpr-containing complexes. We found that Vpr 
hijacks a cellular E3 ubiquitin ligase complex, CRL4A(VprBP), composed of Cullin 4A, 
DDB1 (DNA damage-binding protein 1) and VprBP (Vpr-binding protein).  Moreover, 
we observed that recruitment of the E3 ligase by Vpr was necessary but not sufficient 
for the induction of G2 cell cycle arrest, suggesting that additional events are involved.  
In this context, we provide direct evidence that Vpr usurps the function of 
CRL4A(VprBP) to induce the K48-linked polyubiquitination and proteasomal 
degradation of as-yet-unknown cellular proteins.  These ubiquitination events mediated 
by Vpr were necessary for the activation of ATR.  Moreover, we show that Vpr forms 
chromatin-associated foci that co-localize with VprBP and DNA repair factors.  Our 
data indicate that formation of these foci represent a critical early event in the induction 
of G2 arrest.  Finally, we show that Vpr is able to recruit CRL4A(VprBP) on chromatin 
and we provide evidence that the unknown substrate targeted by Vpr is a chromatin-
associated protein. 
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Overall, our results reveal some of the mechanisms by which Vpr induces cell 
cycle perturbations.  Furthermore, this study contributes to our understanding of the 
modulation of the ubiquitin-proteasome system by HIV-1 and its functional implication 
in the manipulation of the host cellular environment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Virus, accessory proteins, ATR, DNA damage checkpoint, cell cycle, 
ubiquitination, ubiquitin ligase. 
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INTRODUCTION 
 
1. HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) 
 
 Human immunodeficiency virus type 1 (HIV-1) is the causative agent of the 
global epidemics of AIDS.  In 2008, 33.4 million individuals were HIV-1-positive.  An 
estimated 2.7 millions new HIV-1 infections occurred and 2 million people died of 
AIDS- related diseases.  Due to the beneficial effects of the introduction of anti-
retroviral therapy in low-income countries, the estimated number of new HIV-1 
infection cases was 30% lower than at the peak of the epidemics in 1996 and the number 
of AIDS-related death was 10% lower than at the peak of mortality in 2004 [1].   
 
 HIV-1 is a highly heterogeneous virus and, based on genetic similarities, is 
subdivided into 4 groups: M, O, N, and P.  Group M is responsible for the present 
epidemic and, due to founder effects, can be further subdivided into clades or subtypes 
(A to K).  Clade B viruses are the most prevalent in Western countries whereas C is the 
most prominent globally.  Because the epidemic originated in Africa, it has the most 
heterogeneous viral distribution and inter-clade or inter-group recombinants are 
commonly observed.  Groups N, O, and P only represent a minority of cases and are 
typically restricted to some regions of Africa [2-4].  HIV is a zoonosis and each group is 
thought to have originated from a single independent cross-species transmission from a 
primate, the natural reservoir, to a human.  Group M and N likely originated from 
chimpanzees (Pan troglodytes troglodytes) in South Cameroon, group O from either 
chimpanzees or gorillas (Gorilla gorilla gorilla) [5-8], and Group P from gorillas [2].  
There exists a second human immunodeficiency virus called HIV-2.  HIV-2 is 
characterized by a lower pathogenicity and is principally restricted to Western Africa.  It 
probably arose from at least 8 independent cross-species transmissions from sooty 
mangabeys (Cercocebus atys) to humans [5,9].  Recent molecular clocking analyses 
situate the origins of the HIV-1 epidemic to the early 20th century in Belgian Congo 
(now Democratic Republic of Congo).  Trans-species transmissions between 
chimpanzees and humans might have occurred before this period but social conditions 
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and population densities resulting from the establishment of colonial cities such as 
Leopoldville (now Kinshasa) probably generated the optimal conditions for the global 
spread of the sexually transmitted disease [10,11].       
1.1. HIV-1 and the retrovirus family 
HIV-1 belongs to the retrovirus family (Retroviridae), which comprises 
enveloped viruses with linear, non-segmented, positive, single-stranded RNA genomes.  
The hallmarks of this family of viruses are that they require reverse transcription of the 
viral genome into linear double-stranded DNA and subsequently stable integration of 
their genome into the host DNA.  Retroviruses are ubiquitous and are present in all 
classes of vertebrates.  All retroviruses possess three major genes: gag  (group-specific 
antigen), pol (polymerase), and env (envelope).  Particles vary in size from 80 to 120 nm 
in diameter and are covered by envelope glycoprotein spikes [12,13].  The genus 
lentivirus, of which HIV-1 is the prototypic example, comprises complex retroviruses 
that encode additional unique auxiliary proteins.  Other defining characteristics of the 
lentiviral genus include a curved hexagonal viral core called a fullerene cone and a 
biphasic mode of gene expression [14,15].  All lentiviruses can infect macrophages and 
primate lentiviruses exhibit a strong tropism for CD4-expressing cells, including 
macrophages and T helper lymphocytes.  In contrast to several other retroviruses, 
lentiviruses do not directly induce oncogenesis.  Common manifestations of lentiviral 
diseases include long incubation time, persistent chronic viral replication, 
encephalopathy, and suppression of specific haematopoietic or immune cell types [16].          
1.2. Genetic organization 
As mentioned above, HIV-1 like all retroviruses harbours the gag, pol, and env 
genes (Figure 1, p.3).  The HIV-1 gag gene encodes the viral structural proteins matrix 
(MA, p12), capsid (CA, p24), and nucleocapsid (NC, p7) expressed as part of a 
myristilated precursor polyprotein (p55).  Individual components are released following 
the proteolytic processing of the polyprotein by the viral protease.  The gag precursor 
protein also possesses p1, p2, and p6 domains which are not thought to play functions as 
individual proteins but rather contribute to the regulation or functions of the precursor 
polyprotein.  The pol gene produces a precursor polyprotein fused to the Gag 
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Figure 1. HIV-1 genomic organization. 
The HIV-1 genome is flanked by two long-terminal repeats (LTR) and takes advantage 
of its three reading frames.  HIV-1 possesses the conserved retroviral genes gag, pol, 
and env.  The HIV-1 genome also contains six additional genes that encode two 
regulatory proteins (Tat and Rev) and four accessory proteins (Nef, Vif, Vpr, and Vpu). 
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polyprotein via a ribosomal frameshift.  Proteolytic processing of Gag-pol yields the 
viral enzymatic proteins protease (Pr), reverse transcriptase (RT), and integrase (IN).  
The env gene encodes the two envelope subunits, gp120 and gp41, which are first 
expressed as a single precursor protein (gp160) and later cleaved by a cellular furin-like 
protease.  The HIV-1 genome also contains six additional genes that encode the two 
regulatory proteins Tat (transcriptional transactivator) and Rev (regulator of virion gene 
expression) and the four accessory proteins: Nef (negative factor), Vif (viral infectivity 
factor), Vpr (viral protein R), and Vpu (viral protein U).  HIV-2 (human 
immunodeficiency virus type 2) and some simian immunodeficiency virus (SIV) isolates 
of the HIV-2/SIVsm (sooty mangabey) lineage possess a fifth accessory gene called Vpx 
(viral protein X), but do not encode for a Vpu protein.  Tat and Rev are involved in HIV 
gene expression and proper splicing and export of the different mRNA species whereas 
the accessory proteins modulate host immune responses and facilitate viral replication in 
specific cell types.  Except for Vpu and Env, which are expressed from the same 
mRNA, and Pol, which is expressed following a ribosomal frameshift, all the other HIV 
proteins are expressed from their own unique singly or multiply spliced mRNA.   HIV 
genes are enclosed between two identical copies of the long terminal repeat (LTR).  The 
LTR is subdivided in three regions: U3 (unique to 3’end), R (repeated sequence), and 
U5 (unique to 5’end).  The transcription start site is located at the junction of U3 and R 
whereas the poly(A) signal is at the boundary of R and U5.  Finally, the U3 region 
contains most of the transcriptional regulatory elements [13]. 
1.3. Overview of the HIV-1 replication cycle 
 The HIV-1 infection cycle (Figure 2, p.5) starts with the docking of the trimeric 
envelope glycoproteins (containing the gp41 and gp120 subunits) to its cognate cellular 
receptor CD4 [17,18].  The dendritic cell surface molecule DC-SIGN (Dendritic Cell-
Specific Intercellular adhesion molecule-3-Grabbing Non-integrin) can also be used as 
an attachment factor for HIV-1.  Although it can sometimes lead to productive infection 
of dentritic cells, it is generally exploited by HIV-1 as vehicle for dissemination of the 
virus within the host and as a mean to facilitate cell-to-cell transmission [19].  Binding 
of gp120 to CD4 induces a conformational change in gp120 that exposes its V3 loop  
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Figure 2. HIV-1 replication cycle. 
The HIV-1 replication cycle can be subdivided in two phases: early and late.  The early 
phase includes docking of the viral envelop to its primary receptor CD4 and a co-
receptor, inducing fusion and released of the viral core into the cytoplasm.  Entry is 
followed by reverse transcription of the viral genomic RNA into double-stranded DNA 
and ultimately by the stable integration of the viral genome into the host genomic DNA.  
The late phase of the infection consists of the expression of the various viral proteins 
and of the viral genomic RNA, resulting in the assembly and budding of progeny 
virions.  Please refer to the main text for a detailed description of each step. 
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[20,21] enabling an interaction with its primary co-receptor CCR5 (C-C chemokine 
receptor type 5) [22].  A switch to CXCR4 (chemokine (CXC motif) receptor 4) in co-
receptor usage happens late in infection in approximately 50% of infected individuals 
and is associated with rapid disease progression [23]. This second interaction event 
induces a series of conformation changes, this time in gp41, which induces the fusion of 
the viral membrane with the cellular plasma membrane following the insertion of the N-
terminal fusion peptide [24-26].  It was long thought that HIV-1 was entering cells 
through fusion at the plasma membrane.  However, recent evidence shows that although 
fusion might be initiated at the plasma membrane, it is completed after the virus has 
engaged the classical endocytic route [27,28].  Membrane fusion effectively releases the 
viral core into the cytoplasm of the cell [24,25].  There follows a series of poorly 
understood steps called uncoating whereby capsid proteins are shed from the viral core 
[29].  Once the RNA-capsid complex attains a certain level of maturation, reverse 
transcription is initiated [29,30].  It is a complex mechanism that involves multiple 
priming and initiation steps.  The end product of reverse transcription is a double-
stranded linear proviral DNA with a short overhanging structure called DNA flap on the 
positive strand [31].  As reverse transcription proceeds, the viral core continues its 
maturation and is transported along the microtubule networks toward the nuclear 
membrane.  Once it reaches the nuclear membrane it is called the pre-integration 
complex and is now competent for nuclear import and integration into the host genome 
[29,30].  It is actively imported into the nucleoplasm via a nuclear pore and with the 
help of its karyophilic elements Vpr, MA, integrase, and the DNA flap [32].  As the 
provirus reaches the nucleoplasm it is tethered to chromatin via an interaction between 
the viral integrase and the stress-induced transcription factor LEDGF/p75 (Lens 
epithelium-derived growth factor, p75) [33-35].  Multimers of the viral integrase then 
trims two nucleotide at each end of the proviral DNA and catalyzes the nucleophilic 
attack of these ends onto the host genomic DNA [36].  The integration reaction leaves 
DNA overhangs that are subsequently repaired by the cellular DNA repair machinery.  
Which repair and sensor proteins are involved in this process remains highly 
controversial and is probably cell-type specific [37-40].  Once repair is complete, the 
late phase of the infection starts.   
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The dominant factor that promotes expression from the HIV-1 LTR is the viral 
regulatory protein Tat.  It trans-activates the LTR by recruiting the positive transcription 
elongation factor b (P-TEFb) and histone acetyl transferase complexes and by activating 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells).  Overall, Tat 
increases LTR activity by several hundred folds [41-43].  Cis-acting elements in the 
viral RNA leads to the generation of unspliced, partially spliced or fully spliced RNA 
that are going to produce the different viral proteins [44].  Since nuclear export of RNA 
is tightly coupled with splicing, HIV has developed its own mechanism to promote 
efficient nuclear export of unspliced or partially spliced RNA.  Multimers of the viral 
regulatory protein Rev binds to the rev-responsive element (RRE) and mediate nuclear 
export of RNA via an interaction with the nuclear export factor exportin 1.  This mode 
of export is energy-dependent and requires Ran GTPase [45,46].  The primary sites of 
virion assembly are at the plasma membrane and appear to be concentrated in some 
membrane subdomains such as lipid rafts [47,48], tetraspanin-rich domains [49,50] and 
regions of cell-to-cell contact [51].  One of the defining features of viral assembly is the 
interaction of the MA portion of the myristoylated Gag precursor protein with 
membranes containing the lipid PI(4,5)P2.  Gag-Gag and Gag-lipid interactions 
probably cooperate to stabilize Gag assembly at the plasma membrane [52-54].  Gag-Pol 
is similarly incorporated into assembling virions [55,56].  Encapsidation of the viral 
genomic RNA requires an interaction between its packaging signal and the NC domain 
of Gag [57-59].  The envelope precursor protein gp160 is translated in the endoplasmic 
reticulum and forms trimers via disulfide bonds.  It is then transported through the Golgi 
secretory pathway where it is heavily glycosylated and cleaved into its individual 
subunits gp120 and gp41 [60].  The incorporation of envelope glycoproteins into virions 
is still not well understood but probably involves viral as well as cellular proteins [61].  
Budding of virions is mediated by the direct recruitment of the cellular ESCRT-I 
(endosomal sorting complex 1 required for transport) and ESCRT-III (endosomal 
sorting complex 3 required for transport) complexes.  This is achieved via interactions 
between late domains in the p6 region of Gag and the ESCRT protein TSG101 (Tumour 
susceptibility gene 101) and AIP1/Alix (ASK-interacting protein 1).  The ESCRT 
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machinery then induces membrane curvature and finally release of virions [54,62,63].  
The final step of the viral cycle is characterized by the maturation of the spherical viral 
core into a conical core.  This process involves a major conformational rearrangement 
mediated by the viral protease.  The protease sequentially cleaves the individual 
components of the Gag and Gag-Pol precursor proteins resulting in the realignment of 
capsid proteins around the RNA/protein complex [64,65]. 
1.4. Roles of HIV-1 accessory proteins in pathogenesis and immune evasion 
 
The hallmarks of HIV-1 infection have long been considered as the progressive 
infection and destruction of the pool of CD4+ lymphocytes, thus inducing profound 
immune dysfunction and ultimately immunodeficiency [66,67].  However, recent 
observations in simian models have considerably changed our understanding of AIDS as 
well as of the immunobiological paradigms involved in progression towards this 
condition.  Indeed, extensive studies of non-pathogenic infections in sooty mangabeys 
have revealed that despite high levels of viral replication and dramatic CD4+ T-cell 
depletion, these rarely develop AIDS [68].  One central phenotype that distinguishes 
pathogenic versus non-pathogenic infections is sustained immune activation.  In this 
context, disease progression positively correlates with markers of T cells activation and 
is associated with widespread apoptosis in B and T cells as well as increased levels of 
pro-apoptotic and immunosuppressive tumour necrosis factor (TNF), TRAIL (TNF-
related apoptosis-inducing ligand) and FAS ligand (FASL, CD154).  Multiple factors 
and events likely contribute to the establishment of chronic immune activation early 
during HIV-1 infection.  These include direct viral infection of immune cells, release of 
pro-inflammatory cytokines, perturbation of mucosal immunity, translocation of 
microbes across a damaged intestinal epithelium, and an aberrant balance between pro-
inflammatory TH17 (T helper 17) and immunosuppressive TReg cells (regulatory T 
cells) [69-72].  The ability of the virus to establish a persistent infection and avoid 
immune eradication is therefore a prime contributor to the exhaustion of the immune 
system.  The main culprits responsible for ongoing viral replication, immune evasion, 
and immunomodulatory adverse effects are likely to be the HIV-1 accessory proteins: 
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Vif, Vpu, Nef, and Vpr.  They are referred to as ‘accessory’ because they generally only 
have a marginal role in viral replication in vitro but are essential for viral replication and 
pathogenesis in the host [73].   
 
   1.4.1. VIF 
 
HIV-1 viral infectivity factor (Vif) is a 23-kDa acid cytoplasmic protein that is 
expressed at high levels late in the infection [74,75].  Vif is also incorporated at low 
levels in budding virions [76,77].  The most significant function of Vif was recently 
uncovered at the molecular level but had been evident for some years.  Vif was known 
to be essential for the replication of HIV-1 in peripheral blood lymphocytes, 
macrophages, and some cell lines characterized as ‘non-permissive’ cells [78-80].  Vif 
was capable of increasing viral infectivity of virions produced from ‘non-permissive’ 
cells but had no effect on virions produced in ‘permissive’ cells [81-84].  Heterokaryon 
experiments between permissive and non-permissive cells suggested that Vif was able to 
counteract a cellular factor restricting viral infectivity [85,86].  
 
 This cellular ‘restriction factor’ was later identified as APOBEC3G 
(apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G) [87].  
APOBEC3G is a ssDNA cytidine deaminase of the APOBEC family which also 
includes AID.  In the absence of Vif, ABOBEC3G is incorporated into progeny virions 
and impairs the efficiency and accuracy of reverse transcription [88].  The mechanistic 
nature of this inhibition has been however controversial.  Some investigators found that 
APOBEC3G could restrict HIV-1 replication independently of its deaminase activity 
[89-93], whereas others, using stable expression systems mimicking physiological 
conditions, observed that the enzymatic function was critical for the restriction [94,95].  
APOBEC3F, another protein of the same family, was also found to restrict HIV-1 
replication and to be inactivated by Vif [96-99].  Both enzymes preferentially target CC 
dinucleotides although not exclusively and induce G-to-A hypermutations in the plus-
strand of the proviral DNA [96,97,100-102].  In absence of Vif, they are packaged 
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inside virions and associate with the viral core [103,104].  The mechanism of 
encapsidation appears to rely mainly on the packaging of viral genomic RNA [103,104], 
although other components including NC and the cellular 7SL RNA might also be 
required [105].  Vif from HIV-1 and SIVagm (SIV African green monkey) directly 
interacts with APOBEC3G in a highly species-specific manner.  On the other hand, 
SIVmac (SIV macaque) Vif can inhibit APOBEC3G from humans, African green 
monkeys, and rhesus macaques [106] . Surprisingly, a single amino acid residue at 
position 128 in human APOBEC3G was responsible for the species specificity of the 
interaction with Vif.  Conversion of this residue to match the agm sequence (D128K) 
was sufficient to exchange the sensitivity to HIV-1 and SIVagm Vif [107-110].  Vif 
targets APOBEC3G and 3F to a Cullin 5 RING (really interesting new gene)–E3 
ubiquitin ligase complex (CRL5) through a direct interaction with some of its 
components [111-114].  A SLQ(Y/F)LA motif similar to a conserved motif in the BC 
box of the suppressors of cytokine signalling (SOCS) proteins was found to mediate 
association of Vif to elongin C, an adaptor of CRL5 ligases [113].  Vif also directly 
associate with Cullin 5 via its HCCH zinc-binding domain [112,113].  Vif would target 
APOBEC3G and 3F to the CRL5 complex and induce their polyubiquitination and 
resulting in their proteasomal degradation [106,111,113,115].  Evidence for 
APOBEC3G polyubiquitination have however only been obtained in vitro [116,117].  
Mutations of all the possible lysine acceptor sites yielded inconsistent results with some 
investigators finding that it prevented APOBEC3G degradation [118] whereas others 
observed no effect [119].  Some have proposed that Vif itself could be ubiquitinated and 
could act as the degradation signal [119].  Additionally, increasing evidence showed that 
Vif can also inhibit APOBEC3G in a degradation-independent manner.  Expression of 
Vif led to reduced viral incorporation of a degradation-insensitive mutant of 
APOBEC3G [120].  Vif (S144A) induces degradation of APOBEC3G but is unable to 
prevent the restricting activity of APOBEC3G on progeny virions [113].  Therefore, Vif 
has the ability to inactivate APOBEC3G and 3F using degradation-dependent as well as 
degradation-independent mechanisms. 
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Besides the inactivation of APOBEC3G and 3F, Vif performs other functions in 
the viral replication cycle.  Vif was shown to induce cell cycle perturbation in the G2 
phase in infected cells [121,122].  In contrast to Vpr, which arrests cells in G2, Vif 
would only cause delays in cell cycle progression [123].  Recruitment of the CRL5 
ubiquitin ligase by Vif was found to be essential for this activity but the presence of 
APOBEC3 family members was dispensable [123].  It is therefore thought that Vif 
would target a yet-unknown cellular factor for ubiquitination and degradation in order to 
induce this cell cycle delay [123].  The role of this activity of Vif and its potential 
interplay with Vpr-induced G2 arrest is not understood.  Interestingly, a recent report 
shows that Vif might modulate Vpr-induced cell cycle arrest by inducing the 
degradation of Vpr [124].  Other poorly understood functions of Vif include 
contribution to viral assembly [125,126] and protection of viral cores during uncoating 
[127].   
1.4.2. VPU 
 
Vpu is a 16-kDa class I transmembrane protein present in HIV-1 and some SIV 
lineages (chimpanzee, greater spot-nosed monkey, mustached monkey, mona monkey, 
Dent's mona monkey, and gorilla).  The protein is amphipathic and composed of an N-
terminal hydrophobic domain and C-terminal hydrophilic cytoplasmic domain.  Vpu is 
expressed late during infection from an Env-Vpu bicistronic RNA and is inserted in 
membranes at the level of the endoplasmic reticulum [73,128,129].  The C-terminal 
domain of Vpu contains two cysteine residues (S52 and S56) that are phosphorylated by 
casein kinase II [130].  Vpu performs two main biological functions during infection: 
down-regulation of neo-synthesized CD4 and enhancement of viral release by counter-
acting the cellular restriction factor Tetherin.        
 
Down-modulation by HIV-1 of its own primary receptor, CD4, is of capital 
importance for replication and pathogenesis, as evidenced by the fact that the virus 
devotes three proteins (Vpu, Nef, and the envelop precursor gp160) to this process 
[131].  Nef is expressed early during infection and rapidly removes cell-surface CD4 
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molecules by enhancing their endocytosis and lysosomal degradation (see section 1.4.3).  
On the other hand, gp160 and Vpu are expressed late in the infection and interfere with 
transport of neo-synthesized CD4 by respectively sequestering it in the endoplasmic 
reticulum and inducing its proteasomal degradation [132].  The exact beneficial role of 
CD4 down-modulation has remained debated but might include enhancement of virion 
release and infectivity [133-138], diminution of super-infection [139-141], and 
interference with T-cell activation [142].  Degradation of CD4 by Vpu involves the 
recruitment of the cellular Cullin 1-based E3 ubiquitin ligase complex SCF (Skp1/Cullin 
1/F-box) via a direct interaction with the substrate receptor β-TrCP (β-transducin repeat-
containing protein) [143].  Recruitment of this complex requires phosphorylation at S52 
and S56 on Vpu [143].  Vpu was found to act as a bridge between this complex and neo-
synthesized CD4, inducing its ubiquitination and proteasomal degradation [143-145].  
Additional membrane dislocation events reminescent of ERAD (endoplasmic reticulum 
associated degradation) might also be required for CD4 degradation [146,147]. 
   
 Vpu had been known for several years to enhance viral particle release in a cell 
type-dependent manner [148-151].  Heterokaryon experiments between Vpu-sensitive 
and insensitive cells have shown that Vpu was counteracting a putative cellular 
restriction factor [152].  This factor was later discovered to be the interferon-inducible 
cell-surface protein BST-2/CD317, renamed Tetherin because of its ability to trap 
budding viruses onto the plasma membrane and to subsequently induce their 
endocytosis [153-156].  Tetherin activity is not specific to HIV-1 but can also restrict 
release of other retroviruses or even of non-related enveloped viruses including KSHV 
(Karposi’s sarcoma-associated herpesvirus) and Ebola [157-160].  Owing to its unusual 
topology, which includes both transmembrane and GPI (glycosylphosphatidylinositol) 
anchor domains [161], Tetherin is incorporated into nascent viral buds and effectively 
retain them by acting as a bridge to the plasma membrane [162].  The mechanism by 
which Vpu is able to counteract Tetherin has been the subject of an intense debate.  
Some investigators found that Vpu could enhance the endocytosis of cell-surface 
Tetherin, targeting it for lysosomal degradation [163,164] whereas others found that 
Vpu, via recruitment of SCFβ-TrCP, could induce the proteasomal degradation of neo-
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synthesized Tetherin at the level of the endoplasmic reticulum [165,166] or target 
Tetherin for lysosomal degradation from the trans-Golgi network or early endosomes 
[167].  The results of this last study are supported by the observation that localization of 
Vpu to the trans-Golgi network correlates with its anti-Tetherin activity [168]. In 
contrast, other studies did not find that cell-surface down-modulation or intracellular 
degradation of Tetherin could fully account for the antagonizing effect of Vpu [169].  
Moreover, the effect of Vpu was found to be specific to human Tetherin and could not 
relieve the restriction imposed by simian or rodent Tetherins [166,170-172].  
Interestingly, Vpu from SIVcpz (SIV chimpanzee) does not antagonize Tetherin.  
Rather, Nef performs this activity [129].  In HIV-2 or in most other SIV isolates, Nef 
[170,173] or the envelope glycoproteins [174,175] are responsible for inhibiting 
Tetherin, suggesting that intense selective pressure during interspecies transmission 
would have driven different evolutional solutions [129].  Initially, another cellular 
protein called CAML (calcium-modulating cyclophilin ligand) had also been proposed 
to act as an additional Vpu-sensitive viral release restriction or perhaps as a cofactor for 
Tetherin [176], but it has now become apparent that it is probably not the case [177].   
 
Besides its two main biological functions, Vpu has also been shown to down-
modulate cell-surface expression of MHC-I (major histocompatibility complex class I) 
[178] and mature MHC-II (major histocompatibility complex class II) molecules [179].  
However, the mechanisms and functional implications of these events still remain 
poorly understood.   Moreover, expression of Vpu was shown to induce apoptosis by 
sequestering β-TrCP and thus inhibiting its normal function in cell cycle regulation 
[180].  It remains unknown whether Vpu-induced apoptosis in infected cells would 
contribute to HIV-1 pathogenesis and what would be the interplay with other pro-
apoptotic viral factors (i.e. Vpr, Tat, and gp41).  
1.4.3. NEF 
 
The erroneously named negative factor (Nef) is a 27-kDa accessory proteins 
present in all lentiviral lineages and expressed very early in the viral replication cycle.  
14 
 
Myristoylation of its N-terminus is essential for its association to the cytoplasmic side of 
membranes and is critical for all of Nef functions [181].  A striking array of biological 
and immunomodulatory activities have been attributed to Nef including down-
modulation of CD4, MHC class I and MHC class II as well as enhancement of viral 
infectivity and replication [142].  The importance of these Nef functions for viral 
immune evasion and pathogenesis has been illustrated by the observed prolonged 
survival of humans [182,183] or rhesus macaques [184] infected with viral strains 
lacking fully functional Nef proteins.  Nef is however not absolutely required for 
progression to AIDS but instead appears to accelerate it given that individuals [185] or 
macaques [186] infected with Nef-defective viruses eventually develop 
immunodeficiency in absence of reversion to wild type Nef.   
 
As mentioned above, down-modulation of cell-surface CD4 molecules by Nef 
complements the activity of Vpu and gp160 on neo-synthesized CD4 [131].  Nef is able 
to accelerate the endocytosis of CD4 by directly interacting with the cytoplasmic tail of 
the receptor [187,188] and by rerouting a number of intracellular trafficking factors 
[189].  CD4 cell-surface down-modulation requires the recruitment of AP-2 (adaptor 
protein 2) [190-193] by dileucine and diacidic motifs present on the Nef C-terminal 
flexible domain and targets CD4 for endocytosis via clathrin-coated vesicles [194,195].  
Nef subsequently directs CD4 to the multivesicular body (MVB) pathway leading to its 
degradation in the lysosomes in a process that requires ESCRT complexes but was 
surprisingly independent of CD4 and Nef ubiquitination [196].  In contrast, another 
study showed that ubiquitination of Nef on lysine 144 was necessary for CD4 down-
modulation [197].  Finally, other investigators reported that targeting to lysosomes 
involved the direct recruitment of β-COP (coatomer protein complex subunit beta) by 
Nef [198].  It is unclear at present whether the MVB and β-COP pathways might 
somehow be functionally linked. 
 
Nef has also been implicated in the selective down-modulation of the MHC-I 
molecules HLA-A and HLA-B without affecting HLA-C and HLA-E [199].  This 
selective preservation of HLA-C and HLA-E would permit immune evasion from 
15 
 
cytotoxic T-lymphocytes but would protect infected cells against subsets of natural 
killer (NK) cells [199,200].   In contrast to CD4, Nef does not primarily target cell-
surface MHC-I molecules but rather reroute them from the trans-Golgi network to 
lysosomes [189].  Nef accomplishes this by interacting directly with the cytoplasmic tail 
of MHC-I and by recruiting the clathrin adaptor protein 1 (AP-1) [201,202].  
Recruitment of β-COP by Nef would then be necessary to target MHC-I to lysosomes 
[198].  Additionally, Nef marginally accelerates the endocytosis of MHC-I from the cell 
surface in an AP-1-dependent but clathrin-independent pathway and targets it to 
lysosomes [203].  This latter mechanism is thus distinct from cell-surface CD4 
internalization and requires the GTPase ARF6 (ADP-ribosylation factor 6) [204].  
    
HIV-1 Nef was also shown to down-regulate cell-surface MHC-II molecules, 
while increasing cell-surface levels of the invariant chain (Ii).  Both mechanisms would 
lead to defective antigen presentation in macrophages, dentritic cells as well as activated 
helper T-lymphocytes [205].  Additionally, HIV Nef can down-regulate the co-
stimulatory molecule CD28 and chemokine receptors including CXCR4 from the cell 
surface via its interaction with AP-2 (adaptor protein 2)[206,207].  Various other cell-
surface molecules have also been shown to be down-modulated by Nef including 
NKG2D (natural-killer group 2, member D) ligands [208] and NKp44L (natural killer 
protein 44 ligand) [209], effectively promoting viral immune evasion from cytotoxic 
effector cells.  Importantly, down-modulation of CD28, CD4 and MHC-I by Nef are 
genetically separable, suggesting that these molecules are selected independently rather 
than targeted by an overall increase in endocytosis [207].  Conversely and despite down-
modulation of these cell-surface receptors, expression of HIV-1 Nef has been associated 
with an increased T-cell activation following its recruitment to the immunological 
synapse [210-212].  Another recently elucidated function of Nef is its effect on isotype-
class switching in B-lymphocytes.  Nef induces the formation of intercellular long-range 
actin-propelled conduits between infected macrophages and B-lymphocytes in systemic 
as well as gastrointestinal lymphoid follicles.  Nef can penetrate B-cells by travelling 
along these structures in both clathrin-dependent and clathrin-independent vesicles 
[213].  Nef inhibits immunoglobulin class-switch DNA recombination by up-regulating 
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IκBα (inhibitor of NF-κB alpha) and SOCS proteins, thus blocking CD154 and cytokine 
signalling and inhibiting AID expression [214].  It remains to be seen if Nef-mediated 
formation of long-range intercellular conduits could have other implications for viral 
replication and pathogenesis.  
 
Significant phenotypic and structural differences exist between the various 
alleles of Nef.  Notably, most SIV Nef alleles encode longer Nef species of 
approximately 35 kDa that display only low levels of amino acid identity (30%) 
compared to those of the HIV-1 allele [142].  The down-regulation of CD4, CD28, and 
MHC-I is generally well conserved between HIV-1 Nef and several SIV alleles [215].  
One striking difference however is the efficient down-modulation of CD3-TCR by most 
SIV and HIV-2 Nef alleles but not by those of pathogenic HIV-1 or SIV of the 
chimpanzee lineage [215].  Some investigators have recently proposed that down-
modulation of CD3-TCR by SIV would lead to reduced CD4+ T-cell activation, 
proliferation and apoptosis, allowing the host to maintain functional immune responses 
[142]. 
 
In addition to its immunomodulatory role, Nef additionally increases viral 
infectivity at an early step of infection [216-218] by a poorly understood mechanism, 
which requires its expression in virus-producing cells [219] but does not necessitate its 
incorporation in viral particles [220,221].  Increased virion cholesterol content [222], 
increased viral entry [223], reduced susceptibility of viral cores to proteasomal 
degradation [224] as well as facilitated transport of the viral genome through the cortical 
actin network [225] have all been proposed to account for this effect of Nef.  Recently, 
an interaction between Nef and the cellular protein dynamin-2 has also been implicated 
in this function [226].  Finally, Nef can increase viral production by at least two distinct 
mechanisms.  HIV-1 Nef is transcribed very early from pre-integrated proviral DNA 
[227] in a selective process mediated by Vpr [228] and modulates the transcriptional 
activity of resting T-cells [227].  The second mechanism involves the enhancement of 
Tat-mediated transactivation of the LTR [229].  
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1.4.4. VPR 
 
  Viral protein R (Vpr) is a small protein of 96 amino acids (in HIV-1) that is well 
conserved among the different HIV and SIV lineages (Figure 3, p.18) [230,231].  The 
mRNA encoding for Vpr is expressed late during the course of infection [232].  Vpr is 
however present in the early phase of the infection as a PIC (pre-integration complex)-
associated proteins [233-238] since it is encapsidated in virions [239,240] via a direct 
interaction with the p6 domain of the Gag precursor protein [241-244] and is a 
component of the viral core [245,246].  It is also released in the extracellular medium of 
in vitro infected cells [247] and can be found in the plasma and cerebrospinal fluid of 
infected patients [248,249].  Interestingly, Vpr, in its soluble form, has the ability to 
transduce non-infected cells [250-252].  Vpr performs several roles in viral replication 
and pathogenesis including the induction of G2 arrest and apoptosis, the promotion of 
viral replication, the up-regulation of LTR activity and immunomodulation.     
 
Vpr has a simple secondary structure composed of disordered N- and C-termini 
and of three central alpha helices [253-256].  The tertiary structure of a full-length 
synthetic Vpr in 30% acetonitrile has recently been resolved by nuclear magnetic 
resonance (Figure 4, p.19).  In these conditions, Vpr forms a compact hydrophobic core 
centred on the third helix (residues 56-77) with stabilizing hydrophobic intramolecular 
interactions with the first (residues 17-33) and second helices (residues 38-50) [253].  
This closed tertiary structure of Vpr is thought to be important for its functions 
[253,257].  The determinants responsible for viral incorporation have been mapped to 
the first helix [242,258] but may required additional structural elements in the second 
helix [259].  Moreover, Vpr possesses two non-classical nuclear localization signals 
(NLS), in the first and third helices [258,260-264]. The third helix also contains a 
nuclear export signal (NES) and is involved in the nucleocytoplasmic shuttling of the 
protein [260].  A hydrophobic leucine/isoleucine-rich region in the third helix is also 
thought to act as a leucine-zipper, mediating interactions with several cellular proteins 
including Sp1 transcription factor, E1A-binding protein 300 (p300), GR  
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Figure 3. Conservation of Vpr throughout primate lentiviral evolution. 
The amino acid sequences of HIV-1 Vpr (laboratory strains NL4-3 and HxBru) were 
aligned with Vpr sequences from HIV-2 (strains ROD and GH1), SIVsm (isolate PBJ14), 
and SIVmac (isolate 239) using the ClustalW software.  Amino acids highlighted in red 
display perfect identity whereas amino acids written in red show conservation of 
charges.  
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Figure 4. NMR structure of HIV-1 Vpr. 
Two different views of the NMR structure of Vpr are shown.   The first alpha-helix 
(residues 17-33 in blue), the second alpha-helix (residues 38-50 in orange) and the third 
alpha-helix (residues 56-77 in red) are displayed in ribbon form.  Flexible disordered 
structures, including the N- and C-termini, are shown in green.  The side chains of 
residues (T19, L20, L23, L26, H33, F34, L39, L42, I46, W54, I60, L64, L68, H71, and 
F72) stabilizing the hydrophobic core are depicted.  The position of the phospho-residue 
S79 is also indicated.   
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(glucocorticoid receptor), and VprBP (Vpr-binding protein) [265-269].  The flexible C-
terminus of Vpr is enriched in arginine residues and is critical for its biological functions 
[262,270-273].  Finally, the role of the flexible N-terminus is poorly understood [257].  
Several groups have also reported that Vpr can form dimers as well as higher-order 
multimers in vitro as well as in vivo [274-278].  The exact regions of Vpr responsible 
are not known but appear to involve all three alpha helices, implying that formation of 
the hydrophobic core would be essential [257,274-278].  The physiological relevance of 
this oligomerization is however poorly understood but might be important for its 
interaction with Gag and incorporation into budding particles [276].  
 
  In 1995, several groups reported that Vpr, when expressed alone or in the 
context of infection, arrested cells in the G2/M phase of the cell cycle [279-282].  This 
activity of Vpr is conserved among all five primate lentiviral lineages [283,284] and can 
be recapitulated with soluble Vpr [251,252].  Abnormal accumulation of cells in G2 has 
also been observed in infected patients, suggesting that Vpr-induced G2 arrest would 
play an important role in replication and pathogenesis [285].  The most likely 
mechanism by which Vpr would perturb cell cycle is that it would induce the canonical 
DNA damage checkpoint by activating ATR (ataxia telangiectasia and Rad3 related) but 
not its homolog ATM (Ataxia telangiectasia mutated) [285-287].  Activation of ATR by 
Vpr leads to phosphorylation of several effector molecules including H2AX (histone 
2A, variant X), RPA (replication protein a), and Chk1 (checkpoint kinase 1) and is 
accompanied by the formation of DNA repair foci containing γ-H2AX (phosphorylated 
H2AX), 53BP1 (tumour suppressor protein 53-binding protein 1), BRCA1 (breast 
cancer 1, early onset), RPA as well as the 9-1-1 (Rad9-Hus1-Rad1), and Rad17-RFC 
(Rad17-replication factor C) complexes [285,286,288-290].  The downstream result of 
this series of events is the up-regulation of Wee1 following its phosphorylation and the 
14-3-3-dependent inhibition of inactive phosphorylated Cdc25 (cell division cycle 25), 
resulting in the stable phosphorylation of CDK1 (cyclin-dependent kinase 1, also known 
as cdc2 in yeast) to prevent entry into mitosis [279,280,291,292].    Several mechanisms 
have been proposed to explain how Vpr would induce checkpoint activation.  These 
include direct inactivation of Cdc25 by Vpr [293] or direct modulation of the activity of 
21 
 
the cellular factors 14-3-3 [294], Wee1 [295], CSN6VIP/mov34 (COP9 signalosome 
subunit 6) [296], hHR23A (human homolog A of RAD23) [297,298], and SAP145 
(spliceosome-associated protein 145) [299].  However, in most cases, interaction 
between Vpr and these cellular proteins did not correlate with the induction of G2 arrest 
[266,300,301].    These interactions might potentiate checkpoint function by affecting 
downstream effectors but are unlikely to be responsible for ATR activation [302].   
Finally, Vpr was shown to induce the formation of transient nuclear membrane 
deformations or herniations by a yet-unknown mechanism [303].  Although it is 
conceivable that perturbation or the laminar network might result in DNA damages or 
DNA replication stress recognized by ATR, the link between these two possible 
causative events has not been formally established.  Therefore, the proximal causes of 
the activation of the ATR checkpoint by Vpr remain poorly understood. 
 
 Early on, the role of Vpr in facilitating viral replication was established by the 
observation that it weakly increased replication in transformed CD4+ T-lymphocytes 
[304,305].  This effect of Vpr was linked to its ability to transactivate the HIV LTR 
[304].  Infection of rhesus macaques with Vpr-defective mutant viruses reduced viral 
replication and delayed disease progression [306,307].  Moreover, Lang and colleagues 
reported that Vpr mutant viruses quickly reverted to wild type in a majority of cases 
[306].  Mutations affecting Vpr functions have also been identified in individuals 
naturally controlling the infection (long-term non-progressors) [308-313], thus 
emphasizing the relevance of this accessory protein for viral replication and 
pathogenesis in vivo.  It is generally accepted that Vpr, particularly at low multiplicity of 
infection, has a weak (2 to 4 folds) stimulating effect on replication in transformed T-
cell lines, primary CD4+ lymphocytes, PBMCs (peripheral blood mononuclear cells), 
and human lymphoid tissues (HLT) [304,305,314-316].  In contrast, other investigators 
did not observe a significant effect of Vpr on viral replication in quiescent or activated 
primary T-cells nor in cell lines [273,317,318].  Vpr, either as a virion-associated 
protein [236,270,314,317] or as a soluble factor [319], has also been implicated in the 
nuclear import of the pre-integration complex in non-dividing cells such as macrophages 
producing a significant increase in viral replication in these cell types.  Finally, 
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extracellular Vpr can re-activate viral gene expression in latently infected cell lines and 
PBMCs [319]    
  
As mention above, one of the first functions attributed to Vpr is its ability to 
transactivate the HIV-1 LTR and a variety of other viral and cellular promoters [304].  
Although several mechanisms, including interaction with SP1, TFIIB (Transcription 
factor IIB), p300, and GR have been proposed [320], Vpr-induced modulation of 
transcription is likely a direct consequence of the induction of G2 arrest since the 
phenotype can be recapitulated by artificially arresting cells in G2 [321].  Vpr was also 
shown to induce apoptosis of infected cells [302].  The underlying molecular 
mechanism still remains controversial with some investigators finding that it is a direct 
consequence of prolong G2 arrest [288,322,323] whereas others observing that Vpr can 
induce apoptosis independently of G2 arrest [278,324,325].  The latter scenario was 
correlated with the ability of Vpr to bind ANT (adenine nucleotide translocator) and 
perturb the mitochondrial membrane potential [326,327].  Several investigators 
described an interaction between Vpr and the cellular DNA repair enzyme UNG2 
(uracil-DNA glycosylase 2) [328].  While this interaction does not correlate with the 
induction of G2 arrest [329], its potential functional implications has remained 
controversial.  Some investigators found that Vpr could mediate the incorporation of 
UNG2 in viral particles leading to an increased fidelity of reverse transcription 
[330,331] whereas others found that Vpr would instead induce down-modulation of 
UNG2 by proteasomal degradation [332,333] or by transcriptional repression [334].  
Down-modulation of UNG2 was found to be associated with an up-regulation in LTR 
activity [333] or with an inhibition of APOBEC3G activity [332].  On the other hand, 
other investigators did not see any effect of Vpr on the expression and viral 
incorporation of UNG2 [335].  Finally, expression of Vpr was shown to perturb many 
immune functions in infected cells but also in bystander non-infected cells.  These 
immune functions include T-cell activation, DC (dendritic cell) maturation, and NK cell 
function [336-339].  Recently, we and other investigators demonstrated that Vpr-
induced G2 arrest induced the up-regulation of cell-surface NKG2D ligands, leading to 
increased NK cell cytolytic activity [340,341].  However, the functional consequences 
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of all these immunomodulatory functions of Vpr still need to be addressed in a 
physiologically relevant animal model. 
 
2. THE UBIQUITIN-PROTEASOME SYSTEM 
 
  
Vpu, Vif, and as will be exposed later in this thesis, Vpr, all perform their roles 
by hijacking Cullin-RING E3 ubiquitin ligases, which are components of the host 
ubiquitin-proteasome system, in order to inactivate cellular factors.    In contrast, Nef 
appears to bypass the requirement for ubiquitination by directly linking its cellular target 
molecules to trafficking adaptors.  A thorough understanding of the activities and 
regulatory mechanisms of ubiquitin-conjugating enzymes (ubiquitin ligases) is therefore 
warranted to fully appreciate the molecular processes involved in accessory protein 
functions.   
 
2.1. Principles and mechanisms of ubiquitination 
 
 Ubiquitination (also known as ubiquitylation) is characterized by the covalent 
post-translational conjugation of a small protein called ubiquitin (Ub) to target proteins.  
Ubiquitin is 76-amino acid long and is highly conserved among all eukaryotes.  
Ubiquitin is expressed from four different genes: Ubc, Ubb, Uba52, and Uba80.  These 
genes encode polyubiquitin precursors with C-terminal extensions or single ubiquitin 
molecules fused to ribosomal proteins.  These must be proteolytically processed by 
several classes of ubiquitin-specific proteases known as deubiquitinases (DUBs) in order 
to release functional ubiquitin monomers [342-344].  Ubiquitin adopts a common 
structure known as a ubiquitin beta-grasp or fold, exposing its carboxy-terminal tail to 
form covalent linkages with target proteins [345]. 
 
 In order to be conjugated to target proteins (Fig 5, p.24), ubiquitin must first be 
‘activated’ by the enzymes Uba1 (ubiquitin-activating enzyme 1) or Uba6 (ubiquitin- 
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Figure 5. The ubiquitin conjugation cycle. 
An E1 ubiquitin-activating enzyme ‘activates’ ubiquitin by forming a high-energy 
thioester bond on its catalytic cysteine.  Ubiquitin is then transferred to the active site of 
an E2 conjugating enzyme.  The E2 interacts with an E3 RING ligase and transfer the 
ubiquitin to an acceptor amino group on the E3-bound substrate protein.  Multiple 
rounds of ubiquitination (polyubiquitination) target the substrate for proteasomal 
degradation.  Finally, ubiquitin is recycled by the proteasome and can be used again for 
additional cycles of conjugation. 
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activating enzyme 6) commonly referred to as activating enzymes or E1.  This is 
accomplished by the ATP-dependent attachment of the carboxyl group at the extreme C-
terminus of ubiquitin to the sulfhydryl group of the active-site cysteine residue, forming 
a high-energy thioester conjugate [346,347].  The E1-conjugated ubiquitin is then 
transferred to the active-site cysteine residue in the ubiquitin-conjugating domain of an 
E2 conjugating enzyme.  The human genome encodes at least 38 E2s.  Once ubiquitin is 
transferred, the E1 is ejected from the E1-E2 complex, allowing the E2 to specifically 
interact with one of the estimated 600-1000 E3 ubiquitin ligases [346,348,349].  E3 
ubiquitin ligases direct the specificity of ubiquitination by directly interacting with 
target substrate proteins or via multiple cofactors.  They are subdivided in three main 
classes: HECT (Homologous to the E6-AP Carboxyl Terminus), RING, and U-Box.  
HECT ligases possess a conserved cysteine residue that first forms a thioester 
intermediate with ubiquitin and then catalyses the isopeptidic bond formation between 
an acceptor group and ubiquitin.  HECT ligases represent a minor fraction with only 28 
identified members to date.  Notable examples include NEDD4, NEDD4L and HUWE1 
[350].  RING ligases are characterized by their zinc-binding RING finger globular 
domain and are structurally and functionally related to the zinc-free U-Box ligases.  
RING-containing proteins are the most prevalent and constitute more than 95% of the 
E3 ubiquitin ligases.  In contrast to HECT E3s, which directly catalyses transfer of 
ubiquitin to the target protein, RING and U-Box E3s merely serve as adaptors, 
connecting a catalytically active E2 with a target cellular protein.  Although RING E3 
ligases sometimes function as independent units, they are usually part of multiprotein 
complexes in which the E2- and substrate-interacting domain are on different subunits, 
as exemplified by APC/C (anaphase-promoting complex/cyclosome) and Cullin-RING 
ligases (CRLs), [351-353].  Mechanistically, ubiquitin transfer involves the E2- or E3- 
catalyzed deprotonation of the acceptor group, usually an amino group, and its 
nucleophilic attack on the ubiquitin-cysteine thioester conjugate, resulting in an 
isopeptidic (i.e. amide) bond between the C-terminal carboxy group of ubiquitin and the 
amino acceptor group [354].  The acceptor group is usually the ε-amino group of the 
lysine side-chain.  However, more and more examples of ubiquitin transfer at the free N-
terminal amino group of proteins are uncovered [355,356].   Moreover, a few reports 
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have documented ubiquitin transfer to cysteine, threonine, and serine residues.   Because 
of the unstable nature of the thioester or ester bonds formed between ubiquitin and non-
lysine residues, it is unclear at present whether such modifications are widespread or if 
they are only rare occurrences [357-361].   
 
 Not only can E3 ubiquitin ligases promote the transfer of a single ubiquitin 
(monoubiquitination) to a lysine residue on the target protein, but they can also induce 
the formation of an isopeptidic linkage on any of the seven lysine residues of a ubiquitin 
already conjugated to a target protein, forming different types of ubiquitin chains (K6, 
K11, K27, K29, K33, K48, and K63) [362,363].  The functional consequences of this 
diversity in ubiquitin modifications will be discussed in the next section.  The molecular 
processes underlying the processivity and specificity of polyubiquitin chain synthesis 
(polyubiquitination) have been the subjects of considerable work and several models 
have already been proposed to explain the differential behaviours of E3 ligase 
complexes.  1) Rapid E2-RING E3 assembly and disassembly through high affinity 
electrostatic interactions can lead to efficient elongation of the ubiquitin chain.  
Specialized domains in the E2 might interact with the elongating ubiquitin chain and 
help to orient the attacking lysine residue for optimal transfer.  2) The E2 dissociates 
from the RING domain allowing re-loading of ubiquitin but remains in association with 
other domains of the E3 ligase complex.  This topology would permit rapid association 
and dissociation of the E2 at the RING interface.  3) A first E2 initiates chain elongation 
by adding one or a few ubiquitin moieties.  The substrate or the E3 is then bound by a 
chain-elongating E2 (sometimes called E4) to complete the formation of the 
polyubiquitin chain.  4) The ubiquitin chain is pre-formed on the E2 active site and 
transferred en bloc to the substrate.  These models are not mutually exclusive and 
probably explain the different modes of action of E2-E3 pairs [348,364-373].  As for the 
selection of correct linkages, the intrinsic properties of some E2s might be responsible 
for the specificity.  For instance, whether or not cdc34 and UBE2S (ubiquitin-
conjugating enzyme E2S) are in complex with an E3, they specifically catalyze K48- 
and K11 polyubiquitination, respectively [366,367,374].  It is thought that the 
preference for a specific linkage is probably the result of the interaction between the E2s 
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and the acceptor ubiquitin, orienting it to expose solely a specific lysine to its active site.  
Other E2s including UBC13 (ubiquitin-conjugating enzyme 13) form a complex with 
the pseudo-E2 MMS2.  In these cases, MMS2 binds to the acceptor ubiquitin to provide 
linkage specificity [375,376].  On the other hand, E2s like UBCH5 do not show any 
linkage specificity when bound to their cognate E3s and can induce the assembly of 
homotypic chains on all seven lysine residues as well as mixed-linkage chains 
[377,378].  Various combinations of E2s with the same E3 can therefore induce the 
formation of a variety of linkages.  The E3 ligase BRCA1, when in complex with the 
E2s UBCH6 and UBE2E2, induces monoubiquitination of its substrate, whereas when it 
is in complex with MMS2-UBC13 and UBE2K, catalyses the formation of K63- and 
K48-linkages respectively [379].  In the case of HECT ligases, the E3 but not the E2 
appears to be fully responsible for chain elongation processivity and specificity 
[380,381].    
 
2.2. Functional implications of ubiquitin chain topologies  
  
In contrast to phosphorylation, which primarily acts as a binary switch, 
ubiquitination constitutes a versatile multimodal class of post-translational 
modifications.  The different types of ubiquitination can be subdivided in five main 
categories: monoubiquitin, homotypic polyubiquitin chains, mixed chains, head-to-tail 
linear chains, and heterologous chains.   
 
    Monoubiquitination or the conjugation of a single ubiquitin moiety to an 
acceptor lysine residue is one the most abundant types of ubiquitination.  It is involved 
in multiple processes including protein trafficking, signalling, transcription, and DNA 
repair [382].  Although monoubiquitination has been implicated in receptor endocytosis, 
its exact role and its intricate interplays with other types of ubiquitin modifications has 
remained controversial [383,384].  On one hand, directly fusing a polyubiquitination-
defective ubiquitin moiety to the N-terminal of receptor tyrosine kinases such as 
epidermal growth factor receptor (EGFR), demonstrated that monoubiquitination was 
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sufficient to induce internalization and degradation of most receptor-tyrosine kinases in 
response to ligand stimulation, albeit less efficiently than K63-polyubiquitination.  Mass 
spectrometry analysis revealed that native EGFR was modified by monoubiquitin on 
multiple lysine residues (multiple monoubiquitination) as well as by K63-polyubiquitin 
chains on the receptor cytoplasmic tail [383,385,386].  Multiple monoubiquitination and 
K63-polyubiquitination are thought to increase the avidity of the ubiquitin binding 
domains (UBD) of endocytic adaptors such as Eps15 and epsin [387,388].    On the 
other hand, mutants of EGFR defective for ubiquitination were nevertheless internalized 
but did not undergo degradation.  In this case, ubiquitination was found to induce EGFR 
internalization via a clathrin-independent pathway, leading to lysosomal targeting 
whereas, in absence of ubiquitination, EGFR was internalized in clathrin-coated pits, 
retained intracellularly in early endosomes and eventually recycled to the cell surface 
[389,390].  Finally, K63-polyubiquitination of other receptors such as TrkA (tyrosine 
kinase receptor A) induced its internalization but not its degradation whereas multiple 
monoubiquitination could induce its degradation [391,392].  It is therefore plausible that 
different types of ubiquitination might be needed along the endocytic pathways to direct 
the receptors to specific compartments.  The outcomes of these ubiquitination events are 
also probably specific for a given ligand-receptor-adaptor system [383].  Consistent with 
this model, monoubiquitination and multiple monoubiquitination but not K63-
polyubiquitination were found to be necessary for the sorting of membrane proteins into 
multivesicular bodies (MVB) and for the targeting for lysosomal degradation via 
interactions with Vps27/Hrs and other components of the ESCRT machinery [393-395].   
Monoubiquitination has also a central role in DNA replication and repair.  
Monoubiquitination in the DNA clamp PCNA (proliferating cell nuclear antigen) was 
shown to induce the recruitment of error-prone translesion polymerases whereas its 
K63-polyubiquitination at the same residue induced error-free DNA repair [396].  
Moreover, in response to DNA damage, subunits of the 9-1-1, RFC, and Fanconi anemia 
(FA) complexes are also monoubiquitinated to coordinate DNA damage signalling and 
repair [397-399].  Finally, as much as 10-15% of H2A and H2B are monoubiquitinated.  
While H2A monoubiquitination is associated with transcriptional repression, H2B 
monoubiquitination promotes transcription initiation and elongation [400].    
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 Homotypic polyubiquitination is characterized by the formation of a 
polyubiquitin chain on a unique lysine on ubiquitin, forming a homogeneous type of 
linkage (K6, K11, K27, K29, K33, K48, and K63) [401].  All of these linkages can be 
observed in vivo but K48, K11, and K63 are the most abundant [402,403].  K48-
polyubiquitination of proteins generally leads to their degradation by the proteasome.  
The compact topology adopted by four ubiquitin moieties conjugated through K48-
linkages is recognized by multiple specific ubiquitin receptors on the regulatory ‘lid’ of 
the ring-shaped mega-complex termed proteasome.  The bound substrate is then 
unfolded and translocated into the core proteolytic domain by six distinct ATPases.  The 
substrate is finally degraded by proteolytic subunits belonging to the N-terminal 
nucleophile hydrolase family.  Removal of the ubiquitin moieties by deubiquitinases 
(DUBs) is tightly coupled with degradation and permits recycling of ubiquitin [404].  
K48 linkages can also be involved in non-proteolytic functions.  Most of these functions 
involve the recognition and segregation of K48-linked proteins by the AAA (ATPase 
associated with various cellular activities) p97/VCP (valosin-containing protein, also 
known as Cdc48 in yeast).  VCP interacts with several cofactors that differentially 
control the fates of its substrates [405].  This segregase function of VCP is implicated in 
the extraction of misfolded ubiquitinated membrane proteins during ERAD [406].  Most 
of the released substrates are then degraded by the proteasome but some, like Spt23, are 
deubiquitinated and remain stable [407].  Additionally, a recent report shows that VCP 
in complex with the cofactors Ufd1-Np14 (ubiquitin fusion degradation 1-nuclear 
protein localization 4) can extract K48-polyubiquitinated Aurora B kinase from 
chromatin at the end of mitosis, promoting formation of a new nuclear membrane [408].  
       
 In addition to K48-linkages, K63-linkages can also direct proteins for 
degradation.  While a few reports have shown that K63-linkages can induce proteasome 
degradation, most instances of proteolysis following K63-ubiquitination involved 
autophagy [362].  NBR1 and p62 acts as autophagy receptors, binding simultaneously to 
K63-polyubiquitin chains and to the ubiquitin-like autophagy-specific modifiers LC3 
(microtubule-associated protein light chain 3) and GABARAP (Gamma-aminobutyric 
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acid A receptors-associated protein).  These mediate the maturation of autophagosomes, 
fusion to lysosomes, and degradation of the ubiquitinated substrates [409].  K63-
linkages are also involved in a variety of other processes including receptor 
internalization (described above), signalling, and DNA repair.  Two notable examples 
include the NF-κB signalling pathway and the ubiquitin-dependent recruitment of 
BRCA1 to sites of DNA damage.  NEMO (NF-κB essential modulator), a subunit of 
IKK (IκB kinase), is K63-polyubiquitinated by TRAF6, in response to TNF-alpha 
stimulation.  Polyubiquitination of NEMO activates IKK, inducing the phosphorylation 
of the NF-κB inhibitor IκB, targeting it for K48-polyubiquitination and proteasomal 
degradation [410,411].  Upon induction of DNA damage, the E3 ligases RNF8 (RING 
finger protein 8) and RNF168 (RING finger protein 168) are both recruited to DNA 
repair foci in an MDC1(Mediator of DNA damage checkpoint 1)-dependent manner and 
collaborate to induce the K63-polyubiquitination of H2A and H2AX.  These K63-linked 
chains are then recognized by the ubiquitin-binding domain of RAP80 (receptor-
associated protein 80), mediating the recruitment of the BRCA1-RAP80-
ABRA1(Abraxas) complex to DNA repair foci [398,412]. 
 
 Other types of linkages have also been documented but their functions remain 
poorly understood.  K11-polyubiquitination of several substrates by APC/C has been 
shown to be central for progression of cells through mitosis [365,413].  K29-
polyubiquitination of the Notch signalling modulator Deltex was found to target it for 
lysosomal degradation [414].  During DNA damage repair, BRCA1 induces the 
formation of K6-polyubiquitin homotypic chains, but the functional relevance of these 
has not been determined [415-417].  Mixed K29/K33-polyubiquitination (a ubiquitin 
chain containing branched K29- and K33-linkages) of the AMPK (AMP-activated 
protein kinase) family members ARK5 (AMP-related kinase 5) and MARK4 
(MAP/microtubule affinity-regulating kinase 4) kinases blocks their kinase activation by 
interfering with phosphorylation of the activation-loop [418].  Autoubiquitination of the 
polycomb protein Ring1B by K6/K27/K48-mixed linkages does not lead to degradation 
of the E3 ligase but is instead essential for the efficient monoubiquitination of H2A 
[419].  The LUBAC (linear ubiquitin chain assembly complex) E3 ligase complex 
31 
 
catalyses the assembly of linear chains (conjugation of the C-terminus of ubiquitin on 
the free N-terminal amino group of another ubiquitin) [420].  LUBAC-mediated 
modification of NEMO with these linear ubiquitin chains was found to play an 
important role in NF-κB activation [421,422].  Finally, the formation of heterologous 
chains between ubiquitin and other ubiquitin-like proteins such as SUMO (small 
ubiquitin-related modifier) have also been observed.  RNF4 (RING finger protein 4) can 
induce the ubiquitination of a conjugated SUMO moiety on PML (promyelocytic 
leukemia protein), generating Ub/SUMO chains.  Such modifications of PML led to its 
degradation by the proteasome [423].    
 
2.3. Cullin-RING ubiquitin ligases (CRLs) 
2.3.1. Structure and composition 
 
Cullin-RING ubiquitin ligases (CRLs) are characterized by their extended and rigid 
architecture (Figure 6, p.32).  They are based on a large scaffold protein called Cullin.  
The human genomes encode seven Cullin proteins (Cullin 1, 2, 3, 4A, 4B, 5, and 7) and 
one Cullin-like protein (Parkin-like cytoplasmic protein, PARC).  In addition to the 
recruitment of the ubiquitination machinery, these serve as platform to engage multiple 
and distinct sets of adaptors, receptors, and substrates [424].  Cullins have curved N-
terminal stacks of alpha-helices known as Cullin repeats linked to a globular domain at 
its C-terminus.  The RING E3 ligases ROC1/RBX1/HRT1 (regulator of Cullins 1) and 
ROC2/RBX2 (regulator of Cullins 2) (for Cullin 5 only) bind to the Cullin globular 
head.  The E2 is recruited by the Cullin-bound E3 via its RING domain [425-427].  Both 
cdc34 and UBCH5 are utilized as E2s by CRLs, suggesting that these complexes have 
the capacity to generate a variety of ubiquitin linkages [378].  The N-terminus of Cullins 
are involved in the interaction with adaptors such as Skp1 (S-phase kinase-associated 
protein 1) for Cullin 1 or DDB1 for Cullin 4A.  These adaptors will in turn mediate 
interactions with a multitude of substrate receptors that are recruiting substrate proteins.  
It is believed that the rigid architecture of Cullin molecules might juxtapose the E2 and 
the substrate to favour ubiquitin transfer [425-427].     
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Figure 6. Composition and architecture of Cullin-RING E3 ubiquitin ligases. 
The C-terminus of Cullins (1, 2, 3, 4A, 4B, 5, and 7) recruits various E2s via an 
interaction with the RING E3 ligases ROC1 or ROC2.  The N-terminus of Cullins 
engages adaptors and substrates receptors to specifically recruit substrates.  Cullin 1 
recruits substrates through the adaptor protein SKP1 and an F-box-protein substrate 
receptor. Cullin 2 recruit substrates through an elongin-BC adaptor and a 
VHL/BC/Cullin 2-Box substrate receptor.  Cullin 3 recruits substrates through BTB-
domain-containing substrate receptor proteins without the need of an adaptor.  Cullin 4A 
and 4B recruits substrates through the DDB1 adaptor and a WDxR substrate receptor.  
Cullin 5 recruits substrates through an elongin-BC adaptor and a SOCS/BC/Cullin 5-
Box substrate receptor.  Cullin 7 recruits substrates through the adaptor protein Skp1 
and presumably an F-box-protein substrate receptor.      
 
33 
 
The prototypic Cullin 1-RING E3 ligase complexes (CRL1) are generally called 
SCF (Skp1-Cullin 1-F Box).  They use the adaptor Skp1 to bind substrate receptors 
containing an F-Box, a motif that includes WD40 repeats.  F-Box proteins usually bind 
to phosphorylated residues and substrate recognition is therefore regulated by 
phosphorylation [428,429].  Cullin 2 and Cullin 5 complexes are similar in their 
compositions.  They both bind the adaptor elongin C in complex with elongin B and 
recruit substrate receptors containing a BC-box subdomain [430,431].  Despite sharing 
the same adaptor proteins, they bind to two different classes of BC-box substrate 
receptors.  VHL (von Hippel-Lindau protein)-box receptors are recruited to CRL2 
complexes via a C-terminal Cul2-box domain and SOCS-box receptors interact with 
CRL5 complexes via a Cul5-box.  These specific subdomains are thought to mediate a 
direct interaction with their respective Cullin scaffold proteins [432,433].  Another 
notable difference between CRL2 and CRL5 complexes is the apparent preference of 
CRL5 for the E3 ROC2 instead of ROC1 [430].  CRL3 complexes have a different 
architecture than the rest of the CRL family.  They do not appear to use an adaptor 
protein.  Instead, they bind directly to BTB (broad complex, tramtrack, bric-a-brac) 
proteins, which act simultaneously as adaptor and substrate receptor [434-437].  Cullin 
4A contains a limited number of Cullin repeats and use DDB1 as its adaptor.  The 
proper substrate-E2 distance appears to be maintained through the larger size of its 
adaptor [438].  The substrate receptors recruited by DDB1 were recently characterized 
and share a conserved WDxR motif, a subclass of WD40 motif [439].  In addition to its 
role as an adaptor, DDB1 can also bind directly to substrates such as Chk1 [440].  
DDB1 has also been implicated in the formation of E3 ligase complexes independently 
of Cullin.  The kinase DYRK2 (dual-specificity tyrosine-(Y)-phosphorylation regulated 
kinase 2) serves as a scaffold to recruit DDB1 and the HECT E3 ligase EED (embryonic 
ectoderm development) to induce the phosphorylation and subsequent degradation of its 
downstream substrate, katanin p60 [441].  Cullin 4B is a longer paralog of Cullin 4A.  
CRL4A and 4B share DDB1 and numerous substrate receptors and can regulate 
identical substrates.  It is unclear at present whether Cullin 4B can target unique 
substrates or whether both ligases have complementary roles.  Genetic evidence 
implicating Cullin 4B in mental retardation and Cullin 4A in the development of breast 
34 
 
and liver cancers support the likelihood of both scenarios [442,443].  CRL7 complexes 
are poorly characterized.  Cullin 7 uses Skp1 as adaptor and can presumably bind to F-
box substrate receptors, although only Fbw8 (F-box and WD repeat domain containing 
8) has been observed to date [444,445].  There is also an eight putative CRL structured 
around the Cullin 7 homolog PARC, but the adaptors and substrate receptors associated 
with this complex are not known [446].   
2.3.2. Regulation 
 
Since each CRL can associate with over one hundred different substrate 
receptors, they likely regulate the stability and activity of a vast number of proteins.  
Accordingly, these complexes have been implicated in several cellular processes 
including DNA replication, cell cycle regulation, signal transduction, development, and 
transcription.  The activity of these complexes is therefore tightly regulated by several 
independent mechanisms: sequestration, dimerization, proteolysis, and post-translational 
modifications of CRL components as well as of substrates [427]. 
 
 One of the main regulatory systems of CRL activity is the CAND1-Nedd8-CSN 
cycle.  In their inactive form, CRLs are bound to the inhibitor molecule 
TIP120A/CAND1 (Cullin-associated and neddylation-dissociated 1).  CAND1 wraps 
around Cullins, masking the adaptor binding site and completely blocking the Nedd8-
conjugation site [447].  Recruitment of the adaptor-receptor-substrate complex displaces 
the inhibitor CAND1 and allows Nedd8 (neural precursor cell expressed, 
developmentally down-regulated 8) conjugation [448-450].  Nedd8 is a small ubiquitin-
like protein that is conjugated to Cullin at a conserved lysine residue.  This process is 
termed neddylation and is mediated by the sequential action of E1 (NAE1–UBA3), E2 
(UBE2F or UBC12/UBE2M), and E3 (ROC1 or ROC2) enzymes [346,355,451].    
Conjugation of Nedd8 to Cullin subunits plays multiple roles in favouring 
ubiquitination.  First, it induces a conformation shift in Cullin that masks the CAND1 
binding site and that bridges the gap between the initiator ubiquitin at the E2 active site 
and the acceptor amino group on the substrate.  Nedd8-induced Cullin flexibility also 
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enhances recruitment of E2s and formation of the amide bond at the E2 active site, 
promoting ubiquitin chain elongation.  The overall effect of neddylation is that it 
increases the probability that a substrate will acquire sufficient number of ubiquitins 
(four or more) in a single encounter with a CRL [452-454].  The COP9 signalosome 
(CSN) is an eight-subunit complex homologous to the proteasome regulatory subunit.  It 
can also form smaller complexes of two to four subunits.  Individual subunit can bind to 
multiple cellular proteins and probably have functions other than as component of CSN.  
The regulation of CSN interactions with CRLs is poorly understood but its functional 
implications have been extensively studied.  Once the substrate is ubiquitinated, one of 
the CSN subunits, CSN5, catalyses the removal of Nedd8 (deneddylation) from Cullin 
molecules [455].  Deneddylation of Cullin allows CAND1 to somehow displace the 
adaptor/receptor complex and to sequester Cullin in an inactive form [456].           
 
CAND1 and the CSN complex could thus intuitively be considered as negative 
regulators of CRLs.  However, surprisingly, down-modulation of CAND1 or CSN 
inhibits CRL activity.  This apparent paradox can be explained by several observations 
on the stability of substrate receptors.  Indeed, in absence of CSN, substrate receptors 
are auto-ubiquitinated by CRLs and eventually degraded by the proteasome.   In 
contrast, in presence of substrates, substrate receptors are protected from auto-
ubiquitination, presumably because substrates would out-compete substrate receptors as 
acceptor molecules [427].  It appears that the deneddylating activity of CSN is sufficient 
to prevent uncontrolled ubiquitination and catalytic turnover of substrate-bound 
receptors [457].  It is possible that, in some cases, USP15 (Ubp12 in yeast), a 
deubiquitinase associated with the CSN complex, might also participate in this 
regulation by inducing ubiquitin removal from CRL components [458].  In the case of 
CAND1, the mechanism of activation/inhibition is not as evident.  While some substrate 
receptors are degraded in absence of CAND1, most retain their normal levels of 
expression but are nevertheless inactive.  Recent data by Schmidt and colleagues sheds 
light on the mechanisms of CAND1-mediated activation of CRLs [457].  In absence of 
CAND1, highly abundant substrate receptors are preferentially recruited to CRLs 
compared to less abundant receptors.  CAND1 functions by increasing the access of less 
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abundant receptors to CRLs by presumably changing Cullin conformation to increase its 
affinity for rare substrate receptors.  Activation/inhibition cycles of CRLs would 
therefore promote formation of CRLs composed of diverse substrate receptors and 
would allow the substrates to regulate their own ubiquitination and degradation by 
controlling the levels of substrate receptors [427,459].   
 
 CRLs are additionally regulated by several mechanisms controlling receptor 
availability and substrate recognition.  In addition to autocatalytic regulations by CRLs, 
the levels of substrate receptors can be further down-modulated by the activity of other 
E3 ligases.  For instance, APC/CCdh1 induces the degradation of the CRL1 receptor Skp2 
in G1 [427].  Moreover, the activity of several CRL1 complexes is regulated by post-
transcriptional modification of substrates.   Most F-Box receptors can only engage their 
cognate substrates when the binding interface on the substrate is phosphorylated. This 
specialized motif is called a phosphodegron and has the evolutionary advantage of 
coupling phosphorylation-mediated signalling cascade with regulatory ubiquitination 
[428,429].  Substrate recognition can also be limited by spatial constrains [426].  The 
DNA replication-licensing factor Cdt1 (cdc10-dependent transcript 1) is degraded 
during S-phase by CRL4 (Cdt2) to prevent repeated firing of the same origin of 
replication.  Loading of CRL4 (Cdt2) on the origins of replication is controlled by a 
conformational switch in PCNA to ensure that Cdt1 is degraded only during S-phase 
and only on origins where DNA replication has been initiated [460].   
 
Other regulatory mechanisms involve the modulation of CRL catalytic activity 
by cofactors or by changes in complex architecture.  The CSN complex is directly 
involved in the stable inhibitory sequestration of a subset of CRLs, including CRL4A 
(DDB2), CRL4A (VprBP), and CRL3 (Btbd1/2), that are implicated in DNA replication 
and repair [461].  Indeed, in the case of CRL4A (DDB2), UV irradiation induces the 
disengagement of CSN [462], promoting the association of the ligase with damaged 
DNA and ubiquitination of several substrates including the DNA repair protein XPC 
(Xeroderma pigmentosum C) [463].  DDB2 (DNA damage-binding protein 2) is then 
rapidly degraded following autoubiquitination, probably as a consequence of CSN 
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uncoupling [461,463].  The activity of several CRL4A complexes is also modulated by 
the small chromatin-associated protein DDA1.  DDA1 (DET1 and DDB1 associated 1) 
forms a core complex with DDB1 and Cullin 4A and is essential for the activity of 
CRL4 ligases [461].  Conversely, when in association with DET1 (de-etiolated homolog 
1), DDA1 has the opposite effect on CRL4A-mediated ubiquitination [464].  The 
mechanisms underlying the divergent effects of DDA1 are however unclear.  
Dimerization of Cullins (mediated by neddylation or by homo- and hetero-dimerization 
of substrate receptors) and dimerization of substrate receptors on monomeric Cullin are 
other mechanisms that modulate the kinetics of ubiquitin transfer.  These alternate 
complex architectures can enhance ubiquitination of substrates by spatially 
accommodating substrates with divergent sizes or with multiple acceptor residues.  The 
structural flexibility induced by CRL dimerization can also favour transfer of ubiquitin 
to elongating ubiquitin chains [465].  Finally, ubiquitin transfer by CRLs can be 
reversed by deubiquitinases [342].  One notable example is IκBα, which is subjected to 
continuous ubiquitination by CRL1 (β-TRCP).  In presence of exogenous stimuli, the 
USP15 (ubiquitin carboxyl-terminal hydrolase 15) subunit of the CSN complex 
deubiquitinates IκBα and prevents its proteasomal degradation [466].  Another example 
is the inhibition of CRL3-mediated caspase-8 polyubiquitination by the deubiquitinase 
A20 [467].           
  
3. CELL CYCLE REGULATION 
 
HIV-1 encodes two accessory proteins, Vpr and Vif, which perturb the host cell 
cycle.  HIV-1 is not an exception in this regard.  Many viruses, including adenoviruses, 
HCMV (human cytomegalovirus), EBV (Epstein-Barr virus), and HBV (hepatitis B 
virus), have found means to interfere with the host cell cycle, either by blocking it or by 
stimulating it.  The main advantage of controlling host cell cycle is probably to optimize 
the cellular environment for efficient viral replication [468-470].   
3.1. Regulation of cell cycle progression 
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The different phases of the cell cycle are organized by a series of highly 
regulated proteins called cyclins and their associated cyclin-dependent kinases (CDK).  
At each phase, CDKs are responsible for the activation of the different mediators and 
effectors, precisely regulating the expression of essential genes and promoting passage 
through the different cell cycle transitions (G1/S, S, G2/M, M).  Complex combinations 
of CDKs with phase-specific cyclins (Figure 7, p.39) and their sequential inactivation by 
CRL and APC/C ubiquitin ligases are responsible for this temporal regulation [471-
474].   
 
 In the G1 phase, CDK4 (cyclin-dependent kinase 4) and CDK6 (cyclin-
dependent kinase 6) associates with cyclin D and CDK2 associates with cyclin E, 
activating their kinase activity.  These CDKs then phosphorylate Rb (retinoblastoma 
tumor suppressor protein) and the other members (p107 and p130) of the pocket protein 
family in a sequential and concerted manner (see Section 3.2 for further details).  Pocket 
proteins are transcriptional repressor of a number of transcription factors including E2Fs 
(E2F-1, -2, and –3).  Binding of pocket proteins to the transactivation domain of E2Fs 
and recruitment of chromatin repression factors such histone deacetylases on E2F-
responsive genes block the E2Fs transcriptional activity [475,476].  
Hyperphosphorylation of pocket proteins dissociates the complex and therefore induces 
the transcription of numerous genes, including cyclin A, DNA polymerase subunits, 
cdc6, thymidine kinase, and MCM (mini-chromosome maintenance complex) subunits, 
which are essential for the initiation and proper completion of DNA replication 
[477,478].  At the end of G1, E2F-mediated transcription is terminated by CDK2/cyclin 
A.  E2F6 and possibly E2F7 and E2F8 then represses transcription of E2F target genes 
[479-481].  
 
 Loading of the ORC complex, Cdt1, cdc6, and the MCM2-7 helicase onto the 
origins of replication forms the Pre-Replicative Complex (Pre-RC) in G1.  At the G1/S 
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Figure 7. Regulation of cell cycle progression by CDKs and APC/C 
In G1, the mitogen-dependent sequential activation of CDK4/6-Cyclin D and CDK2-
Cyclin E initiates the replication of DNA.  Efficient DNA replication requires CDK2-
Cyclin A.  When DNA replication is complete, CDK1-Cyclin B is activated and 
promotes entry into mitosis by inducing chromatin condensation and breakdown of the 
nuclear envelope.  After chromosome alignment and microtubule attachment, 
APC/Ccdc20 induces sister chromatid separation and cytokinesis.  At the end of mitosis, 
APC/Ccdh1 is activated to promote completion of mitosis and initiation of a new G1 
phase.  See main text for a more detailed description.   
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boundary, CDK2-cyclin E and cdc7-Dbf4 cooperate to recruit MCM10, cdc45, and 
other factors to the pre-RC, inducing unwinding of the origin and stabilization of ssDNA 
by RPA and by the RPA-interacting protein TopBP1 (DNA topoisomerase 2-binding 
protein 1).  Elongation factors, an array of DNA polymerases, and the RFC clamp loader 
complexes are then recruited to these chromatin structures.  Processive DNA initiation 
and replication involves the recruitment of the clamp protein PCNA [482,483].  Once 
replication as started, Cdt1 is ubiquitinated by CRL4A (Cdt2) in a PCNA-dependent 
manner and degraded by the proteasome.  In S/G2/M phases, free Cdt1 and cdc6 are 
phosphorylated by CDK1-cyclin A.  This results in the translocation of cdc6 to the 
cytoplasm and to the degradation of Cdt1 following ubiquitination by CRL1 (Skp2).  
Moreover, Geminin levels increases during S-phase and further inhibit Pre-RC 
formation by sequestering free Cdt1.  Cyclin E is also degraded following ubiquitination 
by CRL1 (Skp2) and CRL1 (Fbw7).  The goal of these feedback mechanisms, globally 
referred to as origin licensing, is to prevent DNA re-replication [484,485].   
 
As DNA replications progresses, several transcription factors, including Lin-9 
and B-myb, up-regulate expression of cyclin B [486,487].  Cyclin B forms a complex 
with CDK1 (also known as cdc2 in yeast) and is phosphorylated by the CDK-activating 
kinase (CAK) and PLK1 (Polo-like kinase 1).  This allows the nuclear import of CDK1-
cyclin B.  As nuclear levels of CDK1 increases, Wee1 and Cdc25 compete to 
respectively inhibit and activate CDK1.  At the onset of mitosis, when enough nuclear 
CDK1 and PLK1 are active, Cdc25 is activated and Wee1 is inhibited by PLK1- and 
CDK1-mediated phosphorylation events, tipping the balance towards a full activation of 
CDK1.  Phosphorylation of Wee1 ultimately results in its ubiquitination by CRL1 (β-
TRCP) and degradation by the proteasome [488,489].  Once activated, CDK1-cyclin B 
mediates breakdown of the nuclear envelope and associates with mature centromeres in 
an Aurora A- and PLK1-dependent manner where it assists the formation of the 
kinetochores.  Until all kinetochores are attached to their respective spindle, the mitotic 
checkpoint remains active (see section 3.4) and blocks the separation of sister 
chromatids [472,490,491].  The last stages of mitosis are governed by a large ubiquitin 
ligase complex called the anaphase-promoting complex/cyclosome (APC/C).    
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At the end of DNA replication, PLK1 phosphorylates the inhibitory 
heterodimeric complex Evi5 (ecotropic viral integration site 5)-Emi1 (early mitotic 
inhibitor 1), targeting Emi1 for ubiquitination and degradation via CRL1 (β-TRCP) 
[484,492].  This partially activates APC/Ccdc20 which can trigger cyclin A degradation 
[484].  APC/Ccdc20 localized on kinetochores is phosphorylated at multiple sites by 
PLK1 and CDK1.  As the spindle checkpoint remains active cdc20 is inhibited, but after 
proper chromosomal attachment, the checkpoint is silenced and cdc20 is released [493-
495].  This induces the APC/Ccdc20-mediated ubiquitination of several substrates 
including cyclin B and securin, promoting sister chromatids separation and cytokinesis.  
Following degradation of cyclin B, APC/Ccdh1 is activated by a poorly understood 
mechanism and will sequentially degrade mitotic factors such as cdc20, PLK1, Aurora 
A and B.  These degradation events are necessary for spindle disassembly, chromosomal 
decondensation and reformation of the nuclear envelope [496].  APC/Ccdh1 remains 
active throughout G1 and induces the degradation of geminin to promote re-assembly of 
Pre-RC on origins of replication [484,496].    
 
3.2. Mitogenic restriction point 
 
Unicellular organisms primarily respond to concentrations of nutrients to 
determine whether to undergo cell division or to remain in a state of latency 
(quiescence).  In multicellular metazoans however, nutrients are generally plentiful, and 
other regulatory mechanisms have evolved to ensure that cells do not undergo division 
in an uncontrolled manner but only when required for the development of the whole 
organism or maintenance of its homeostasis.  The decision to initiate cell division 
encompasses two opposing forces: pro-mitotic signals (mitogens) generally in the form 
of soluble molecules (growth factors, pro-inflammatory cytokines, etc.) and cellular 
regulatory network that inhibits initiation of S-phase (checkpoint).  Not only must cell 
division be regulated temporally but also spatially to restrict growth to tissue 
microenvironment and to conserve tissue organization and architecture.  This checkpoint 
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therefore additionally integrates multiple signalling pathways responding to extracellular 
anti-proliferative signals, cellular confluency, and cell adhesion.  Failure to respond to 
any of these signals can lead to the development of proliferative syndromes, aberrant or 
invasive cellular masses, and cancer [497-499].  Initiation of DNA replication is 
ultimately regulated by the E2F family of transcription factors, which induces the 
expression of S-phase essential genes.   Control of E2Fs activity is therefore the prime 
objective of an intricate regulatory loop involving pocket proteins, CDKs, CDK 
inhibitors, CRL1 (Skp2), and APC/CCdh1 [500-502].   
  
 
 During quiescence (G0), expression and translation are mainly repressed except 
for a subset of genes involved in housekeeping.  Consequently, cells in G0 are generally 
smaller in size and have a lower metabolism.  One protein that is highly expressed in G0 
is the pocket protein p130.  Binding of p130 to E2Fs suppresses transcription of cell 
cycle genes.  It was generally accepted that mitogenic induction of CDK4/6-Cyclin D 
would permit the re-activation of cell cycle [500].  However, a recent study showed that, 
in physiological conditions, cyclin D and CDK4/6 are absent in most quiescent cell 
types and could therefore not be involved in the phosphorylation-mediated inhibition of 
p130.  Instead, another complex, CDK3-Cyclin C, would hypophosphorylate p130 at 
sites distinct from those of CDK4/6 and CDK2, partially relieving the inhibition 
imposed by p130.  The regulation or even the ubiquity of the CDK3-mediated G0 exit 
remains unclear at present [501,502].  In early G1, mitogen-dependent expression of 
cyclin D permits the formation of CDK4/6-Cyclin D complexes.  CDK4/6-cyclin D 
induces a second round of phosphorylation of pocket proteins, notably Rb, permitting 
the E2F-mediated expression of cyclin E.  Finally, CDK2-cyclin E then completely 
inhibits pocket proteins (hyperphosphorylation) and fully transactivates E2F-mediated 
transcription of S-phase essential genes.  The pocket proteins p107 and p130 also 
negatively regulate G1/S progression by directly binding and inhibiting cyclin E/CDK2 
and cyclin A/CDK2.  Phosphorylation of both pocket proteins by cyclin D-CDK4/6 
relieves this repression [475,476].  Finally, E2Fs are regulated at the level of translation 
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by cellular miRNAs.  Mitogen-mediated up-regulation of miR-17 and miR-20a down-
modulates expression of E2F-1 to prevent its premature accumulation [503,504].  
 
Besides transcriptional regulation of their activating cyclins or direct inhibition 
by pocket proteins, CDKs are also negatively regulated by the cyclin-dependent kinase 
inhibitors (CKIs).  There are two classes of these inhibitors: the INK4 family (p15Ink4b, 
p16Ink4a, p18Ink4c and p19Ink4d) and the Cip/Kip family (p21Cip1, p27Kip1 and 
p57Kip2).  INK4 members are specific for CDK4/6 whereas Cip/Kip proteins have a 
broader CDK inhibitory spectrum [505,506].  In G0 and early G1, Cip/Kip proteins bind 
to CDK4/6-cyclin D and block the CDK active site.  Phosphorylation of Cip/Kip 
members by several mitogenic pathways, including MAPK (mitogen-activated protein 
kinase) and ERK (extracellular signal-regulated kinase), induces a change in 
conformation that reveals the CDK active site, therefore activating the CDK4/6-cyclin D 
complex [507].  In addition to their activation following an absence of mitogenic 
signalling (serum starvation), Cip/Kip proteins are also induced by cell-to-cell contact 
(confluency) and by lost of cell adhesion [508].  INK4 proteins bind directly to CDK4/6 
and induce an allosteric change that prevents association to cyclin D [506,509].  In 
contrast to Cip/Kip members, INK4 proteins are not expressed at high levels in most 
conditions.  However, antiproliferative signals such as those induced by TGF-β (tumor 
growth factor beta) or over-activation of a proto-oncogene up-regulates INK4 genes.  
Binding of INK4 to CDK4/6 displaces Cip/Kip proteins and allows the latter to inhibit 
CDK2-cyclin E and –cyclin A complexes [505,510].  Cip/Kip proteins are also targeted 
for proteasomal degradation by the CRL1 (Skp2) ubiquitin ligase to further increase 
CDK activity [508].  But before this can happen, Skp2 needs to be induced by increased 
transcription and decreased proteolysis.  In early G1, Spk2 transcription is actively 
repressed by pocket proteins, notably Rb.  At the same time, APCCdh1 is also active, 
ubiquitinating Skp2 and targeting it for proteasomal degradation.  Mitogen-dependent 
CDK4/6-cyclin D-mediated phosphorylation of pocket proteins promotes E2F-mediated 
expression of Skp2 as well as of the APC/C inhibitor Emi1, resulting in a transcriptional 
up-regulation of Skp2 and an increased stability of the protein [473,496,501].  
Moreover, CDK2-mediated phosphorylation of Skp2 protects it from degradation by 
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APCCdh1 [511].  Finally, in late G1, phosphorylation of Cdh1 by CDK2-Cyclin A 
dissociates the activating subunit from the complex to further inhibit the E3 ligase [512].  
Besides its role in mid-late G1, inactivation of APCCdh1 is also necessary for the 
stabilization of cyclin A, an event essential for proper replication of DNA and 
progression into mitosis [473,484,513]. 
 
 
The inhibition of CDK4/6-cyclin D and CK2-cyclin E complexes by CKIs and 
the regulation of these CKIs by the Skp2-APCCdh1 axis entail constant mitogenic 
stimulation to maintain the activity of these CDK complexes.  If stimulation is deprived, 
E2F-mediated transcription is shut down, re-establishing a quiescent state (G0) until 
sufficient mitogenic signalling can re-induce cell cycling.  Mitogen-dependent cell cycle 
progression is required until the cell cycle reaches a certain point in mid-late G1, the 
restriction point.  Past the restriction point, mitogenic signalling becomes dispensable 
until the end of mitosis, probably because pocket proteins are already 
hyperphosphorylated and because of high E2F transcriptional activity.    
 
3.3. DNA damage checkpoint 
 
The genome is under constant threat from exogenous agents such as genotoxic 
chemicals or radiation.  Endogenous processes such as base deamination, DNA 
replication problems or the generation of reactive oxygen species (ROS) can also 
generate DNA damages.  These genotoxic lesions must be repaired, preferentially before 
mitosis, to avoid the transmission of deleterious mutations to progeny cells.  Cells have 
developed a series of regulatory mechanisms to halt cell cycle progression and promote 
repair of these different genotoxic insults.  These mechanisms are collectively known as 
the DNA damage checkpoint and are coordinated by two damage-sensing kinases of the 
PIKK (phosphoinositide-3-kinase-related protein kinase) family: ATM and ATR (Figure 
8, p.45).  The activities of ATM and ATR can be artificially divided in three stages: 
damage recognition, signal amplification and promotion of DNA repair, and checkpoint  
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Figure 8.  The DNA damage checkpoint. 
The DNA damage sensor ATM is recruited to DNA double-strand breaks by the MRN complex 
and is activated by an amplification cascade involving H2AX, MDC1, ubiquitin ligases, and 
BRCA1.  ATR and its cofactor ATRIP are loaded on RPA-coated ssDNA by TopBP1, the 
Rad17-RFC complex, and the 9-1-1 complex.  ATR is then activated by a poorly understood 
mechanism involving H2AX, MDC1 and BRCA1.  ATM- and ATR-mediated phosphorylation 
activates respectively Chk2 and Chk1.  ATM, ATR, Chk1 and Chk2 inactivate cdc25 and PLK1 
and activate Wee1, resulting in inhibition of CDK activity at various stages of the cell cycle.   
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activation.  Extensive levels of cross-talk exist between the two sensors but each appears 
to respond to specific damages in a cell-cycle phase-dependent manner.  ATM primarily 
recognizes DNA double-strand breaks (DSBs) in G1 whereas ATR reacts to a variety of 
genotoxic stresses including base damages, bulky adducts, stalled replication forks, and 
DSBs in S and G2 phases [514-516].   
 
In order for ATR and ATM to be activated, they first need to recognize or sense 
DNA damages.  They do not however directly bind to damages but are instead recruited 
to processed intermediates.  In absence of lesions, ATM forms an inactive homodimer.  
Upon the occurrence of DSBs, binding of the Ku70/Ku80 heterodimers to both ends of 
the DSB protects them from resection by exonucleases.  The MRN complex (Mre11-
Rad50-NBS1) then associates to the ends of DSBs, presumably independently of the Ku 
heterodimers.  The NBS1 (Nijmegen breakage syndrome 1) subunit is responsible for 
the direct recruitment of ATM to DSBs [517].  Both NBS1 and the presence of DNA 
induce ATM autophosphorylation (at S367, S1893 and S1981), leading to dissociation 
of the homodimer into active monomers [518].  In the case of ATR, the primarily 
recognition signal are long stretches (50-75 nucleotides) of ssDNA coated with RPA.  
ATR does not function as an independent unit but instead in association with its cofactor 
ATRIP (ATR-interacting protein).  ATRIP mediates the recruitment of ATR to RPA-
coated ssDNA by direct interactions with both proteins.  This localizes ATR to the sites 
of DNA damages or replication stalling but it does not activate it.  In order to activate 
ATR, the 9-1-1 clamp complex must first be loaded at the 5’DNA junction by the clamp 
loader Rad17-RFC in a RPA-dependent manner.  Then, recruitment of TopBP1 by 9-1-1 
permits the activation of ATR by contacting regions within ATRIP and ATR [519].  The 
order in which TopBP1 and 9-1-1 are recruited is controversial and might be damage 
type-dependent.  Indeed, in the context of stalled replication TopBP1 along with 
polymerase alpha appear to be necessary for the recruitment of 9-1-1 and not the inverse 
[520].  Additionally, ATR-ATRIP might be recruited to sites of damages in an ssDNA-
RPA-independent manner.  In presence of replication stress, Cdc6 appears to recruit 
directly ATR-ATRIP to chromatin and some mismatch repair proteins might also recruit 
ATR-ATRIP to bulky adducts during DNA replication.  Paradoxically however, most 
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DNA damages, including bulky adducts and DSBs do not directly induce formation of 
long stretches of RPA-coated ssDNA but can nevertheless activate ATR.  Base damages 
such as oxidation (e.g. 8-oxo-guanine) by reactive oxygen species (ROS) or spontaneous 
deamination are directly recognized and repaired by the base excision repair (BER) 
pathway [521,522].  Bulkier base damages including intra-strand base crosslinks such as 
pyrimidine dimers caused by UV or chemically induced inter-strand crosslinks are 
resolved by the nucleotide excision repair (NER) pathway [523,524].  Both of these 
repair pathways generate short stretches of single-strand ssDNA (a few nucleotides in 
the case of BER and up to 35 nucleotides for NER) as repair intermediates.  These might 
have served as platform to recruit RPA and subsequently ATR, but they appear to be too 
short in length.  Indeed, a recent study by the Chen’s laboratory has demonstrated that 
ATR is recruited to sites of UV damages and activated only after DNA replication has 
been initiated [200].  It is therefore the RPA-coated stalled replication forks or stalled 
DNA polymerases themselves that would be the primary signal for ATR recruitment and 
activation by bulky adducts.  In S- and G2-phases, DSBs can arise, as in G1, when high-
energy ionizing rays hit DNA.  In addition, unresolved DBSs from G1 and partially 
repaired damages from G1 (gaps or nicks) lead to replication fork collapses and generate 
DSBs in the replicating strands [514].  As in G1, the DSB ends are initially recognized 
by the Ku heterodimers and by the MRN complex, activating ATM.  However, 
phosphorylation of the MRN-associated exonuclease subunit CtIP by S- and G2-phase 
CDKs, and its subsequent ubiquitination by BRCA1-BARD1 (BRCA1 associated RING 
domain 1) induce the resection of DSBs, generating a long stretch (>50 nucleotides) of 
ssDNA.  The generation of these ssDNA overhangs induces the dissociation of MRN 
from the DSBs and attenuates ATM activation.  The ssDNA overhangs are then coated 
with RPA, finally recruiting ATRIP-ATR.  [525,526]   
 
Simple activation of ATR and ATM is insufficient to promote repair and to 
activate the checkpoints.  Further amplification of the signal is warranted.  After 
activation, ATM catalyzes the phosphorylation of the histone variant H2AX on S139, 
allowing recruitment of MDC1.  MDC1 increases the activation status of ATM by 
promoting accumulation of MRN.  In turn, ATM phosphorylates the N-terminus of 
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MDC1.  Phosphorylated MDC1 then serves as a platform for the recruitment of the E3 
ubiquitin ligase RNF8, which induces K63-linked polyubiquitination of H2A and 
H2AX.  Ubiquitinated histones are subsequently recognized by another E3 ligase, 
RNF168, which further ubiquinates histones and other yet-unknown cellular factors to 
amplify the signal.  These ubiquitinated proteins are finally recognized by the RAP80 
subunit of the BARD1-BRCA1-ABRA1-RAP80 complex.  BARD1-BRCA1 is itself 
another E3 ubiquitin ligase but most of its substrates are still unknown.  Its role is 
however essential in checkpoint activation, in stimulating DSB repair, and for the 
induction of apoptosis.  How ubiquitination events by RNF168 would allow recruitment 
of 53BP1 is still not known but they would presumably promote the association of 
53BP1 with the dimethylated lysine 20 of histone 4 [412,527].  The exact role of 53BP1 
in promoting repair is not clear but might involved increased motility of DSB ends.  A 
recent study shows that the presence of 53BP1 at DSB repair foci stimulates the MRN-
ATM activation loop and is essential for the recruitment of KAP-1/TRIM28, suggesting 
a role for 53BP1 in the relaxation of heterochromatin to promote repair [528].  In G1, in 
absence of sister chromatids, NHEJ (non-homologous end-joining) is the first mode of 
repair for DSBs and involves the religation of the free DSB ends.  This repair 
mechanism is coordinated by the PIKK DNA-PKcs (DNA-dependent protein kinase 
catalytic subunit), which maintain both ends in proximity of each other.  Recruitment 
and activation of Ligase4–XRCC4 by DNA-PKcs finally induces the ligation of both 
ends.   Repair of DSBs by NHEJ can sometimes be error-prone and can result in small 
insertions or deletions [529].  In the case of ATR, the mechanisms for signal 
amplification are not as clear [530].  Although ATR induces the phosphorylation of 
H2AX and MDC1, the recruitment of 53BP1 to sites of UV-induced lesions is largely 
RNF8-independent [531].  The choice of repair that ATR promotes is context-
dependent: homologous recombination (HR) repair for DSBs and damage-bypass 
mechanisms for stalled replication forks.  In S- and G2 phases, the favoured mode of 
repair for DSBs is homologous recombination (HR) because an identical sister 
chromatid can be used as a template to promote error-free repair [532].  The transition 
from ATM to ATR signalling is the critical event leading to HR-mediated repair instead 
of NHEJ.  When activated at DSBs, ATR phosphorylates RPA to promote its 
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displacement by RAD51.  ATR-mediated activation of Chk1 leads to phosphorylation of 
RAD51 and initiates HR [525,526].  ATR activation also permits the recruitment and 
phosphorylation of several factors including BRCA1, the FA complex, as well as the 
WRN (Werner syndrom protein) and BLM (Bloom syndrom protein) proteins to 
promote homologous recombination repair [514,533,534].  HR is a complex process that 
involves RAD51-mediated strand invasion and displacement to generate templates that 
are used by polymerases to re-generate continuous DNA strands [535].  At stalled 
replication forks, ATR phosphorylate numerous cellular factors associated with the 
replication complex.  These include the MCM2-7 complex, MCM10, and several DNA 
polymerases to stabilize stalled forks and promote their recovery.  Phosphorylation of 
MCM2 recruits PLK1 and might promote the CDC45-dependent firing of neighbouring 
origins to complete replication in the problematic region [530,536].  Additionally, ATR 
can promote two distinct mechanisms to bypass damages in order for replication to 
proceed.  The first mechanism, called translesion synthesis (TLS), involves DNA 
replication across the genotoxic lesion by a highly processive translesion polymerase.  
This repair process is fast but is generally error-prone.  The second mechanism is called 
template switching (TS) and involves re-priming downstream of the lesion and 
replacement of the damaged DNA portion.  TS mechanistically resembles HR and is 
mediated by several cellular factors involved in HR [537].  How ATR chooses one 
repair mechanism over the other is unclear but appears to rely on the ubiquitination 
status of PCNA.  Monoubiquitination of PCNA on K164 induces translesion synthesis 
whereas K63-polyubiquitination leads to template switch damage-bypass.  The factors 
and mechanisms upstream and downstream of PCNA ubiquitination are however not 
well established but implicate Chk1 and the ubiquitin ligases Rad5 and Rad18 
[396,538,539].         
  
Because some DNA damages and DNA replication hurdles like DSBs or stalled 
replication fork can take multiple rounds of trials and errors, cell cycle progression has 
to stop to allocate sufficient time to repair these damages.  Both activated ATM and 
ATR arrest cell cycling by targeting CDK activity via activation of the checkpoint 
kinases 1 and 2 (Chk1 and Chk2).  ATM-mediated phosphorylation of Chk2 on T68 and 
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ATR-mediated phosphorylation of Chk1 on S317/345 induce their kinase activity.  
Chk1/2-mediated phosphorylation of Cdc25, at various stages of the cell cycle, induces 
CRL1(β-TrCP)-mediated ubiquitination and proteasomal degradation, leading to Wee1-
induced inhibition of CDK activity.  This results in the inhibition of CDK2/4/6 in G1, 
resulting in inhibition of E2F transcriptional activity, and inhibition of CDK2 in S-
phase, inhibiting origin firing.  In G2, phosphorylation of PLK1 (inhibitory) by ATM 
and/or ATR and of Wee1 (activating) by Chk1 additionally contributes to the 
inactivation of CDK1-Cyclin B [530,540,541].  Recent data also show that APC/CCdh1is 
re-activated following checkpoint activation and induces the degradation of PLK1 [542].  
Finally, phosphorylation of p53 by ATM, ATR, Chk1, and Chk2 activates the CKI 
p21CIP and results in the inhibition of cell cycle progression in a CDK-independent 
manner.  Activation of p53, p21, and BRCA1 by ATM and ATR eventually induce 
apoptosis following prolonged stimulation [543].  When damages are finally repaired, 
the checkpoint has to be inactivated and cell cycle has to be re-activated.  This process 
involves the resorption of DNA repair foci by an absence of activating signal as well as 
by the activity of numerous protein phosphatases (PP) including PP2A, PP4, and PP6 
which will directly inhibit checkpoint and repair factors [544,545].  In this context, 
Claspin appears to play a fundamental role in recovery from the G2 checkpoint by 
modulating Chk1 activity.  During damage response, the association of Claspin with 
Chk1 is essential to induce and maintain Chk1 activity.  During recovery from 
checkpoint response, reactivation of PLK1 by a yet-unknown mechanism activates 
Claspin to induce its CRL1(β-TrCP)-mediated ubiquitination and proteasomal 
degradation.  Claspin proteolysis is essential for the rapid inactivation of Chk1 and the 
re-establishment of CDK2-cyclin B activity [546].         
 
3.4. Mitotic checkpoint 
 
The separation of each copy of a pair of sister chromatids into their respective 
daughter cell is crucial for the maintenance of genetic material.  Defects in chromosome 
segregation leads to aneuploidy or hyperploidy, which are major causes of 
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developmental abnormalities.  Proper separation of sister chromatids relies on the 
kinetochore, which monitors appropriate microtubule attachment as well as the bi-
directionality of chromosome segregation.  These monitoring mechanisms are globally 
called the mitotic checkpoint or the spindle checkpoint [494].   
 
During S-phase, factors present in the replication complex such as claspin, RFC, 
and Ctf4 (chromosome transmission fidelity protein 4) promotes attachment of the 
replicating DNA strands (soon-to-be sister chromatids) via formation of cohesin 
complexes.  Failure to maintain sister chromatids cohesion would be catastrophic during 
metaphase.  During prophase, cohesin is hydrolyzed along the length of the chromosome 
except at the centromere, where sister chromatids attachment is maintained [547].  
Centromeres are complex structures composed of CENP proteins (called CCAN, 
constitutive centromere associated network) and are the sites of the kinetochore 
assembly.  Kinetochore proteins including the NDC80 (NDC80 homolog, kinetochore 
complex component) and spc105 (spindle complex 105) complexes accumulates at the 
centromere forming the inner and outer kinetochores [548]. The Ndc80 complex on the 
outer kinetochore must first properly capture the +end of the microtubule.  This step is 
mediated by Aurora B, which, by phosphorylating Ndc80 and other kinetochore 
components, keeps the attachment labile until the end of the microtubule is properly 
oriented on the Ndc80 complex.  It is postulated that Aurora B detects correct 
microtubule attachment by sensing tension.  If each sister kinetochores are attached to 
microtubules from opposite microtubule-organizing centres (centrioles), it creates a 
tension on the kinetochores.  On the other hand, if only one kinetochore is attached to a 
microtubule (monotelic) or if each sister kinetochores are attached to microtubules from 
the same microtubule-organizing centre (syntelic), there is no opposing mechanical 
forces to create tension between the sister centromere/kinetochore complexes.  Tension 
presumably increases the distance between Aurora B and its kinetochore substrates, 
permitting the stabilization of the attachment.  Aurora B appears to function in a similar 
manner in respect to its role in maintaining activation of the mitotic checkpoint [549].         
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The mitotic checkpoint (also called spindle checkpoint) is composed of several 
kinetochore-associated kinases, including Bub1 (budding uninhibited by benzimidazoles 
1 homolog), Bub3 (budding uninhibited by benzimidazoles 3 homolog), BubR1 
(budding uninhibited by benzimidazoles 1 homolog beta), and Mps1 (monopolar spindle 
1).  The relationship between these enzymatic elements and structural components of the 
checkpoint is still controversial.  However, recent data have begun to unravel some of 
the interaction networks and underlying mechanisms.  When microtubules are not 
properly attached, Aurora B can trigger a phosphorylation cascade involving Bub1, 
Bub3, and Mps1 [550].  This cascade results in the phosphorylation of Mad1(mitotic 
arrest deficient 1)-bound Mad2 (mitotic arrest deficient 2) and somehow induces a 
change in conformation in Mad2, allowing its activation and its dimerization.  In G2, 
soluble BubR1 binds to Cdc20 and inhibits the activity of APC/C by blocking the 
premature recruitment of the substrates cyclin B and securin.  When Mad2 is in its 
active conformation, it recruits the BubR1-Cdc20-APC/C complex to the kinetochore 
and locks it in an inactive conformation [494,551].  Upon microtubule attachment, 
Aurora B is unable to phosphorylate its substrates.  This event would somehow activate 
the phosphatase PP1, which will rapidly dephosphorylate checkpoint components, 
ultimately activating the APC/Ccdc20 complex.  Other mechanisms such as inhibition of 
Mad2 by p31comet and direct inactivation of BubR1 upon microtubule attachment are 
likely to be involved as well [552].  Once activated, APC/Ccdc20 will ubiquitinate 
securin, resulting in the activation of separase, in the removal of cohesin and ultimately 
in separation of the sister chromatids [547].   
 
4. OBJECTIVES OF THE PRESENT STUDY 
 
  
As exposed in the introduction to this thesis, the HIV-1 accessory protein Vpr 
induces a cell cycle arrest in the G2/M phase by a poorly defined mechanism.  While 
Vpr is known to trigger the canonical DNA damage checkpoint mediated by the sensor 
ATR, the proximal causes of this activation remain unknown.   
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HIV-1 accessory proteins do not possess enzymatic activities but generally 
perform their role by usurping the function of cellular proteins, notably those involved 
in the ubiquitin-proteasome system.  We therefore hypothesised that Vpr would activate 
ATR and promote the establishment of a G2/M cell cycle arrest by hijacking host 
proteins.  Although several cellular proteins had already been shown to interact with 
Vpr, none had been convincingly implicated in Vpr-mediated G2 arrest.  The first 
objective of the present study was to identify new cellular partners of Vpr and 
demonstrate their potential role in cell cycle perturbation (Chapter 1).  The 
identification, in Chapter 1, of a Vpr-interacting cellular E3 ubiquitin ligase complex 
called CRL4A(VprBP) and the characterization of its involvement in G2 arrest 
suggested indirectly that Vpr might act as a connector between the ubiquitin-proteasome 
system and target proteins.  The second objective of this study was therefore to 
investigate the mechanisms by which Vpr was utilizing this E3 ligase to promote G2 
arrest (Chapter 2).  Finally, the last objective was to establish in what subcellular 
compartments Vpr was recruiting CRL4A (VprBP) and to correlate this localization 
with the induction of G2 arrest (Chapter 3).        
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CHAPTER 1: HIV-1 VPR-MEDIATED G2 ARREST INVOLVES 
THE DDB1-CUL4VPRBP E3 UBIQUITIN LIGASE  
 
 
RÉSUMÉ 
 
La protéine Vpr (Viral protein R) du VIH-1 cause un arrêt de cycle cellulaire en 
phase G2 en induisant l’inactivation ATR-dépendante de p34cdc2.  Cependant, les 
facteurs cellulaires directement impliqués dans ce processus demeurent inconnus.  Nous 
avons utilisé la purification d’affinité en tandem pour isoler des complexes natifs 
contenant Vpr.  Nous avons trouvé que DDB1, VprBP et CUL4A, tous des composantes 
du complexe E3 ubiquitine ligase DDB1-CUL4AVprBP, s’associaient à Vpr.  La 
diminution de l’expression de VprBP à l’aide d’ARN d’interférence a inhibé l’induction 
de l’arrêt de cycle par Vpr.  Il est important de noter, qu’en absence de Vpr, la 
diminution de l’expression de VprBP n’affecte pas la progression du cycle cellulaire ni 
l’activation de point de contrôle d’ATR, suggérant ainsi que le role de VprBP dans 
l’arrêt de cycle en G2 est spécifique à Vpr.  De plus, des mutants de Vpr dans le 
domaine riche en leucines et isoleucines, atténués pour leur interaction avec VprBP et 
DDB1, sont aussi atténués pour l’induction de l’arrêt de cycle.  En revanche, des 
mutations dans le domaine C-terminal inhibent l’arrêt de cycle mais n’affectent pas 
l’interaction avec ces deux protéines, suggérant que l’interaction de Vpr avec VprBP et 
DDB1 est nécessaire mais non suffisante pour bloquer la progression du cycle cellulaire.  
Globalement, ces résultats suscitent l’élaboration d’un modèle dans lequel Vpr agirait 
comme connecteur entre le complexe ubiquitine ligase DDB1-CUL4AVprBP et un facteur 
cellulaire inconnu.  L’ubiquitination de ce facteur induirait sa protéolyse ou modulerait 
son activité, ce qui mènerait à l’activation d’ATR et à un arrêt de cycle en G2.
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ABSTRACT 
 
HIV-1 viral protein R (Vpr) has been shown to cause G2 cell-cycle arrest in human cells 
by inducing ATR-mediated inactivation of p34cdc2, but factors directly engaged in this 
process remain unknown. We used tandem affinity purification to isolate native Vpr 
complexes. We found that DDB1, VprBP and Cul4, which are components of a Cul4 E3 
ubiquitin ligase complex, DDB1-Cul4VprBP, were able to associate with Vpr.   Depletion 
of VprBP by siRNA impaired Vpr-mediated induction of G2 arrest.  Importantly, VprBP 
knockdown alone did not affect normal cell cycle progression or activation of ATR 
checkpoints, suggesting that the involvement of VprBP in G2 arrest was specific for 
Vpr.  Moreover, leucine/isoleucine-rich domain Vpr mutants impaired in their ability to 
interact with VprBP and DDB1 also produced strongly attenuated G2 arrest. In contrast, 
G2 arrest-defective C-terminal Vpr mutants were found to maintain their ability to 
associate with these proteins, suggesting that the interaction of Vpr with the DDB1-
VprBP complex is necessary but not sufficient to block cell cycle progression.   Overall, 
these results point towards a model in which Vpr could act as a connector between the 
DDB1-Cul4VprBP E3 ubiquitin ligase complex and an unknown cellular factor whose 
proteolysis or modulation of activity through ubiquitination would activate ATR-
mediated checkpoint signaling and induce G2 arrest. 
 
INTRODUCTION 
 
Human Immunodeficiency Virus type 1 (HIV-1) viral protein R (Vpr) accessory 
protein is a small 96-amino acid protein that plays several roles during virus infection 
(reviewed in [1,2]). In particular, the protein mediates cell cycle arrest at the G2/M 
transition in various mammalian cells [3-6], a cytostatic ability that is well-conserved 
among the primate lentiviruses [7]. Its biological significance is not fully understood but 
may be related to general activation of virus expression [8] and/or induction of  
apoptosis [9]. Vpr suppresses cell proliferation by preventing the activation of the 
p34cdc2/cyclin B complex [3,4]. Accumulating evidence indicate that Vpr-mediated cell 
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cycle arrest depends on DNA damage response, but precise mechanisms of its induction 
remain obscure. 
 
Phosphatidylinositol 3 kinase-like ATM (ataxia telangiectasia mutated) and ATR 
(ataxia and telangiectasia mutated and Rad3 related) are key components of the G2/M 
checkpoint. In addition, ATR also activates S-phase checkpoint in replication stress 
response resulting from stalled replication [10]. Depending on the type of stress, ATR- 
or ATM-mediated checkpoints are fully activated by the coordinated activity of Rad9-
Rad1-Hus1 (9-1-1), Rad17-RFC, BRCA1, and 53BP (reviewed in [11-13]). ATR- or 
ATM-dependent phosphorylation of the histone variant H2AX triggers the formation of 
γ-H2AX/BRCA1 or 53BP foci.  These foci are presumed to help in the recruitment 
and/or retention of DNA repair machinery and checkpoint effectors at the damaged 
DNA sites, thus promoting checkpoint signal amplification [12]. Downstream activation 
of Chk1 or Chk2 kinases by ATM and ATR results in the inactivation of Cdc25 
phosphatase and increased expression of both Wee1 kinase and the 14-3-3 family of 
proteins. Inactivation of cdc2/cyclin by hyperphosphorylation and cytoplasmic retention 
prevents entry into mitosis before the completion of DNA repair [10,12].  
 
Several groups have reported that Vpr expression induces Rad17- and Hus1-
dependent activation of ATR but not of ATM, and induces the formation of nuclear γ-
H2AX/BRCA1 foci [14-16]. However, the mechanism by which Vpr triggers ATR 
activation is still not well understood. Some authors proposed that Vpr would interfere 
with normal DNA replication leading to stalled replication forks [15,17] while others 
suggested that the protein may promote the formation of DNA double-strand breaks by 
recruiting unknown endonucleases to the chromatin [18]. Both models imply direct Vpr 
interactions with host chromatin [15,18]. On the other hand, blockade of the 
proliferation might rely on the mislocation of key cell cycle regulators, due to alterations 
in the nuclear envelope induced by membrane-anchored Vpr [19]. 
 
To identify Vpr-interacting cellular proteins responsible for the initial events 
leading to the induction of G2 arrest, we used the proteomic Tandem Affinity 
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Purification (TAP) procedure followed by mass spectrometry. Native complexes 
containing TAP-Vpr were purified from human cells by two consecutive affinity 
chromatographic steps under mild conditions. Here, we identify a novel protein complex 
comprising Vpr, the damaged DNA binding protein 1 (DDB1), the newly identified 
DDB1-Cul4-associated factor (DCAF), VprBP [20-22], and the E3 ubiquitin ligase 
scaffold protein Cullin 4 (Cul4), and provide functional evidence indicating that Vpr 
interaction with this E3 ubiquitin ligase complex is involved in induction of G2 cell 
cycle arrest.  
 
RESULTS  
 
Vpr interacts with DDB1 and VprBP  
In order to purify cellular protein complexes interacting with HIV Vpr, Vpr was 
fused to a TAP tag containing two immunoglobulin-binding domains of protein A from 
Staphylococcus aureus, a cleavage site for the tobacco etch virus (TEV) protease, and 
the calmodulin-binding peptide (CBP). Since Vpr C-terminal modifications have been 
reported to alter its cytostatic abilities [23], the bipartite tag was introduced N-
terminally. Purification of TAP-Vpr containing complexes was then conducted in 
HEK293T cells, although the tagged protein induced cell-cycle arrest less efficiently 
than wild-type Vpr (data not shown). After electrophoresis and silver staining, two 
bands corresponding to high-molecular weight proteins were repeatedly observed (data 
not shown). MALDI-TOF mass spectrometric analysis revealed that the upper band 
corresponded to VprBP, a 180-kDa protein that had been isolated as Vpr-binding factor 
a decade ago, but whose function still remained obscure [21,22]. The other 120-kDa 
protein was identified as damaged DNA binding protein 1 (DDB1). DDB1 was initially 
considered as part of a heterodimeric complex containing damaged DNA binding 
protein 2 (DDB2), involved in a cellular response to UV-induced DNA damages 
[24,25].  However, the protein is now emerging as a central scaffolding factor in the 
DDB1-Cul4-ROC1 E3 ubiquitin ligase complex associated with the COP9 signalosome 
[26]. Importantly, the WD40 protein VprBP has been recently demonstrated to interact 
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with DDB1 and most probably serves as an adapter to confer substrate specificity to the 
DDB1/Cul4/ROC1 E3 ubiquitin ligase complex [20].  
 
We sought to confirm the interaction of Vpr with DDB1 and VprBP in 
HEK293T cells transfected with TAP or TAP-Vpr expression plasmids. TAP pull-down 
experiments were performed on cell lysates using IgG-coated sepharose beads. Co-
precipitated endogenous DDB1 and VprBP were detected by western blot using specific 
antibodies. As shown in Fig. 1A, endogenous DDB1 and VprBP could be pulled-down 
when co-expressed with TAP-Vpr (lane 3) but not when the protein was in presence of 
the native TAP tag (lane 2), thus indicating that DDB1 and VprBP binding was specific 
to TAP-Vpr.  These interactions could be detected in conditions containing 1% NP-40 
(data not shown) as well as 0.5% Triton X-100 (Fig. 1A).   
 
In order to confirm the specificity of the interaction between Vpr and DDB1, we 
performed pull-down assays in cells co-transfected with TAP-Vpr and HA-DDB1-
encoding plasmids (Fig. 1B). We were able to observe that HA-DDB1 could be co-
precipitated specifically in presence of TAP-Vpr (lane 6), but not in presence of the 
empty plasmid (lane 2) or a TAP-expressing plasmid (lane 5). We also constructed 
TAP-DDB1 as well as GFP-DDB1 expression plasmids to verify whether the interaction 
could be observed in the reversed orientation.   However, immunoprecipitation using 
endogenous, TAP-tagged, HA-tagged or GFP-fused DDB1 as bait and wild-type or HA-
tagged Vpr yielded inconsistent results (data not shown). These discrepancies between 
HA- and TAP-Vpr abilities to bind to DDB1 are reminiscent of the versatile association 
between DDB1 and the DNA replication licensing factor Cdt1. In that case, detection of 
DDB1/Cdt1 complexes in absence of chromatin was dependent on the amount of 
antibody used for the immunoprecipitation [20]. Given that Cdt1 has been shown to 
interact indirectly with DDB1 via the adapter protein Cdt2 [27,28], it would be tempting 
to hypothesize that Vpr would likewise interact indirectly with DDB1 through an 
adapter protein, perhaps VprBP, and that the TAP/IgG bead complexes may somehow 
stabilize the interaction. 
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To confirm the specificity of interaction between Vpr and VprBP in our system, 
we performed co-immunoprecipitation experiments in presence of endogenous VprBP 
and over-expressed HA-Vpr (Fig. 1C).  We could specifically detect co-
immunoprecipitated VprBP in presence of HA-Vpr (lane 2) but not in presence of the 
empty plasmid (lane 1).  Finally, we could also observe an interaction between over-
expressed HA-Vpr and Myc-tagged VprBP (Fig. 1D), confirming the specificity of the 
interaction between Vpr and VprBP.   
 
DDB1 appears to bind to Vpr indirectly 
To further investigate the apparent association between TAP-Vpr and DDB1, 
Vpr, Tap and TAP-Vpr sequences were subcloned in yeast two-hybrid expression 
constructs. Saccharomyces cerevisiae cells were co-transformed with each combination 
of plasmids. Interaction affinities were determined by measurement of the β-
galactosidase activity. As expected, Vpr appeared to form homodimers, leading to a 
strong activity of the reporter gene (Fig. 2A). Surprisingly, no binding could be detected 
between Vpr and DDB1, a result consistent with the lack of interaction observed with 
some co-immunoprecipitation experiments. We found that dimerization of TAP-Vpr 
was 3-fold weaker compared to that of the wild-type protein. Hence, N-terminal addition 
of large peptide appears to disturb the tertiary structure of Vpr, explaining at least in part 
the reduction of TAP-Vpr cytostatic abilities. Importantly, we found that β-galactosidase 
activity remained undetectable in cells co-expressing TAP-Vpr and DDB1.  This lack of 
stable interaction between Vpr and DDB1 did not result from lack of DDB1 expression 
in yeast, since we could observe DDB1 expression, by western blot in Vpr-expressing 
yeast cells (Fig. 2A).  Finally, an association between Vpr and DDB1 could not be 
detected in co-immunoprecipitation experiments using in vitro-translated T7-Vpr and 
HA-DDB1 proteins (Fig. 2B) in conditions which have demonstrated an association 
between Vpr and VprBP [21], suggesting that the binding observed in human cells 
might be indirect and may involve a bridging factor.     
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Vpr associates with a DDB1-Cul4VprBP E3 ubiquitin ligase complex   
One possible explanation for the apparent association between Vpr and DDB1 is 
that Vpr would associate with the DDB1/Cul4/ROC1 ubiquitin ligase complex through 
perhaps a direct interaction with VprBP.  Indeed, the WD40 protein VprBP has been 
recently demonstrated to interact with DDB1 and most probably serves as an adapter to 
confer substrate specificity to the DDB1/Cul4/ROC1 E3 ubiquitin ligase complex [20]. 
To assess the possibility that the Vpr/VprBP/DDB1 complex might be part of an 
ubiquitin E3 ligase complex, we investigated whether Vpr could associate with the E3 
ligase scaffold protein Cul4.  HEK293T cells were transfected with plasmids expressing 
TAP and TAP-Vpr, and pull-down assays were performed on cell extracts containing 
endogenous Cul4.  These assays demonstrated that endogenous Cul4 could specifically 
associate with TAP-Vpr but not with native TAP (Fig. 3A, lane 3), thus suggesting that 
Vpr does indeed associate with a Cul4-scaffolded E3 ligase complex  Moreover, anti-
Cul4 immunoprecipitation experiments on cells that had been transfected with an empty 
plasmid or an HA-Vpr-expressing plasmid revealed that HA-Vpr co-
immunoprecipitated with a Cul4-containing complex (Fig. 3B, lane 2), thus confirming 
that Vpr can associate with a E3 ligase complex with potential ubiquitinating activities.  
Importantly, VprBP could be co-immunoprecipitated along with Cul4 (Fig. 3B).  
Therefore, given the mutual association of Vpr (Fig. 1A, 1C, and 1D therein and 
[21,22]) and Cul4 (Fig 3B therein and [20]) with VprBP, these results suggest  that  Vpr  
interacts with the DDB1-Cul4VprBP E3 ubiquitin ligase in a single complex  and that this 
association might occur via the intermediary of  VprBP.        
 
The interaction between DDB1-Cul4VprBP and Vpr is required for the induction of G2 
arrest 
We then sought to study the potential role of DDB1-Cul4VprBP E3 ubiquitin 
ligase in the induction of G2 cell cycle arrest by Vpr.  DDB1 depletion by siRNA has 
been reported to induce the accumulation of cells in G2/M due to DNA re-replication 
[28] and, consequently, this strategy could not be used to demonstrate the involvement 
of DDB1-Cul4VprBP in the induction of Vpr-mediated G2 arrest. As an alternative 
strategy, we analyzed the effect of siRNA-mediated VprBP knockdown on Vpr 
62 
 
cytostatic properties. Cells transfected with VprBP siRNA displayed a major reduction 
of VprBP at the mRNA level (Fig. 4A) as well as at the protein level (Fig. 4B) 
compared to scrambled siRNA-transfected cells.  We thus transfected HEK293 cells 
with siRNA against VprBP and, 24 hours later, transduced these cells with a lentiviral 
vector co-expressing GFP and native Vpr.  We observed that cells transfected with 
VprBP siRNA displayed strongly attenuated Vpr-mediated G2 arrest as compared to 
cells that received scrambled control siRNA (Fig. 5A).  This difference in the induction 
of G2 arrest was not due to a defect in infectivity potentially resulting from VprBP 
knockdown because the levels of transduction were equivalent in all the conditions 
tested (data not shown).  To verify that this defect in the induction of G2 arrest in 
VprBP-depleted cells was specifically the result of the abrogation of the Vpr-VprBP 
interaction rather than a defect in cell growth, we treated these cells with nocodazole 
with the rationale that properly cycling cells should accumulate in mitosis due to the 
effect of the drug on microtubule polymerization (Fig. 5B).  In response to nocodazole, 
cells transfected with VprBP siRNA alone or with the concomitant expression of Vpr 
accumulated at the G2/M phase, indicating that knockdown of VprBP specifically 
impaired Vpr-mediated G2 arrest functions.  Moreover, the knockdown of VprBP did 
not produce any observable defects in the activation of the ATR-mediated checkpoints, 
since treatment with low concentrations of aphidicolin, a DNA replication inhibitor 
known to produce DNA double-strand breaks at fragile chromosomal sites and to 
activate the ATR-mediated intra-S checkpoint [29,30,31], blocked cell cycle progression 
at the S phase in scrambled as well as VprBP siRNA-transfected cells (Fig. 5C).   
Finally, we analyzed the role of VprBP in the induction of G2 arrest by Vpr in the 
context of viral infection.  SiRNA-transfected cells were infected with VSV-G-
pseudotyped fully infectious isogenic viruses defective (NL4-3∆Vpr-GFP, vpr-) or 
proficient (NL4-3-GFP, vpr+) for Vpr expression.  Forty-eight hours after infection, 
cells were analyzed for their cell cycle profile.  As expected, cells transfected with 
scrambled control siRNA accumulated in G2 after infection with the vpr+ but not with 
the vpr- virus (Fig. 5D).  Knockdown of VprBP almost completely abrogated the 
accumulation of cells in G2 in response to vpr+ virus infection but did not significantly 
affect the cell cycle profile of vpr- virus-infected cells.  Again, these differences in G2 
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arrest were not the result of differential infectivity (data not shown). Overall, these 
results indicate that VprBP is necessary for Vpr-induced G2 arrest, thus suggesting that 
the DDB1-Cul4VprBP E3 ligase complex might be involved in this Vpr biological 
activity. 
 
To examine whether the association of Vpr to the E3 ligase complex is required, 
we tested the ability of several TAP-tagged Vpr mutants to associate with VprBP and 
DDB1 and their effect on Vpr-induced G2 arrest. HEK293T cells were transfected with 
plasmids expressing mutants of TAP-Vpr and TAP pull-down experiments were 
performed on these transfectant cellular extracts. As previously observed, TAP-Vpr was 
able to pull-down endogenous VprBP and DDB1 (Fig. 6A, lane 3). Interestingly, the 
classical Vpr mutants S79A and R80A that are attenuated for the induction of G2 arrest 
(Fig. 6C and [32,33]) could still associate with VprBP and DDB1 at levels comparable 
with the wild type protein (Fig. 6A, compare lane 3 with lanes 5 and 6), suggesting that 
the association between Vpr and the DDB1-VprBP complex per se is not sufficient to 
block cell cycle progression.  Moreover, W54R, a mutant of Vpr that was previously 
shown to be defective for the interaction and degradation of uracil-DNA glycosylase 
(UNG2) [34], was still capable of associating with the DDB1-Cul4VprBPcomplex (Fig. 
6A, lane 4) and mediate G2 arrest (Fig. 6C), suggesting that UNG2 and VprBP bind to 
two distinct domains on Vpr.  Zhao et al. had previously mapped the domain of 
interaction of VprBP to the leucine/isoleucine (LR)-rich domain of Vpr [22].  We thus 
analyzed whether the L64A and Q65R mutations in this domain of Vpr could abrogate 
binding to VprBP.  Using our TAP-Vpr pull-down assay, we observed a very strong 
reduction of binding to VprBP and DDB1 with the Q65R mutant (under longer exposure 
VprBP could be detected) (Fig. 6B, compare lanes 3 and 4). A residual association with 
DDB1 was observed under these conditions, most likely reflecting difference in 
antibody affinities. Additionally, the reduction of TAP-Vpr binding to VprBP and 
DDB1 could be observed with the L64A mutant, albeit it was less pronounced (Fig. 6B, 
compare lanes 5 and 6).  Interestingly, with both mutants, the reduced affinity for 
VprBP was accompanied by a concomitant decrease in the association with DDB1, 
again suggesting that VprBP and DDB1 are likely to form a single complex with Vpr 
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(Fig. 6B, compare lane 3 with lane 4 and lane 5 with lane 6).  Importantly, we found that 
Vpr (L64A) and Vpr (Q65R) were strongly attenuated for the induction of G2 arrest 
(Fig. 6C).  Indeed, the residual level of G2 arrest observed with these two mutants was 
comparable to the attenuated G2 arrest produced by the R80A mutation. Taken together 
these results suggest that the interaction of Vpr with the DDB1-Cul4VprBP E3 ubiquitin 
ligase complex is necessary but not sufficient to induce G2 arrest. 
 
DISCUSSION 
 
The induction of G2 arrest by the HIV-1 accessory protein Vpr has been 
described more than 10 years ago [3-6] however, the mechanism by which Vpr can 
accomplish this function has remained elusive.  Several recent reports have 
demonstrated that expression of Vpr leads to activation of ATR as well as the formation 
of DNA repair foci containing BRCA1 and γ-H2AX [14-16].  Nonetheless, the initial 
events leading to ATR checkpoint signaling are not known.  Herein, we have used the 
TAP method to isolate cellular protein complexes interacting with HIV-1 Vpr in order to 
identify cellular factors that would be involved in Vpr-mediated ATR activation and 
subsequent G2 arrest.   Using this strategy, we have identified DDB1 and VprBP as 
cellular factors forming a complex with Vpr.     
 
DDB1 is part of the DDB1/Cul4/ROC1 E3 ubiquitin ligase complex that targets 
proteins for degradation via the COP9 signalosome [26].   In this complex, DDB1 serves 
as a scaffold protein presenting substrate to the E3 ubiquitin ligase.  The protein is 
structurally complex, and contains three seven-bladed β propellers (βPA, βPB and βPC) 
[35].   The βPB propeller is involved in the interaction with Cul4 whereas the βPA-βPC 
double-propeller fold has been shown to be responsible for substrate presentation via 
interaction with WD40-repeat proteins [35].  Over 15 different WD40-containing 
substrate receptors, including Ddb2, CSA, Det-Cop1 and Cdt2, have been shown to 
interact with DDB1 and are thought to confer substrate specificity [20,35-37].  
However, only a few cellular proteins have been found to date to be regulated by the 
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DDB1/Cul4/ROC1 complex. In human cells, DDB1-Cul4DDB2 promotes the 
ubiquitylation of histone 2A [38], histone 3, histone 4 [39], and the xeroderma 
pigmentosum group C protein (XPC) to regulate their activity [40]. In contrast, DDB1-
Cul4CSA and DDB1-Cul4Det1-Cop1 promote proteolysis  of  Cockayne syndrome type B 
gene product (CSB) [26] and  c-JUN [41] .  Recently, DDB1, via the WD40 adapter 
Cdt2, has been shown to prevent DNA re-replication during normal S-phase progression 
or in response to S-phase accumulation of DNA lesions by regulating the degradation of 
the replication licensing factor Cdt1 [27,28].  
 
Interestingly, DDB1 also forms complexes with two other viral proteins, namely 
HBV X protein [42-44] and simian paramyxovirus SV5 V protein [45,46]. Whereas the 
mechanisms underlying the DDB1-dependent cytotoxicity induced by HBV X protein 
remain poorly understood, it has been established that SV5 V protein facilitates the 
ubiquitination and subsequent signalosome-mediated degradation of STAT1 [45]. 
Several data argue in favor of a functional involvement of DDB1/Cul4/ROC1 in Vpr 
functions. Cullin 4A has been implicated in Vpr-induced degradation of UNG2 and 
SMUG1 proteins [47] and Vpr was shown to interact with VIP/mov34/CNS6, one of the 
subunits of Cul4-associated signalosome [48].  
 
In our system, an interaction between Vpr and DDB1 was observed when Vpr 
was fused to a TAP tag (TAP experiments, Fig. 1A, and B).  However, co-precipitations 
in the reverse direction with DDB1 fused to other tags (TAP, HA or GFP) only yielded 
inconsistent interaction results (data not shown). The lack of apparent interaction 
between DDB1 and Vpr in that context may be due to our experimental conditions or to 
the type of association that engages Vpr and DDB1.  In that regard, the lack of 
interaction between Vpr and DDB1 in the yeast two-hybrid system (Fig. 2A) as well as 
in in vitro co-precipitation experiments (Fig. 2B) argued for an indirect interaction 
between these two proteins, although definite demonstration of this will require a more 
thorough analysis of this association in the future.  These results were in contrast to SV5 
V protein, which can directly interact with the DDB1 βPA-βPC domain [35,49].  
Through the use of TAP procedures (data not shown), immunoprecipitation experiments 
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(Fig.1) as well as several Vpr mutants (Fig. 6), we identified VprBP as a cellular factor 
also in a complex with Vpr and DDB1 and possibly permitting the recruitment of a 
DDB1-Cul4 E3 ubiquitin ligase complex.  The cellular function of VprBP has recently 
been uncovered through different proteomic approaches.   It is a WD40 protein linked to 
the DDB1/Cul4/ROC1 complex and probably serves as an adapter presenting protein 
substrate for degradation [20].  Interestingly, no VprBP ortholog has been identified in 
yeast [21], explaining perhaps why we did not observe an interaction between Vpr and 
human DDB1 in S. cerevisae (Fig. 2A) and why the DDB1 ortholog was not found 
among the putative Vpr-interacting proteins isolated by TAP assay in S. pombe (data not 
shown).   
 
To further characterize the possibility that Vpr might interact with a DDB1-
Cul4VprBP E3 ligase complex, we investigated whether the scaffold protein Cul4 could 
associate with Vpr.  Interestingly, we could demonstrate the formation of a complex 
containing Vpr and Cul4 using two different approaches: by TAP-Vpr pull-down (Fig. 
3A) and by anti-Cul4 immunoprecipitation (Fig. 3B).  Therefore, it appears that Vpr can 
indeed recruit an E3 ligase complex with potential ubiquitinating activity.  In these 
experiments, VprBP was found in respective association with Vpr (TAP experiments, 
Fig. 1A, C, and D), as well as with Cul4 (Fig. 3B).  Therefore, taking into account these 
interaction results and previous reports demonstrating the association between Vpr and 
VprBP [21,22] as well as the association between Cul4 and VprBP [20], it is thus most 
likely that Vpr interacts with the DDB1-Cul4 E3 ligase complex via the intermediary of  
VprBP, although direct proof of that will require further analysis of the protein complex 
architecture.   
 
Importantly, we also observed that VprBP but also the formation of a Vpr-
DDB1-Cul4VprBP complex was required for Vpr-mediated induction of G2 arrest.  
Indeed, siRNA targeting VprBP strongly impaired the induction of G2 arrest in the 
context of a lentiviral vector expressing Vpr and of a fully infectious provirus (Fig. 5A 
and 5D).   Knockdown of VprBP did not produce cell cycle aberrations (Fig. 5B and 5C) 
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nor did it reduce viral/vector infection efficiency, suggesting that the observed defect in 
G2 arrest was specific to the association of Vpr with VprBP.      
 
It has been extensively shown that Vpr C-terminal residues 78-96 are important 
for G2 arrest [23,50-52], but we found that TAP-tagged Vpr mutants S79A and R80A 
attenuated for cell cycle arrest were nevertheless competent for association with DDB1 
(Fig. 6). This was not surprising given that Zhao et al. previously showed that VprBP 
binding required the leucine/isoleucine-rich domain of Vpr [22]. In fact, L64A and 
Q65R, two mutations in the leucine/isoleucine-rich domain reduced to different extent 
the binding of Vpr to VprBP (Fig. 6B).  We also observed a concomitant decrease of 
affinity between Vpr and DDB1 as a result of these mutations, suggesting that a single 
complex comprising VprBP and DDB1 is binding to the leucine/isoleucine-rich domain 
of Vpr.  Importantly, these two mutations strongly attenuated Vpr-induced G2 arrest 
(Fig. 6C).  Overall, these results suggest that recruitment of DDB1-Cul4VprBP by Vpr is 
necessary but not sufficient to induce G2 cell cycle arrest.  
 
One possible model to explain how Vpr induces G2 arrest via the DDB1-
Cul4VprBP complex would be that Vpr could cause generalized defect in the activity of 
the whole DDB1 complex In this context, other investigators have shown that 
abrogation of DDB1 function using siRNA resulted in the failure to degrade Cdt1, thus 
leading to the accumulation of re-replicated DNA fragment and the induction of an 
ATR-dependent G2 arrest [28].  Therefore, Vpr, through a potential sequestration of 
DDB1, might be capable of inducing the defective regulation of Cdt1 or other DDB1-
Cul4 E3 ligase complex substrates leading to ATR-mediated G2 arrest.  However, we 
did not observe any obvious effect of Vpr on the S-phase degradation of Cdt1 (data not 
shown), suggesting that the DDB1/Cul4/ROC1 complex was fully functional.  Another 
possible explanation would be that Vpr could block the proper ubiquitination of natural 
substrates of DDB1-Cul4VprBP thereby affecting their biological activities or preventing 
their degradation.  However, this is unlikely because siRNA-mediated knockdown of 
VprBP did not produce G2 arrest (Fig. 5).  The most probable model would be that Vpr 
would trigger the degradation of a yet-unknown modulator of cell cycle progression by 
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targeting it to the substrate receptor VprBP, itself linked to the DDB1/Cul4/ROC1 E3 
ligase complex.  This situation would be highly similar to the mechanism by which Vpu 
induces the degradation of CD4 by recruiting directly CD4 to the SCFβ-TRCP E3 ubiquitin 
ligase complex [53]. However, we cannot exclude the possibility that the Vpr-VprBP 
interaction might modulate the activity of substrates through ubiquitination, as was 
described for XPC and histones [38-40].  Therefore, the formation of a complex 
between Vpr and DDB1-Cul4VprBP through the Vpr leucine/isoleucine-rich domain could 
permit the hypothetical interaction of Vpr, through its C-terminal domain, with other 
cellular factors whose ubiquitination would induce the initial events in Vpr-mediated 
cell cycle arrest. 
 
In conclusion, we presented biochemical and functional evidence suggesting that 
Vpr is likely the third protein encoded by HIV-1, besides Vif and Vpu, to interact with 
the ubiquitination machinery. Vpr was found to associate with DDB1 and Cul4, which 
are components of the   DDB1/Cul4/ROC1 E3 ligase complexe through possibly the 
intermediary of the WD40 substrate receptor VprBP. Importantly, the interaction 
between Vpr and the VprBP-DDB1 complex was shown to be required for the induction 
of G2 arrest.  Vpr could act as a connector to the DDB1-Cul4VprBP E3 ubiquitin ligase 
and recruiting via its C-terminal residues an unknown cellular factor whose proteolysis 
or modulation of activity through ubiquitination would activate ATR-mediated 
checkpoint signaling and cause G2 arrest. 
 
MATERIALS AND METHODS 
 
Cells and antibodies  
Human embryonic kidney (HEK) 293 and HEK293T cells were maintained as 
described elsewhere [54].  The anti-HA tag and anti-Myc tag monoclonal antibodies 
were, respectively, clones 12CA5 and 9E10.  Rabbit polyclonal antibody against VprBP 
was distributed by Accurate Chemical and Scientific Corporation (Westbury, NY).  The 
mouse monoclonal antibody against DDB1 was obtained from BD Biosciences 
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(Mississauga, Ontario, Canada).  The goat polyclonal antibody against Cul4 was 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA).  Vpr was detected using a 
rabbit polyclonal antibody directed againt a Vpr  N-terminal peptide [55]. 
 
Plasmid constructions  
For the construction of mammalian expression plasmid psvCMV-TAP, N-
terminal TAP tag was first PCR amplified from the pBS1479 plasmid [56] using primers 
5'-TCTAGACATATGGCAGGCCTTGCGCAAC-3’ and 5'-
GGATCCTCACTACTCGAA-TCGTCATCATCAAGTGCC-3’, the last one containing 
two stop codons between the XhoI and BamHI restriction sites. The XbaI/BamHI-
digested PCR fragment was then inserted into psvCMV plasmid [54] linearized with 
XbaI/BglII. For the construction of the psvCMV-TAP-Vpr expression plasmid, wild-
type and mutant Vpr genes were PCR-amplified from the respective psvCMV-HA.Vpr 
plasmids [54] using oligonucleotides 5'-CTCGAGATGGAACAAGCCCCAG-3’ and 5'-
GGATCCCTAGGATCTACTGGCT-3’. XhoI/BamHI Vpr fragments were finally fused 
to the XbaI/XhoI TAP sequence within psvCMV by 3-fragment ligation. Mammalian 
expression plasmids pSRAS-3HADDB1 and pSRAS-GFP.DDB1 [44] were kindly 
provided by M. Strubin (University of Geneva, Switzerland). The TAP-DDB1 
expression plasmid was constructed by inserting the XbaI/XhoI TAP fragment in 
Xba/SalI linearized pSRAS-3HA.DDB1 plasmid.  The Myc-VprBP expression plasmid 
was constructed by PCR amplification of the VprBP cDNA from Image clone ID 
5547856 (American Type Culture Collection, Manassas, VA).  The resulting PCR 
product was then subcloned in pCMV-Myc (Clontech, BD biosciences, Mississauga, 
Ontario, Canada) at the SalI and NotI sites.  For the construction of the yeast expression 
plasmids, TAP and TAP-Vpr sequences were subcloned after PCR amplification in the 
BamHI sites within pEG202. The DDB1 sequence was extracted from pSRAS-
3HADDB1 by SalI/NotI digestion, and introduced in pJG4-5. Vpr-expressing pJG4-5 
and pEG202 plasmids have been described previously [57]. 
 
The second-generation self-inactivating lentiviral vector pWPI and pWPXL, as 
well as the packaging plasmid psPAX2 were obtained from D. Trono (School of Life 
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Sciences, Swiss Institute of Technology, Lausanne, Switzerland). A lentiviral vector 
tranducing Vpr and GFP (pWPI-Vpr) was generated from pWPI.  Vpr was PCR-
amplified from psvCMV-Vpr [54], using primers: 
5’AAGGATCCATGGAACAAGCCCCAGAAGACC-3’ and 5’-
TACGACTAGTCTAGGATCTACTGGCTCCATTT-3’, containing a BamHI site at the 
5’end and a SpeI site at the 3’end, respectively.  The BamH1/SpeI cleaved- PCR product 
was then ligated into pWPXL linearized at the same sites.  A fragment containing the 
Vpr-coding sequence and the EF1-alpha promoter was excised with SpeI (Klenow-
treated) and NotI and then ligated into pWPI at the PmeI and NotI sites to yield pWPI-
Vpr.   
 
Tandem affinity purification  
Purification was done according to previously published procedures [56]. 
Briefly, HEK293T cells were seeded onto five to ten 150mm-diameter plates. The day 
after, cells were transfected with 10 µg of psvCMV TAP-Vpr plasmid. Forty hours later, 
cells were collected, washed and lysed in IPP150 buffer (10mM Tris-Cl pH 8.0, 150mM 
NaCl, 0.1% nonidet NP40) supplemented with EDTA-free complete protease inhibitors 
(Roche Diagnostics Canada, Laval, Qc, Canada). Cell debris were removed by low-
speed centrifugation, and cleared supernatants were loaded onto IgG sepharose columns 
(Amersham BioSciences Canada, Baie d’Urfe, Qc, Canada). After extensive washes 
with IPP150 buffer, and a final wash with TEV cleavage buffer (10mM Tris-Cl pH8.0, 
150mM NaCl, 0.1% NP40, 0.5mM EDTA, 1mM DTT), TAP-containing complexes 
were eluted by overnight digestion using 100 units of TEV protease  (Invitrogen 
Canada, Burlington, Ontario, Canada) diluted in 1 ml of TEV buffer. Columns were 
eluted and washed with 3 ml of IPP150-calmodulin buffer (10mM β-mercaptoethanol, 
10mM Tris-Cl pH8.0, 150mM NaCl, 1mM Mg-acetate, 1mM imidazole, 2mM CaCl2, 
0.1% NP40) supplemented with 3 ml of 1M CaCl2 and EDTA-free complete protease 
inhibitors. Fractions were passed through calmodulin columns (Stratagene, La Jolla, 
CA), washed in IPP150 buffer and finally eluted with a minimal volume of IPP150 
elution buffer (10mM β-mercaptoethanol, 10mM Tris-Cl pH8.0, 150mM NaCl, 1mM 
Mg-acetate, 1mM imidazole, 2mM EGTA, 0.1% NP40). Recovered proteins were 
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resolved by denaturing 12.5% SDS-PAGE. Bands detected after silver staining were cut 
and sent to Taplin Biological Mass Spectrometry Facility (Harvard Medical School, 
Boston, MA, USA) for MALDI-TOF mass spectrometry. 
 
Transfection and immunoprecipitation  
Cells were transfected using the calcium phosphate precipitation method. Two 
days later, cells were harvested, washed and lysed in Triton lysis buffer (50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.5% Triton X-100, and EDTA-free complete protease 
inhibitors). TAP pull-down assays were performed using 10 µl of IgG-coupled beads. 
After extensive washes in Triton lysis buffer, beads were resuspended in 100 µl of TEV 
cleavage buffer with 2 units of TEV and incubated for 16 hours at 4ºC.  Cleaved 
proteins were diluted in Laemmli buffer, heat-denatured and loaded onto 12.5% 
acrylamide gels for SDS-PAGE. After protein transfer onto Hybond-ECL membrane 
(Amersham BioSciences Canada, Baie d’Urfe, Qc, Canada), proteins were detected by 
western blotting using specific antibodies.  Immunoprecipitation experiments were 
performed on cell extracts lysed in the Triton lysis buffer as described previously [58].  
 
In vitro translation  
T7-Vpr and HA-DDB1 were in vitro translated using the Active ProTM In vitro 
translation kit (Ambion, Austin, TX, USA) according to manufacturer instructions.  
 
Cell cycle analyses  
Cell cycle analysis of HEK293 cells transduced by lentiviral vectors was 
performed as previously described in [54]. The mathematical model MODFIT was used 
to calculate the proportions of cells in the G2/M phases and G1 phase of the cell cycle.  
For analysis of cell cycle profile in the context of TAP-Vpr, HEK293T cells were co-
transfected with 1 µg of a GFP-expressing and 15 µg of TAP-Vpr expressing plasmids.  
Forty-eight hours after transfection, cells were fixed with 1% paraformaldehyde for 15 
min followed by fixation/permabilization with 70% ethanol for 10 min.  The rest of the 
procedure was as described previously [54] except that flow cytometry analysis was 
performed on the GFP-positive cell population.    
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Yeast two-hybrid assay  
The yeast ‘bait’ strains were made by transforming the EGY48 yeast strain with 
a URA3 lacZ (beta-galactosidase) reporter plasmid and the different bait plasmids 
(expressing the HIS3 gene) by the lithium acetate method. The yeast ‘bait’ strain 
harboring the bait and reporter plasmids were transformed with different prey plasmids 
and selected for the tryptophan autotrophy phenotype (in addition to the His and Ura 
nutritional markers for the bait and LacZ reporter plasmids, respectively). Determination 
of the respective interactions was performed as previously described [57]. 
 
Lentiviral vector production, titration, and transduction   
VSV-G-pseudotyped viral particles were produced by transient transfection of 
40 µg  of vector (pWPI or pWPI-Vpr), 30 µg of the packaging construct psPAX2, and 
12 µg of the VSV-G-expressing plasmid psvCMV-IN-VSV-G in five millions 
HEK293T cells using the calcium phosphate precipitation method.  The vector-
containing supernatant was harvested 48 and 72 hours post-transfection, 0.45 micron-
filtered, and concentrated by ultracentrifugation on a sucrose cushion.  Concentrated 
vectors were resuspended in culture medium and stored at –80ºC. Vectors were titered 
as described previously with some modifications [59].  Briefly, 5X104 HEK293T cells 
were transduced with serial dilutions of the vector preparations in absence of polybrene.  
Twenty-four hours later, cells were fixed with 2% PFA for 30 min and the percentage of 
GFP-expressing cells was determined by flow cytometry.  The vector titer was 
calculated as the number of transduction unit (TU) in the linear range of transduction (5-
10% of GFP-positive cells).  For transduction experiments, 1X105 HEK293 cells seeded 
in the wells of a 6-well plate were incubated for 24 hours with WPI or WPI-Vpr vectors 
(at a multiplicity of infection (MOI) of 1) in presence of 8 µg /ml polybrene, typically 
achieving a transduction efficiency of 90-95%.  Twenty-four hours later, cells were 
harvested for flow cytometry analysis of cell cycle profiling and GFP expression. 
 
Viral clones and infection   
The infectious molecular clones, pNL4.3-GFP and pNL4-3∆Vpr-GFP, were 
obtained from Dr Juan Lama, Department of Medicine, University of California, San 
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Diego and described in [60].  Virus was produced by transfecting 5X106 HEK293T cells 
with 40 µg of proviral DNA and 10 µg of the VSV-G expressing plasmid psvCMV-IN-
VSV-G as described previously [54].  Virus-containing supernatant were titered by a 
standard RT assay as previously described [54].  Virions, at a concentration of 100 
cpm/cell, were used to infect HEK293 cells in 1 ml of culture medium, in absence of 
polybrene.  Forty-eight hours after infection, cells were harvested for flow cytometry 
analysis of cell cycle profiling and GFP expression. 
 
SiRNA-mediated protein knock-down   
SiRNA targeting VprBP (siGenome SMARTpool M-021119-00) and scrambled 
control siRNA (non-targeting siRNA #2) were obtained from Dharmacon Inc, Chicago, 
IL, USA.  SiRNA were transfected using Oligofectamine (Invitrogen Canada, 
Burlington, Ontario, Canada), according to the manufacturer instructions.  Briefly, 300 
pmol of siRNA was pre-incubated with 15 µl of Oligofectamine and overlayed on cells 
at 50% confluence (the final concentration of siRNA was 125nM).  Twenty-four hours 
after transfection, cells were transduced with lentiviral vectors.  In some experiments, 
cells were subjected to two sequential transfections of 300 pmol of siRNA, 24 hours 
apart.  
 
RT-PCR   
RNA was extracted from siRNA-transfected cells at given time using the Qiagen 
RNeasy kit (Qiagen, Mississauga, Ontario, Canada), according to the manufacturer 
instructions.  After elution, RNA was stored at -80ºC .All reagents for RT-PCR were 
purchased from Invitrogen Canada (Burlington, Ontario, Canada). RNA was reverse 
transcribed into cDNA using five hundred ng of RNA, which in a final volume of 12 µl 
supplemented with 1 µl of oligo (dT)12-18 (500 µg/ml), and 1 µl of 10mM dNTP mix 
were incubated at 65ºC  for 5 min. The mixture was cooled on ice and supplemented 
with 50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 2 units/µl 
RNaseOUT recombinant ribonuclease inhibitor, and 10 units/µl of M-MLV RT.  
Finally, the reverse transcription reaction mixture was incubated at 37ºC for 50 min and 
heat-inactivated at 70ºC for 15 min.  One µl of the reverse transcription reaction was 
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subsequently used for PCR amplification of β-actin and VprBP sequences.  Briefly, the 
PCR amplification mix was composed of 20mM Tris-HCl pH 8.4, 50mM KCl, 1.5 mM 
MgCl2, 50 µM dNTPs, 1 µM of sense and antisense primers, and 0.05 units/µl of Taq 
DNA polymerase.  Primers 5'-GCTCGTCGTCGACAACGG-CTC-3' and 5'-
CAAACATGATCTGGGTCATCTTCTC-3' were used for β-actin amplification and 
primers 5’-AGGCCATCCACAAGTTTGAC-3’ and 5’-
TCATCTGCCTGCAACATAGC-3’ were used for VprBP amplification.  The PCR 
amplification conditions for VprBP were as follow: 94ºC for 2 min; 25 cycles of (94ºC  
for 45 sec; 57ºC  for 30 sec; 72ºC  for 1 min); 72ºC  for 5 min.  The conditions of 
amplification for β-actin were the same except that 18 cycles of amplification were used.    
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FIGURES 
 
Figure 1. Immunoprecipitation of DDB1/Vpr and VprBP/Vpr complexes. (A) 
HEK293T cells were mock transfected (lanes 1) or transfected with either TAP (lanes 2) 
or TAP-Vpr expressing plasmids (lanes 3). Two days later, immunoprecipitations of 
TAP tag were performed on cell lysates using IgG-coupled beads and purified 
complexes were eluted by cleavage with TEV protease. The levels of endogenous 
VprBP and DDB1 were monitored in crude lysates and pulled-down fractions by 
western blot using specific antibodies. TAP, TAP-Vpr and cleaved Vpr were detected 
using a polyclonal rabbit antibody directed against a Vpr  N-terminal peptide. (B) 
HEK293T cells were mock transfected (lanes 1-2) or transfected with either TAP (lanes 
3 and 5) or TAP-Vpr expressing plasmids (lanes 4 and 6). Cells were 
transcomplemented with the empty vector (lanes 1, 3, and 4) or HA-DDB1- encoding 
plasmid (lanes 2, 5, and 6). (C) HEK293T cells were mock transfected (lanes 1) or 
transfected with HA-Vpr expressing plasmid (lanes 2).  Immunoprecipitations using 
anti-HA antibodies were performed on cells extracts using protein A-sepharose beads.  
The levels of HA-Vpr and endogenous VprBP were monitored in cell extracts as well as 
immunoprecipitated fractions by western blotting using specific antibodies.  (D)  
HEK293T cells were mock transfected (lanes 1 and 3) or transfected with a HA-Vpr 
expressing plasmid (lanes 2 and 4). Cells were transcomplemented with the empty 
vector (lanes 1 and 2) or Myc-VprBP encoding plasmid (lanes 3 and 4).  Anti-HA 
immunoprecipitations were performed as described above. 
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Figure 2. Absence of direct Vpr binding to DDB1 in yeast. The EGY48 reporter 
strain containing LexA-TAP, LexA-Vpr, or LexA-TAP-Vpr (« bait ») was transformed 
with B42, B42-DDB1 or B42-Vpr-expressing plasmid (« prey »). (A) The binding 
affinity between the different proteins was assessed by assaying beta-galactosidase 
activity using the o-nitrophenyl- -D-galactopyranoside (ONPG) method. Histograms 
represent averaged data from 2-4 different clones, and are representative of two 
independent assays. Western blot analysis of induced and non-induced B42-HA-DDB1 
expression in the B42 and B42-DDB1-transformed EGY48/LexA-Vpr reporter strain is 
shown below. (B) In vitro-translated T7-Vpr was immunoprecipitated with an anti-T7 
antibody in presence or absence of in vitro translated HA-DDB1.  Amounts of protein 
initially added to the assay (input) are shown in the left panel.  * Represents non-specific 
proteins immunoprecipitated by the ani-T7 antibody. 
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Figure 3.  Vpr associates with the ubiquitin ligase scaffold protein Cul4.  (A) Five 
million HEK293T cells were transfected with 40 µg of empty (lanes 1), TAP-expressing 
(lanes 2) or TAP-Vpr-expressing plasmids (lanes 3).  Forty-eight hours after 
transfection, TAP pull-downs were performed on cell lysates using IgG-coupled beads 
and purified complexes were eluted by cleavage with TEV protease. The levels of 
endogenous Cul4 were monitored in crude lysates and pulled-down fractions by western 
blot using a polyclonal goat anti-Cul4 antibody.  TAP, TAP-Vpr and cleaved Vpr were 
detected using a polyclonal rabbit antibody directed against a Vpr N-terminal peptide.  
(B) Ten million HEK293T cells were transfected with 80 µg of empty plasmid (lanes 1) 
or with HA-Vpr expressing plasmid (lanes 2).  Immunoprecipitation of endogenous 
Cul4 was performed using a goat polyclonal anti-Cul4 antibody and protein A-sepharose 
beads.  The levels of endogenous Cul4, VprBP and over-expressed HA-Vpr were 
monitored in crude lysates and immunoprecipitated fractions by western blot using, 
respectively, a polyclonal goat anti-Cul4 antibody, a polyclonal rabbit anti-VprBP 
antibody and a monoclonal mouse anti-HA antibody. * represents a non-specific protein 
detected by the anti-Cul4 antibody.  The anti-Cul4 antibody generally recognized a 
doublet of Cul4 when the gel resolution was sufficiently high.  In the TAP pull-down 
fractions only the upper band of Cul4 was detected.     
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Figure 4. Depletion of VprBP using siRNA.  HEK293 cells were transfected with 300 
pmol of VprBP-targeting siRNA or control scrambled siRNA using Oligofectamine.  
(A) At twenty-four, forty-eight and seventy-two hours after transfection, RNA was 
extracted and analyzed by RT-PCR to determine the extent of VprBP down-regulation at 
the mRNA level.  PCR products were analyzed in the exponential phase of 
amplification.  Actin levels were used as a control for RNA quality and reverse 
transcription efficiency. (B)  Forty-eight hours after siRNA transfection, cells lysates 
were harvested and analyzed by western blot using a polyclonal rabbit anti-VprBP 
antibody to demonstrate the downregulation of VprBP at the protein level.  Actin levels 
were used as a control for protein loading. 
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Figure 5.  Effect of VprBP depletion on Vpr-induced G2 arrest.  HEK293 cells were 
transfected with 300 pmol of VprBP-targeting siRNA or control scrambled siRNA using 
Oligofectamine, followed by the same transfection twenty-four hours later.  Twenty-four 
hours after the second siRNA transfection, cells were transduced at a MOI of 1 with 
lentiviral vectors expressing Vpr (WPI-Vpr) or the empty vector (WPI).  Cell cycle 
profiles were analyzed twenty-four hours after transduction by flow cytometry using 
propidium iodide staining (A).  To determine if cell growth (B) or checkpoint activation 
(C) were affected by VprBP knockdown, HEK293 cells were transfected once with 
siRNA, as described above, and treated respectively with 1 µg/ml nocodazole and 0.5 
µM aphidicolin twenty-four hours later. Cell cycle profiles were analyzed twenty-four 
hours after drug treatment.  To determine if VprBP knockdown could also abrogate the 
induction of G2 arrest in the context of viral infection, siRNA-transfected cells were 
infected with NL4.3-GFP and NL4-3∆Vpr-GFP at a concentration of 100 cpm/cell and 
cell cycle profiles were analyzed forty-eight hours later (D).  Percentages of G1 and 
G2/M cell populations were determined using the ModFit software.   These results are 
representative of the data obtained in at least two independent experiments. 
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Figure 6.  DDB1 and VprBP binding affinities of TAP-tagged Vpr mutants. (A) 
HEK293T cells were transfected with TAP-Vpr plasmids encoding for wild-type Vpr 
(lanes 3), or Vpr mutants W54R (lanes 4), S79A (lanes 5) and R80A (lanes 6). As 
control, cells were mock transfected (lanes 1) or transfected with a TAP-expressing 
plasmid (lanes 2).  Following TAP pull-down using IgG-coupled beads, the levels of 
endogenous VprBP and DDB1 were monitored in crude lysates and pulled-down 
fractions by western blot using specific antibodies. TAP, TAP-Vpr and cleaved Vpr 
were detected using a polyclonal rabbit antibody directed against a Vpr N-terminal 
peptide.  (B) HEK293T cells were transfected with TAP-Vpr plasmids encoding for 
wild-type Bru Vpr (lanes 3) and wild-type NL4-3 Vpr (lanes 5), or Vpr mutants  Bru 
Q65R (lanes 4), and NL4-3 L64A (lanes 6). As control, cells were mock transfected 
(lanes 1) or transfected with a TAP expressing plasmid (lanes 2).  TAP pull-downs and 
immunodetection of VprBP, DDB1, TAP, and Vpr were performed as described for 
panel A.  (C) HEK293T cells were co-transfected with 1 µg of GFP-expressing plasmid 
and 15 µg of TAP-Vpr plasmids expressing wild-type or mutant proteins.  Cell cycle 
analysis was performed using propidium iodide staining on the GFP+ cell population as 
described in Materials and Methods.  Percentages of G1 and G2/M cell populations were 
determined using the ModFit software. 
 
94 
 
 
 
 
 
 
 
 
 
 
95 
 
CHAPTER 2: HIV-1 VPR INDUCES THE K48-LINKED 
POLYUBIQUITINATION AND PROTEASOMAL DEGRADATION 
OF TARGET CELLULAR PROTEINS TO ACTIVATE ATR AND 
PROMOTE G2 ARREST  
 
RÉSUMÉ 
 
La protéine Vpr (Viral protein R) du VIH-1 induit un arrêt de cycle cellulaire en 
phase G2/M par un mécanisme impliquant l’activation du senseur de dommage à l’ADN 
ATR.  Certaines recherches incluant les nôtres ont récemment démontré que Vpr 
remplissait cette fonction en détournant l’activité de la E3 ubiquitine ligase DDB1-
CUL4A (VprBP).  Vpr pourrait donc agir comme connecteur entre la E3 ligase et un 
facteur cellulaire inconnu.  L’ubiquitination de ce facteur induirait un arrêt de cycle 
cellulaire.  Cependant, ce modèle est uniquement basé sur l’observation indirecte que 
certains mutants de Vpr sont incapables d’induire un arrêt de cycle tout en conservant 
leur interaction avec la E3 ligase.  En utilisant une approche de purification d’affinité en 
tandem, nous avons observé que Vpr interagissait avec des protéines ubiquitinées.  Ces 
interactions requéraient une E3 ligase active car la diminution de l’expression de VprBP 
à l’aide d’ARN d’interférence ainsi que la surexpression d’un mutant dominant-négatif 
de CUL4A réduisaient l’association aux protéines ubiquitinées.  De plus, des mutants C-
terminaux de Vpr, inactifs pour l’induction de l’arrêt de cycle, ont une association 
réduite aux protéines ubiquitinitées.  Nous avons aussi démontré que l’inhibition de 
l’activité protéosomale augmentait cette association et que les chaînes d’ubiquitine était 
en partie constituées de liens classiques K48.  L’inhibition de la polyubiquitination de 
type K48 a inhibé spécifiquement la phosphorylation de H2AX induite par Vpr mais n’a 
pas affecté celle induite par les rayons ultraviolets.  Globalement, nos résultats apportent 
des preuves directes que l’association de Vpr à la E3 ubiquitine ligase DDB1-CUL4A 
(VprBP) induit la polyubiquitination de type K48 de facteurs cellulaires encore 
inconnus, menant à leur dégradation protéosomal et à l’activation d’ATR.
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ABSTRACT 
  
HIV-1 viral protein R (Vpr) induces a cell cycle arrest at the G2/M phase by a 
mechanism involving the activation of the DNA damage sensor ATR.  We and others 
recently showed that Vpr performs this function by subverting the activity of the DDB1-
CUL4A (VprBP) E3 ubiquitin ligase.  Vpr could thus act as a connector between the E3 
ligase and an unknown cellular factor whose ubiquitination would induce G2 arrest.  
While attractive, this model is solely based on the indirect observation that some 
mutants of Vpr retain their interaction with the E3 ligase but fail to induce G2 arrest.  
Using a tandem affinity purification approach, we observed that Vpr interacts with 
ubiquitinated cellular proteins and that this association requires the recruitment of an 
active E3 ligase given that depletion of VprBP by RNA interference or overexpression 
of a dominant-negative mutant of CUL4A decreased this association.  Importantly, G2-
arrest-defective mutants of Vpr in the C-terminal putative substrate-interacting domain 
displayed decreased association with ubiquitinated proteins.  We also found that 
inhibition of proteasomal activity increased this association and that the ubiquitin chains 
were at least in part constituted of classical K48 linkages.  Interestingly, inhibition of 
K48 polyubiquitination specifically impaired Vpr-induced phosphorylation of H2AX, an 
early target of ATR, but did not affect UV-induced H2AX phosphorylation.  Overall, 
our results provide direct evidence that association of Vpr with the DDB1-CUL4A 
(VprBP) E3 ubiquitin ligase induces the K48-linked polyubiquitination of yet-unknown 
cellular proteins resulting in their proteasomal degradation and ultimately leading to 
activation of ATR and G2 arrest. 
 
INTRODUCTION 
 
Viruses have evolved ways to modulate the host cellular environment in order to 
promote efficient viral replication and to disrupt elements of innate or acquired 
immunity.   One strategy particularly favored by viruses to achieve these goals is to 
hijack components of the host ubiquitin-proteasome system in order to induce 
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degradation, block the degradation, or modulate the expression and activity of specific 
cellular factors [1-3]. Human immunodeficiency virus (HIV) is no exception to this 
precept.  HIV harbors two extensively studied accessory proteins, viral protein U (Vpu) 
and viral infectivity factor (Vif), that are usurping the cellular ubiquitin-proteasome 
system in order to respectively degrade neo-synthesized CD4 and the cytidine 
deaminases APOBEC3F (apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3F) and 3G [4].  Recently, we and several other investigators 
demonstrated that a third accessory protein of HIV, viral protein R (Vpr), would also 
exert its function by usurping the host ubiquitination machinery via recruitment of an E3 
ubiquitin ligase complex composed of VprBP (viral protein R binding protein, also 
known as DCAF1), damaged DNA binding protein 1 (DDB1) and Cullin 4A (CUL4A) 
[5-11].   
 
Ubiquitination is a post-translational modification that involves the isopeptidic 
covalent linkage of the C-terminus of a small protein called ubiquitin most commonly to 
lysine acceptor residues.  Conjugation of ubiquitin is performed by E3 ubiquitin ligase 
complexes, which also control specificity via direct interaction with substrates [12,13].  
The Cullin-RING E3 ubiquitin ligases (CRL) structured around the scaffold protein 
CUL4A (CRL4A) interact with the 126-kDa DDB1 adaptor in order to recruit substrate 
receptors of the WDxR family [14].  Mass spectrometric analyses of CUL4A-DDB1 
complexes have revealed physical interactions to at least 30 different WDxR substrates 
receptors [15-18], suggesting that CRL4A E3 ligases would likely regulate the function 
of hundreds of cellular proteins.  Surprisingly however, relatively few cellular proteins 
have been shown to date to be regulated by these complexes. CRL4A (DDB2) promotes 
the ubiquitination of histone 2A, 3 and 4 [19,20], of xeroderma pigmentosum group C 
protein (XPC) [21] and probably of xeroderma pigmentosum group A protein (XPA) 
[22] to facilitate UV damage repair.  CRL4A (CSA) and CRL4A (DET1-COP1) induce 
the proteolysis of respectively Cockayne syndrome type B gene product (CSB) [23] and 
c-JUN [24]. PCNA (proliferating cell nuclear antigen), via the recruitment of a CRL4A 
(CDT2) ligase, has been shown to regulate the degradation of the replication licensing 
factor CDT1 [25,26] as well as of the CDK inhibitor p21 [27,28].  The 180-kDa 
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VprBP/DCAF1 WDxR substrate receptor was identified more than a decade ago as a 
Vpr-interacting protein and was found to be expressed at the mRNA level in most 
tissues [29,30].  However, its normal cellular functions remained elusive until recently.  
Huang and Chen demonstrated that CRL4A (VprBP) induces the rapid degradation of 
the tumor suppressor Merlin (NF2, neurofibromin 2) following serum stimulation [31].  
Moreover, depletion of VprBP reduced the rate of DNA replication, blocked cells in S-
phase, and impeded cellular proliferation [10,32].  Consequently, genetic ablation of 
VprBP in mouse [32] and in the evolutionary distant Arabidopsis thaliana [33] led to 
embryonic lethality, suggesting an essential role for VprBP in cell cycle as well as in 
development. 
 
 The small HIV-1 accessory protein Vpr induces a cell cycle arrest in the G2/M 
phase in various cell types including transformed cell lines as well as primary 
lymphocytes [34-36]. Notably, abnormal accumulation of infected cells in G2 can be 
observed in tissues from patients infected by HIV-1 [36].  Although the function of this 
cell cycle arrest has remained elusive, its molecular mechanism has recently begun to be 
elucidated.  Several investigators reported that Vpr activates the canonical ATR (ataxia 
telangiectasia and Rad3 related) DNA damage/stress checkpoint [36-40].  Vpr-mediated 
activation of ATR is accompanied by the formation of DNA repair foci that include 
RPA (replication protein A), HUS1, RAD17, BRCA1 (breast cancer 1, early onset), 
TP53BP1 (tumor protein p53 binding-protein 1), and γ-H2AX (phosphorylated histone 
2A variant X) [36-38,40] and by activation of the CHK1 kinase [39].  This series of 
events leads to inactivation of the CDC2/cyclin B complex, a master regulator of the G2 
to M transition, and ultimately prevents entry into mitosis.    In addition, Vpr was 
recently found to associate with DDB1 and CUL4A via a direct interaction with VprBP 
[5-11].   Depletion of VprBP by RNA interference drastically impaired Vpr-mediated 
G2 arrest.  Similarly, mutations of Vpr in the hydrophobic leucine-rich core region 
abrogated binding to CRL4A (VprBP) and concomitantly impaired G2 arrest.  In 
contrast, mutants of Vpr in the C-terminal arginine-rich domain were not compromised 
for the association with the E3 ligase but nevertheless failed to induce G2 arrest [5-11].  
These later mutants also displayed trans-dominant negative activity [11], thus indicating 
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that the recruitment of this E3 ubiquitin ligase is essential but not sufficient to induce G2 
arrest.  The simplest explanation for these observations is that Vpr would recruit cellular 
substrates to be ubiquitinated by the complex.  Ubiquitination of these yet-unknown 
proteins would lead to their degradation or modulation of their activity, ultimately 
resulting in ATR activation and G2 arrest [41].  This is not the only instance in which 
Vpr would be implicated in the degradation of a cellular protein.  Vpr directly interacts 
and induces the proteasomal degradation of the cellular enzyme UNG2 (uracil-DNA 
glycosylase 2; also known as CCNO) independently of the induction of a cell cycle 
arrest [6,42].  Vpr-induced degradation of UNG2 was found to be mediated by DDB1 
[6] but surprisingly did not require VprBP [9].  In addition, viral protein X (Vpx), a 
paralog of Vpr present in HIV-2 and some SIV isolates, is also able to recruit CRL4A 
(VprBP) [5,43-45].  In contrast to Vpr, Vpx does not induce G2 arrest, but counteracts a 
putative cellular restriction factor expressed in macrophages and dendritic cells that 
targets a post-entry step critical for efficient reverse transcription [4]. Importantly, the 
presence of an active proteasome system and the recruitment of CRL4A (VprBP) by 
Vpx were shown to be required for the inhibition of the restriction factor, suggesting 
that, similarly to Vpr, Vpx would act via the CRL4A (VprBP)-mediated ubiquitination 
and proteasomal degradation of cellular proteins [43-46]. 
 
 While very attractive, this model is however solely based on the indirect 
observation that some C-terminal mutants of Vpr retain their interaction with the E3 
ligase but fail to induce G2 arrest.  Other models for the activity of Vpr have also been 
proposed and include inhibition of DDB1 functions [6] or overall increased activity of 
CRL4A (VprBP) [10].  Moreover, it is unclear whether this association of Vpr with 
CRL4A (VprBP) is the result of overexpression in transformed cell lines and whether 
this interaction would occur during infection of primary lymphocytes. Therefore, we 
sought to confirm the physiological significance of the Vpr-VprBP interaction as well as 
obtain more direct evidence that Vpr is indeed recruiting cellular proteins and inducing 
their ubiquitination and proteasomal degradation. Herein, we show that Vpr interacts 
with VprBP and DDB1 during infection of primary CD4+ T-lymphocytes.  In addition, 
using a tandem affinity approach and overexpression of a dominant-negative tagged 
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ubiquitin mutant, we observed that wild type Vpr could specifically associate with 
unknown ubiquitinated cellular proteins and that this interaction required the recruitment 
of an active CRL4A (VprBP) E3 ubiquitin ligase complex.  Moreover, C-terminal G2-
arrest-defective mutants of Vpr displayed reduced association to these ubiquitinated 
proteins. We also provide evidence that Vpr induces the K48-linked polyubiquitination 
of these cellular proteins leading to their rapid proteasomal degradation.  Finally, these 
Vpr-induced ubiquitination events were specifically necessary for Vpr to induce 
phosphorylation of H2AX, an early marker of ATR-mediated DNA damage/stress 
checkpoint activation. 
RESULTS 
 
Vpr associates with VprBP and DDB1 in primary CD4+ lymphocytes 
 The interaction between Vpr and the CRL4A (VprBP) E3 ubiquitin ligase and 
its functional importance for Vpr-induced G2 arrest, although strongly established, were 
however solely demonstrated by overexpression studies in transformed cell lines.  In 
order to determine whether Vpr could recruit the CRL4A (VprBP) E3 ubiquitin ligase in 
more physiological conditions, primary CD4+ T-lymphocytes were infected with 
HxBru-derived virus expressing hemagglutinin (HA)-tagged Vpr (HA-Vpr) or deleted 
for Vpr at a multiplicity of infection of 0.01.  Five days after infection, cells were 
harvested and subjected to immunoprecipitation using anti-HA-conjugated agarose 
beads and immunoprecipitated proteins were detected by western blot.  Endogenous 
VprBP and DDB1 could be detected in the lysate of activated primary CD4+ T-
lymphocytes, thus confirming their expression at the protein level (Fig 1).  Co-
immunoprecipitation of VprBP and DDB1 could be observed in cells infected with 
HxBru (HA-Vpr) viruses but not in HxBru (Vpr-) or mock-infected cells (Fig 1).  
Therefore, recruitment of VprBP and DDB1 by Vpr occurs in conditions mimicking an 
in vivo infection and is thus not the result of overexpression of Vpr in transformed cell 
lines.     
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Vpr interacts with ubiquitinated cellular proteins 
 We next sought to obtain additional data on the mechanisms by which Vpr 
utilizes this complex to induce G2 arrest. If Vpr indeed acts as a connector between an 
E3 ubiquitin ligase complex and cellular proteins and that this association leads to 
ubiquitination of these substrates, we hypothesized that we should be able to observe 
Vpr interacting with some of these unknown ubiquitinated proteins.  To assess this 
premise, we developed a tandem affinity purification (TAP) procedure [7] that takes 
advantage of a Myc-tagged ubiquitin K48R mutant with the unusual properties of acting 
as a weak chain terminator and stabilizing polyubiquitinated products [47,48].  Of note, 
the TAP-tagged Vpr (TAP-Vpr) construct used in the procedure is able to induce G2 
arrest although to a lower extent than untagged native Vpr (Fig S1 and [7]).  In these 
conditions, we were able to detect an interaction between TAP-Vpr and unknown 
cellular ubiquitinated proteins, as revealed by the anti-Myc-reacting protein smear in the 
TAP-Vpr pulldown, but not with the TAP tag alone (Fig 2A).  This association was also 
detected in stringent extraction conditions such as in RIPA buffer and in high salt buffer 
(400 mM NaCl) (data not shown).  The Myc-tagged ubiquitination signal detected in 
presence of pulled-down Vpr was the result of bound cellular ubiquitinated proteins and 
not of ubiquitination of Vpr itself since heat-denaturation of proteins in RIPA buffer 
prior to purification of TAP-Vpr complexes abolished this signal. (Fig 2B, compare lane 
3 to lane 4)   For this experiment, we could not perform the full tandem affinity 
purification procedure because the TAP tag could not bind to calmodulin beads 
following denaturation. Consequently, these experiments involved solely an IgG 
pulldown step, hence explaining why the enrichment of ubiquitination observed with 
Vpr is less important in this particular condition (Fig 2B, compare lane 3 to lane 1).  
Nevertheless, retention of the ubiquitination signal under denaturating conditions would 
have indicated that this ubiquitination originated from ubiquitin covalently conjugated to 
Vpr itself and not to associated proteins.  Therefore, in agreement with our model, Vpr 
is capable of associating with ubiquitinated cellular proteins.   
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Recruitment of a catalytically active CRL4A (VprBP) complex is required to observe 
Vpr-associated ubiquitinated proteins   
 This association of Vpr with cellular ubiquitinated proteins suggests that these 
proteins might be ubiquitinated by Vpr following recruitment of the CRL4A (VprBP) 
E3 ubiquitin ligase.  On the other hand, these cellular proteins might be already 
ubiquitinated as part of their normal metabolism before their interaction with Vpr and 
would thus not constitute substrates of the Vpr ubiquitin ligase complex.  To distinguish 
between these two possibilities, we analyzed the effect of knocking down VprBP on the 
association of Vpr with ubiquitinated proteins.  Transient depletion of VprBP with 
shRNA (small hairpin RNA) resulted in a significant decrease in the association of Vpr 
with cellular ubiquitinated proteins (Fig 3A, compare lanes 3 and 4), suggesting that the 
association of ubiquitinated proteins to Vpr involves the recruitment of the CRL4A 
(VprBP) E3 ligase.  Moreover, overexpression of a dominant negative construct of 
CUL4A (Cul4A DN) produced a similar decrease in the association of TAP-Vpr with 
ubiquitinated proteins, thus corroborating the results obtained with the depletion of 
VprBP and indicating that the CRL4A (VprBP) E3 ligase must be catalytically active in 
order to detect these Vpr-associated ubiquitinated proteins (Fig 3B, compare lanes 3 and 
4).  However, these results do not exclude the possibility that this association of Vpr 
with ubiquitinated proteins might result from the sole association with ubiquitinated 
components of the E3 ligase complex without necessarily implicating ubiquitinated 
substrates.    
 
  To address this issue, we investigated this association in the context of Vpr 
mutants defective for their interaction with the E3 ligase or for the putative G2 arrest 
substrate protein. Surprisingly, the Q65R mutation in Vpr, which results in a strong 
reduction of the interaction with VprBP and DDB1 [5,7,8,11], displayed an increased 
association with ubiquitinated proteins (Fig 4A), independently of its higher level of 
expression.  These unexpected results may be explained by non-specific interactions that 
might result from the accumulation of this non-functional mutant protein.  To test 
whether the association of Vpr (Q65R) with ubiquitinated proteins was independent of 
the recruitment of CRL4A (VprBP), we constructed 293T-based stable monoclonal cell 
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lines expressing shRNA against VprBP or non-targeting scrambled shRNA control (Fig 
S2A).  Importantly, we did not detect any significant effect of VprBP depletion on the 
cell cycle profile (Fig S2B).  We did however observe a slight decrease in the growth 
kinetics of these cells (Fig S2C) but it did not result in a significant increase in apoptosis 
(Fig S2D).  The level of stable VprBP knockdown achieved in this cell line was 
sufficient to almost completely abolish Vpr-mediated G2 arrest compared to the 
scrambled control cell line (Fig S2E).  We then used this pair of cell lines to assess the 
levels of cellular ubiquitinated proteins associated with the Q65R mutant of Vpr.    As 
expected, the increased association of ubiquitinated proteins with Vpr (Q65R) was 
independent of the recruitment of the E3 ligase given that depletion of VprBP did not 
affect the levels of ubiquitinated proteins associated with this mutant of Vpr (Fig 4A, 
compare lanes 5 and 6).  In comparison, in this system, we observed a significant 
reduction of the association of wild type Vpr with ubiquitinated proteins in the VprBP-
knocked-down cell line versus the control cell line (Fig 4A, compare lanes 3 and 4), 
corroborating results obtained with transient knockdown experiments.  Therefore, we 
hypothesize that the Q65R mutation, in addition to its effect on the binding to VprBP, 
might also results in major conformational defects that would lead to this non-specific 
association to ubiquitinated proteins.  Indeed, we observed that, in contrast to wild type 
Vpr which oligomerizes and displays a nuclear localization, Vpr (Q65R) accumulates in 
part in the cytoplasm as discrete puncta and also fails to efficiently oligomerize 
(manuscript in preparation).  We also investigated the effect of a C-terminal deletion of 
Vpr, Vpr (1-78), a mutant that fails to induce G2 arrest (Fig S1) while maintaining the 
interaction with VprBP [5].  Importantly, Vpr (1-78), which should thus not interact 
with the putative substrate responsible for G2 arrest, failed to interact with ubiquitinated 
proteins (Fig B, compare lanes 2 and 3).  Other deletions (1-84, 1-86, 1-90) or point 
mutations (R87A, R88A) in the C-terminal domain impaired G2 arrest (Fig S1) and led 
to a significant decrease of the association with ubiquitinated proteins (Fig. 4C) while 
maintaining their association to VprBP (data not shown).  Our data indicate that these 
proteins are not solely ubiquitinated UNG2 molecules given that C-terminal deletions of 
Vpr retain their interaction with UNG2 [49].  Therefore, in agreement with our model, 
these data further indicate that the putative G2 arrest substrate(s) is ubiquitinated in 
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presence of Vpr and that abrogation of Vpr-substrate(s) or Vpr-CRL4A (VprBP) 
interactions impairs Vpr-mediated ubiquitination.  Overall, these results provide direct 
interaction-based evidence that Vpr acts as a connector between an E3 ubiquitin ligase 
complex and substrate proteins.  
 
Vpr induces the K48-linked polyubiquitination of cellular proteins leading to their 
proteasomal degradation  
 To determine the fate of proteins ubiquitinated by Vpr, we used the tandem 
affinity purification method in combination with an HA-tagged ubiquitin construct 
which does not significantly stabilize polyubiquitinated products and does not protect 
substrates from proteasome degradation [50].  In this system, we detected ubiquitinated 
proteins associated with Vpr (Fig 5A), but the ubiquitination signal detected in these 
conditions did not rely on the recruitment of the E3 ligase complex since knockdown of 
VprBP did not have any effect on the levels of ubiquitination (data not shown), 
suggesting that in absence of interference with polyubiquitination, the Vpr-targeted 
substrates might be rapidly degraded.  In support of this scenario, a 16-hour treatment of 
cells co-expressing HA-Ub and TAP-Vpr with the proteasome inhibitor MG132 resulted 
in an increased association of Vpr with cellular ubiquitinated proteins (Fig 5A, compare 
lanes 3 and 4).  We could also observe an increase of polyubiquitinated proteins for 
shorter MG132 treatment (5 hours) but to a lesser extent (data not shown).  Most 
notably, this significant increase in levels of HA-polyubiquitinated proteins associated 
with Vpr following treatment with MG132 required the recruitment of the E3 ligase 
because depletion of VprBP with shRNA drastically reduced the extent of 
polyubiquitination (Fig 5B).  Therefore, these results suggest that following 
polyubiquitination by the Vpr-CRL4A (VprBP) complex, substrates are rapidly 
degraded by the proteasome.   
 
 To determine whether the observed degradation of Vpr-associated ubiquitinated 
proteins resulted from a classical K48-linked polyubiquitination, we analyzed the effect 
of the ubiquitin K48R mutation on Vpr-associated ubiquitination.  Cells were co-
transfected with plasmids expressing TAP or TAP-Vpr with either of HA-Ub (wt) or 
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HA-Ub (K48R).  In contrast to Myc-tagged Ub (K48R) which acts as a weak chain 
terminator and stabilizes polyubiquitin products [47,48], this HA-Ub (K48R) construct 
has been previously shown to potently block ubiquitin chain elongation through lysine 
48 [50].  We also used the polyubiquitination-null construct HA-Ub (K0), in which all 
lysines were mutated for arginines, as control.  Following MG132 treatment, the K48R 
mutation in ubiquitin significantly reduced the levels of ubiquitinated proteins 
associated with Vpr, compared to wild type ubiquitin (Fig 6, compare lanes 6 and 8).  
However, the reduction of ubiquitination did not reach the levels achieved with the K0 
mutation (Fig 6, compare lanes 7 and 8).  These data suggest that Vpr induces at least in 
part a classical K48-linked polyubiquitination of cellular substrate proteins, leading to 
their proteasomal degradation.  However, given that the levels of ubiquitination 
observed with the K48R mutant did not reach the ones observed with the 
polyubiquitination-null mutant K0, we cannot exclude the possibility that other lysine 
residues in ubiquitin might be involved in the formation of mixed ubiquitin linkages.     
   
Vpr-induced K48-polyubiquitination is required for phosphorylation of H2AX   
 Other investigators demonstrated that blocking the activity of the proteasome 
using small molecule inhibitors or blocking polyubiquitination via expression of a 
dominant negative mutant of ubiquitin (Ub K48R) abrogated Vpr-mediated G2 arrest 
[8,11].  However, caution has to be used when interpreting these results given that 
inhibition of polyubiquitination or proteasome function might have pleiotropic effects 
on checkpoint function without necessarily implicating the direct inhibition of Vpr’s 
activity.  Therefore, to evaluate the direct role of K48-linked polyubiquitination in Vpr’s 
activity, we instead monitored phosphorylation of  H2AX (γ-H2AX), an early marker of 
ATR–mediated checkpoint activation previously implicated in Vpr-mediated G2 arrest 
[37,38].  Following exogenously induced DNA damages, phosphorylation of H2AX 
occurs in absence of any ubiquitination events [51], and should thus not be directly 
affected by the K48R mutation in ubiquitin.  Indeed, ectopic expression of HA-Ub 
(K48R) or HA-Ub (K63R) in HeLa cells did not have any effect on the number of cells 
displaying γ-H2AX foci following UV irradiation (Fig S3).  To analyze the effect of Ub 
(K48R) on Vpr-induced γ-H2AX focus formation, we transiently transfected HeLa cells 
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with a plasmid expressing HA-Ub (K48R) or expressing HA-Ub (K63R) (used as 
negative control).  Twenty-four hours after transfection, cells were transduced with a 
lentiviral vector expressing GFP alone (WPI) or co-expressing Vpr and GFP (WPI-Vpr).  
Two days later, cells were processed for immunofluorescence detection using anti-HA 
antibody to detect HA-Ub-expressing cells, anti-GFP (to amplify the GFP signal, a 
marker of transduced cells) and with anti-phospho-H2AX (Fig 7A).  Cells with greater 
than ten γ-H2AX foci were considered positive.  In mock-transfected cells, transduction 
with the lentiviral vector expressing Vpr induced a significant increase in the percentage 
of cells positive for γ-H2AX compared to the control lentiviral vector (83.9% vs 12.3%, 
P<0.0001) (Fig 7A and 7B).   In presence of HA-Ub (K48R), we observed a drastic 
decrease in the number of Vpr-expressing cells with γ-H2AX foci (25.9% vs 83.9%, 
P<0.0005) (Fig 7A and 7B).  In contrast, overexpression of HA-Ub (K63R) only weakly 
altered the ability of Vpr to induce γ-H2AX foci, demonstrating the specific requirement 
for K48-linkages over other types of linkages. Therefore, overexpression of the K48R 
mutant of ubiquitin specifically inhibited Vpr-induced phosphorylation of H2AX (Fig 
7A and 7B) without affecting UV-induced phosphorylation of H2AX (Fig S3).  These 
observations thus suggest that K48-linked ubiquitination would be specifically essential 
for the activity of Vpr toward early checkpoint activation but not for exogenously 
induced DNA damages.    Therefore, taken together, our results provide direct evidence 
that Vpr recruits the CRL4A (VprBP) E3 ubiquitin ligase complex to induce the K48-
linked polyubiquitination of one or several yet-unknown cellular proteins resulting in 
their proteasomal degradation and ultimately leading to ATR-mediated phosphorylation 
of H2AX and G2 arrest. 
 
DISCUSSION 
 
 Identification of the substrates targeted by the Vpr-CRL4A (VprBP) complex 
represents an important aim not only to fully understand how Vpr activates ATR 
signaling and promote G2 arrest but also to comprehend the functional relevance of 
these biological activities. Given that Vpr induces a G2 cell cycle arrest, it is not 
conceivable to develop approaches that rely on the differential expression pattern of 
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proteins in the presence or absence of Vpr because Vpr cytostatic activity may affect the 
expression profile of numerous proteins without necessarily implicating a direct 
recruitment to the Vpr-CRL4A (VprBP) E3 ligase.  On the other hand, identification of 
substrates of E3 ubiquitin ligases by interaction-based proteomic analyses remains a 
long-standing challenge due to several different inherent and technical problems.  
Notably, ubiquitinated proteins are present at low abundance, display a rapid turnover 
rate and are subjected to rapid deconjugation [52,53].  Therefore, special care must be 
taken to enrich and stabilize ubiquitin conjugates using tagged ubiquitin constructs or 
proteasome inhibitors.  To demonstrate a potential interaction of Vpr with its cognate 
ubiquitinated substrates, we used a combination of both approaches.  First, we used a 
Myc-tagged ubiquitin K48R mutant with the unusual properties of acting as a weak 
chain terminator and stabilizing polyubiquitinated products [47,48] coupled with a 
highly specific tandem affinity purification procedure [7] in order to enrich Vpr-
interacting ubiquitinated proteins.  With this method, we were able to show a specific 
interaction between Vpr and cellular ubiquitinated proteins (Fig 2A and 2B).  Secondly, 
using a HA-tagged ubiquitin construct concomitantly with treatment with the 
proteasome inhibitor MG132, we were also able to reveal a specific association of Vpr 
with cellular ubiquitinated proteins (Fig 5A).  In both cases, a significant part of the 
Vpr-associated ubiquitinated signal was dependent on the recruitment of an active 
CRL4A (VprBP) ligase since depletion of VprBP by shRNA (Fig 3A and Fig 5B) as 
well as overexpression of a dominant-negative form of CUL4A (Fig 3B) drastically 
reduced this association.  Surprisingly, the Q65R mutation in Vpr, which virtually 
abrogates the interaction with VprBP and should thus reduce binding to ubiquitinated 
proteins, had the opposite effect: it increased the interaction with ubiquitinated proteins 
(Fig 4A).  However, we observed that the Q65R mutation led to accumulation of 
substantial amounts of Vpr in the cytoplasm and to inefficient oligomerization of the 
protein (manuscript in preparation), indicating that this mutation has pleiotropic effects 
on the functions of Vpr and probably induces conformational defects.  Therefore, 
knockdown of VprBP and the use of a dominant-negative mutant of CUL4A, both of 
which reduced binding to ubiquitinated proteins, represent a more reliable assessment of 
the role of the E3 ligase in the association of Vpr with ubiquitinated proteins.  
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Importantly, deleting the entire putative substrate-interacting C-terminal domain of Vpr 
resulted in an abrogation of G2 arrest (Fig S1) and of the association with ubiquitinated 
proteins (Fig 4B), indicating that these Vpr-associated ubiquitinated proteins are 
probably not components of the E3 ligase itself.    Shorter deletions or point mutation in 
the C-terminal domain of Vpr also led to an inhibition of G2 arrest (Fig S1) and to a 
significant reduction in binding to ubiquitinated proteins (Fig 4C) suggesting that at 
least a significant fraction of these Vpr-associated ubiquitinated proteins would be 
substrates forcibly recruited by Vpr to the E3 ligase.  Given that C-terminal deletions of 
Vpr retain their interaction with UNG2 [49], our data indicate that these ubiquitinated 
proteins do not contain detectable levels of ubiquitinated UNG2, therefore excluding the 
possibility that they are solely ubiquitinated UNG2.   These are most likely substrates 
independently recruited by Vpr rather than an increased ubiquitination of VprBP’s own 
substrates because overexpression of the minimal Vpr-interacting domain of VprBP was 
reported to increase the association of Vpr with DDB1 as well as the efficiency of Vpr-
mediated G2 arrest [5].  It is arguably unlikely that this minimal domain, which also 
contains the WDxR motif responsible for the association with DDB1 [5,18], would also 
possess the determinants mediating substrate recognition.  Finally, our results do not 
contradict the previous observations that Vpr would increase neddylation of CRL4A 
(VprBP) [10] given that recruitment of substrates as well as substrate adaptors to CRL 
complexes, including CRL4A ligases, were shown to markedly promote neddylation 
[54]. 
 
 As mentioned above, we found that MG132 stabilized Vpr-associated HA-
tagged ubiquitinated protein (Fig 5A), suggesting that in absence of MG132, Vpr’s 
substrates would be degraded by the proteasome.  Indeed, in support of this 
interpretation, in absence of proteasome inhibition, the association of Vpr with cellular 
ubiquitinated proteins was independent of the recruitment of CRL4A (VprBP) (data not 
shown) whereas, when cells were treated with MG132, depletion of VprBP significantly 
decreased the levels of Vpr-associated ubiquitinated proteins (Fig 5B).   Moreover, Vpr 
was found to induce, at least in part, the classical K48-linked polyubiquitination of its 
substrates (Fig 6), thus further supporting our evidence that these substrates are 
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degraded by the proteasome given that this type of homopolymeric ubiquitin chain 
generally leads to proteasomal proteolysis [55,56].   
 
 Several investigators reported that Vpr activates ATR in a variety of cell types 
including primary CD4+ T-lymphocytes.  Vpr-mediated activation of ATR was 
accompanied by the formation of DNA repair foci that included RPA, HUS1, RAD17, 
BRCA1, TP53BP1, and ϒ-H2AX.  In contrast to other investigators that have used 
accumulation of cells in G2/M as a marker of Vpr activity [8,11], we reasoned that using 
an early marker of checkpoint activation would likely constitute a more direct and less 
ambiguous strategy to assess the role of Vpr-mediated ubiquitination in its G2 arrest 
function.  Phosphorylation of H2AX represents such a marker.  Indeed, Mailand et al 
recently reported that MG132-mediated depletion of nuclear ubiquitin did not impair 
phosphorylation of H2AX in response to exogenous genotoxic stresses such as DNA 
double-strand breaks induced by ionizing radiation [51].  Moreover, overexpression of 
HA-tagged Ub (K48R) or Ub (K63R) in HeLa cells did not inhibit H2AX 
phosphorylation following UV irradiation (Fig S3).  Therefore, H2AX phosphorylation 
appears to be independent of ubiquitination.  In contrast, in the case of Vpr-induced 
H2AX phosphorylation, overexpression of Ub (K48R) but not Ub (K63R) significantly 
reduced H2AX phosphorylation (Fig 7A and 7B), suggesting that this effect was most 
probably due to a direct inhibition of Vpr-induced K48-polyubiquitination rather than a 
pleiotropic inhibition of checkpoint function.  These functional data demonstrating the 
role of Vpr-induced ubiquitination in its G2 arrest activity are also supported by 
biochemical evidence whereby G2-arrest-defective mutants of Vpr in the putative C-
terminal substrate-recruitment domain, still competent for association with CRL4A 
(VprBP), failed to interact with ubiquitinated cellular proteins (Fig 4B).  Therefore, 
taken together, our results strongly suggest that Vpr-mediated K48-linked ubiquitination 
and degradation of one or several putative substrates are responsible for Vpr-induced G2 
arrest.   
 
 Zimmerman and colleagues previously observed that Vpr was unable to induce 
checkpoint activation in macrophages due to the absence of ATR in these cells, while 
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gamma irradiation led to ATM (ataxia telangiectasia mutated) activation [36].  
Importantly, Vpr did not appear to cause DNA double-strand breaks in cycling cells in 
conditions where ATR was activated [37]. The authors concluded that Vpr likely causes 
DNA replication stresses rather than direct DNA damages such as DNA double-strand 
breaks that would otherwise activate ATM [36]. Thus, it would appear that the cellular 
substrate(s) targeted by Vpr might have important roles in DNA replication and that its 
degradation by Vpr would cause DNA replication stress as demonstrated by the 
formation of RPA foci [37], ultimately leading to ATR activation [39] and accumulation 
of cells in G2/M.  Interestingly, Vpr was previously shown to form nuclear foci that co-
localized with DNA repair foci containing γ-H2AX and RPA [37].  It would be tempting 
to speculate that Vpr would recruit CRL4A (VprBP) onto chromatin to degrade directly 
at this site a chromatin-bound component of the DNA replication machinery.  
Alternatively, the degradation of the substrate(s) might not directly cause DNA 
replication stresses but might somehow mimic signals induced by those.  Recently, 
forced tethering of DNA repair factors including ATM, MDC1 (mediator of DNA 
damage checkpoint 1) and NBS1 (Nijmegen breakage syndrome 1, nibrin) to chromatin 
was shown to induce the formation of fully competent DNA repair foci in absence of 
any DNA damages [57].  It is thus conceivable that ubiquitination and degradation of a 
DNA repair regulator(s) by Vpr might somehow induce the incorrect recruitment of 
DNA repair proteins to chromatin in absence of any DNA replication stress.   
 
 In conclusion, using a tandem affinity purification approach, we provide 
additional and more direct evidence that Vpr recruits the CRL4A (VprBP) E3 ubiquitin 
ligase complex to induce the K48-linked polyubiquitination of one or several putative 
substrates, resulting in their proteasomal degradation.  Proteolysis of these putative 
substrates would lead to phosphorylation of H2AX, an early target of ATR activation, 
and ultimately G2 arrest.  Identification of the cellular proteins degraded by Vpr will be 
central in the understanding of how Vpr triggers ATR activation and why Vpr induces a 
cell cycle arrest.  The tandem affinity purification procedure presented in this study 
represents a powerful approach to isolate and identify cellular ubiquitinated substrates 
interacting with Vpr.  
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MATERIALS AND METHODS 
 
Cell lines and antibodies 
HEK293T and HeLa cells were cultured as previously described [58].  The anti-HA tag 
and anti-Myc tag monoclonal antibodies were, respectively, clones 12CA5 and 9E10.  
Rabbit polyclonal antibodies against VprBP and DDB1 were respectively obtained from 
Accurate Chemical and Scientific Corporation (Westbury, NY, USA) and Santa Cruz 
Biotechnology (Santa Cruz, CA, USA).  Vpr was detected using a rabbit polyclonal 
antibody directed against a Vpr N-terminal peptide [59].  The anti-GFP antibody was 
obtained from Molecular Probes (Invitrogen, San Diego, CA, USA) and the anti-
phospho-H2AX (Ser139) antibody was clone JBW301 from Upstate (Millipore, 
Billerica, MA, USA).  The rabbit anti-actin antibody was obtained from Sigma-Aldrich 
(St. Louis, MO, USA) 
 
Plasmid construction 
Plasmids SVCMV-TAP, SVCMV-TAP-Vpr (WT), and SVCMV-TAP-Vpr (Q65R) 
were described previously [7].  Plasmids expressing TAP-Vpr (1-78), TAP-Vpr (1-86), 
and TAP-Vpr (R87A, R88A) were generated by subcloning the SalI-BamH1 fragment 
from respectively SVCMV-3HA-Vpr (1-78), SVCMV-3HA-Vpr (1-86), and SVCMV-
3HA-Vpr (R87A, R88A) [60] into SVCMV-TAP-Vpr (WT).   Plasmids expressing 
TAP-Vpr (1-84) and TAP-Vpr (1-90) were generated by PCR using a strategy described 
previously [7].  Plasmids expressing Myc-His-tagged ubiquitin K48R [48] and HA-
tagged ubiquitin (WT, K0, and K48R) [50] were kind gifts of Dr R. Kopito (Stanford 
University, CA, USA) and Dr T. Dawson (Johns Hopkins University, Baltimore, USA).  
The plasmid expressing HA-Ub (K63R) was constructed by site-directed mutagenesis 
using the Quickchange II mutagenesis kit (Stratagene, La Jolla, CA, USA).  The GFP-
expressing plasmid pQBI-25 was obtained from Qbiogene (Carlsbad, CA, USA).  
Vectors expressing scrambled shRNA and VprBP shRNA were obtained from Open 
Biosystems (Huntsville, AL, USA).  The CUL4A dominant-negative construct [9] was 
kindly donated by Dr C. de Noronha (University of Albany, NY, USA).  The 
construction of the infectious molecular clone HxBru (Vpr-) was described previously 
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[61].  HxBru (HA-Vpr) was generated by PCR by adding an HA-tagged at the N-
terminus of Vpr, which resulted in the addition of 9 extra amino acids at the C-terminus 
of Vif.  The lentiviral vectors WPI and WPI-Vpr as well as the SVCMV-IN-VSV-G 
expression construct were described previously [7]. 
 
Transfection, tandem affinity purification (TAP) and immunoprecipitation 
HEK293T cells were transfected using the calcium phosphate precipitation method. 
Forty-eight hours later, cells were harvested, washed and lysed in triton lysis buffer (50 
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% Triton X-100, and complete protease 
inhibitors) or RIPA buffer (8 mM Na2HPO4 pH 7.2, 2 mM NaH2PO4, 140 mM NaCl, 
1% NP-40, 0.05% SDS, 12 mM deoxycholate, and complete protease inhibitors). 
Tandem affinity purification was performed as described previously [7]. In some 
experiments, where indicated, IgG pulldown assays were performed instead of the full 
tandem affinity purification, as described previously [7].    Immunoprecipitations were 
performed using 50 ul of 50% anti-HA-coupled agarose beads (Sigma-Aldrich, St. 
Louis, MO, USA) followed by extensive washes in triton lysis buffer and elution with 
100 µg/ml HA peptide.  Eluted proteins were separated on a 12.5% SDS-PAGE gel and 
western blot analyses of eluted proteins were performed.  Ubiquitinated proteins were 
revealed using monoclonal antibodies directed at Myc or HA tags depending on the 
ubiquitin construct used. 
 
Production and titration of viruses and viral vectors 
The production and titration of infectious viral particles as well as of the lentiviral 
vectors expressing GFP (WPI) or co-expressing GFP and Vpr (WPI-Vpr) were 
performed as described previously [7,60].  Murine leukemia virus-based retroviral 
vectors expressing VprBP-targeting (ShVprBP) or scrambled control (shControl) 
shRNA were produced by transfection of 15 µg of vector, 12 µg of the packaging 
construct pCIG3-N [62], and 5 µg of the VSV-G-expressing plasmid pSVCMV-IN-
VSV-G in 1.5 million HEK293T cells using the calcium phosphate precipitation 
method.  Vector-containing supernatants were 0.45 micron-filtered and used 
immediately. 
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Infection of primary lymphocytes 
Peripheral blood mononuclear cells (PBMCs) were extracted by the Ficoll method from 
whole blood obtained from consenting healthy adult donors who gave written informed 
consent under research protocols approved by the research ethics review board of the 
Institut de recherches cliniques de Montreal.  CD4+ T-lymphocytes were purified from 
PBMCs by magnetic negative selection using the CD4+ T cell isolation Kit II and the 
AutoMACS Pro system according to the manufacturer instructions (Miltenyi Biotec, 
Auburn, CA, USA).  CD4+ T-cells were cultured as previously described [60].  Ten 
millions activated CD4+ cells were mock-infected or infected with HxBru (Vpr-) or 
HxBru (HA-Vpr) viruses at a MOI of 0.01.   Five days after infection, cells were lysed 
in triton lysis buffer and subjected to anti-HA immunoprecipitation as described above. 
 
Fluorescence immunohistochemistry  
Fifty thousand HeLa cells were seeded on cover slips in 24-well plates and transfected 
with lipofectamine 2000 reagent according to the manufacturer’s intruction.  Twenty-
four hours after transfection, cells were transduced with WPI or WPI-Vpr at a 
multiplicity of infection of 2.5 in presence of 8 µg/ml polybrene.  Two days later, cells 
were processed for confocal fluorescence immunohistochemistry as previously 
described [63]. 
 
Generation of HEK293T cells with stable depletion of VprBP 
HEK293T cells were transduced with ShControl and ShVprBP retroviral vectors in 
presence of 8 µg/ml polybrene.  Two days after transduction, cells were selected for 10 
days with 1 µg/ml puromycin and single-cell clones were then isolated by the limited 
dilution method.  Western blot were performed on ShControl- and ShVprBP-transduced 
stable clones and the clone with the most significant decrease in VprBP expression was 
selected. 
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Cell cycle, cell proliferation and apoptosis assays 
Cell cycle profiles were determined by flow cytometry using propidium iodide staining 
as previously described [7].  Apoptosis was assayed by flow cytometry using Annexin V 
and propidium iodide as a dead cell counter-stain as described previously [58].  Cell 
proliferation kinetics was monitored by flow cytometry using a standard CFSE 
(carboxyfluorescein succinimidyl ester) assay. 
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FIGURES 
 
FIGURE 1.  Vpr interacts with VprBP and DDB1 during infection of primary 
CD4+ T-lymphocytes.   
Ten millions activated primary CD4+ T-lymphocytes were mock-infected or infected 
with viruses defective for Vpr (HxBru Vpr-) or encoding HA-tagged Vpr (HxBru Ha-
Vpr) at a multiplicity of infection of 0.01.  Five days after infection cells were harvested 
in triton lysis buffer and immunoprecipitation against HA was performed as described in 
Materials and Methods.  Co-immunoprecipitated endogenous VprBP and DDB1 were 
detected by western blot using specific rabbit polyclonal antibodies.  HA-tagged Vpr 
was detected using a monoclonal anti-HA antibody. 
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FIGURE 2. Vpr interacts with unknown cellular ubiquitinated proteins.   
A) HEK293T cells were transfected with plasmids encoding TAP (lanes 1 and 3) or 
TAP-Vpr (lanes 2 and 4).   Cells were co-transfected with either an empty plasmid 
(lanes 1 and 2) or a Myc-Ub (K48R)-encoding plasmid (lanes 3 and 4).  Two days later, 
tandem affinity purification was performed on cell lysates as described in Materials and 
Methods.  The levels of ubiquitinated proteins were determined by western blot in crude 
lysates and pulled-down fractions using a monoclonal anti-Myc antibody.  B) Cells were 
co-transfected with plasmids expressing TAP-Vpr and Myc-Ub (K48R) (lanes 3 and 4) 
or with plasmids expressing TAP and Myc-Ub (K48R) as control (lanes 1 and 2).  Forty-
eight hours post-transfection, cells were lysed in triton lysis buffer (lanes 1 and 3) or 
heat-denatured following lysis in RIPA buffer (lanes 2 and 4).  Cell extracts were 
subjected to IgG pulldowns using pre-coupled beads and complexes were eluted 
following cleavage with tobacco etch virus (TEV) protease.  The levels of ubiquitinated 
proteins were determined using a monoclonal anti-Myc antibody and Vpr was detected 
using a polyclonal antibody. 
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FIGURE 3. Association of Vpr with ubiquitinated proteins involves the 
recruitment of an active E3 ubiquitin ligase complex.   
HEK293T cells were co-transfected with a plasmid encoding Myc-Ub (K48R) and with 
either TAP- (lanes 1 and 2) or TAP-Vpr-encoding plasmids (lanes 3 and 4). Cells were 
transcomplemented with A) plasmids expressing scrambled shRNA or shRNA targeting 
VprBP and B) with an empty plasmid or a plasmid encoding a dominant-negative 
mutant form of CUL4A (Cul4A DN) as indicated.  Two days after transfection, cell 
extracts were subjected to tandem affinity purification as described in Materials and 
Methods.  The levels of ubiquitinated proteins were determined by western blot in crude 
lysates and pulled-down fractions using a monoclonal anti-Myc antibody.  Vpr and 
VprBP were detected using polyclonal antibodies. * Denotes a non-specific band 
detected by the anti-VprBP antibody used as a loading control. 
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FIGURE 4. Analysis of the association of Vpr mutants with ubiquitinated proteins.  
A) HEK293T monoclonal cell lines stably expressing a control shRNA (ShControl) or a 
shRNA against VprBP (ShVprBP) were co-transfected with a plasmid encoding Myc-
Ub (K48R) and plasmids expressing TAP, TAP-Vpr (WT), or TAP-Vpr (Q65R) as 
indicated.  Two days after transfection, cell extracts were subjected to tandem affinity 
purification as described in Materials and Methods.  B) HEK293T cells were co-
transfected with a plasmid encoding Myc-Ub (K48R) and plasmids expressing TAP, 
TAP-Vpr (WT), and TAP-Vpr (1-78) as indicated.  Cell extracts were processed as in 
panel A.  C) HEK293T cells were co-transfected with a plasmid encoding Myc-Ub 
(K48R) and plasmids expressing TAP, TAP-Vpr (WT), TAP-Vpr (R87A, R88A), TAP-
Vpr (1-84), TAP-Vpr (1-86), and TAP-Vpr (1-90), as indicated.   Two days after 
transfection, cell extracts were subjected to tandem affinity purification as described in 
Materials and Methods.  Pulldown eluates (lanes 7, 8, 10, 12, 14, 16) and 2-fold 
dilutions of pulldown eluates (lanes 9, 11, 13, 15, 17) were resolved by SDS-PAGE for 
analysis.  For all panels, the levels of ubiquitinated proteins were determined by western 
blot in crude lysates and pulled-down fractions using a monoclonal anti-Myc antibody.  
Vpr and VprBP were detected using polyclonal antibodies.  * Denotes non-specific 
bands used as loading controls. 
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FIGURE 5. Vpr-associated ubiquitinated proteins are degraded by the proteasome. 
A) HEK293T cells were co-transfected with a plasmid encoding HA-Ub (WT) and with 
either TAP- (lanes 1 and 2) or TAP-Vpr-encoding plasmids (lanes 3 and 4).  Twenty-
four hours after transfection, cells were treated (lanes 2 and 4) or not (lanes 1 and 3) 
with 5 µM MG132 for 16 hours.  B) Cells were co-transfected with a plasmid encoding 
HA-Ub (WT) and with either TAP- (lanes 1 and 2) or TAP-Vpr-encoding plasmids 
(lanes 3 and 4). Cells were transcomplemented with plasmids expressing scrambled 
shRNA or shRNA targeting VprBP as indicated.  Twenty-four hours after transfection, 
cells were treated with 5 µM MG132 for 16 hours.  For both panels, cell extracts were 
subjected to tandem affinity purification.  Ubiquitinated proteins were detected using a 
monoclonal anti-HA antibody.  Vpr and VprBP were detected using polyclonal 
antibodies.  * Denotes a non-specific band detected by the anti-VprBP antibody used as 
a loading control. 
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FIGURE 6. Vpr induces the K48-linked polyubiquitination of unknown cellular 
substrates.   
HEK293T cells were transfected with a plasmid encoding either TAP (lanes 1 to 4) or 
TAP-Vpr (lanes 5 to 8).  Cells were transcomplemented with plasmids expressing HA-
Ub (WT) (lanes 2 and 6), HA-Ub (K0) (lanes 3 and 7), HA-Ub (K48R) (lanes 4 and 8) 
or with an empty plasmid as negative control (lanes 1 and 5).  Twenty-four hours after 
transfection, cells were treated with 5 µM MG132 for 16 hours and cell extracts were 
subjected to tandem affinity purification.  The levels of ubiquitinated proteins were 
determined by western blot in crude lysates and pulled-down fractions using a 
monoclonal anti-HA antibody.  Vpr was detected using a polyclonal antibody. 
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FIGURE 7. K48-linked polyubiquitination is required for Vpr-induced H2AX 
phosphorylation.  
A) HeLa cells were transiently transfected with an empty plasmid or plasmids 
expressing HA-Ub (K48R) or HA-Ub (K63R).  Twenty-four hours after transfection, 
cells were transduced with a lentiviral vector expressing GFP alone (WPI) or co-
expressing Vpr and GFP (Vpr).  Two days later, cells were fixed, permeabilized and 
stained with antibodies against GFP (green), γ-H2AX (red), and HA (blue).  Cells with 
more than ten γ-H2AX foci were considered positive for H2AX phosphorylation.  B) 
Results depicted in the graphs are the means of three independent experiments.  Error 
bars represent standard deviations.  Statistical significance was determined with a 
Student t-test with 95% confidence (p < 0.05).    
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SUPPLEMENTAL MATERIAL 
 
SUPPLEMENTAL FIGURE 1.  Analysis of the induction of G2 arrest by TAP-
tagged wild type Vpr and mutants.   
HEK293T cells were co-transfected with 1.5 ug of the GFP-expressing plasmid pQBI-
25 and with 15 ug of control plasmid or plasmids expressing native Vpr (WT), TAP tag, 
or TAP-tagged Vpr (WT) and mutants, as indicated.  Two days after transfection, cell 
cycle profiles were determined on the GFP-positive population by flow cytometry and 
PI staining. 
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SUPPLEMENTAL FIGURE 2. Characterization of stable cell lines expressing 
control and VprBP-targeting shRNA.   
A) Western blot analysis of VprBP levels in control non-targeting shRNA-expressing 
cell line (shControl) and VprBP-knocked down cell line (shVprBP).  Actin and VprBP 
were detected using rabbit polyclonal antibodies.  B) The cell cycle profiles of shControl 
and shVprBP cell lines were determined using flow cytometry and propidium iodide 
(PI) staining.  Percentages of cells in G1, S, and G2 phases, as determined by the Modfit 
software, are shown in each graph.  C) The growth kinetics of ShControl and ShVprBP 
cell lines was monitored by flow cytometry using CFSE (carboxyfluorescein 
succinimidyl ester) staining.  Percentages of cells in generations 3, 4, and 5 (G3, G4, and 
G5) are shown in each graph.   D) Levels of apoptotic cells were determined by flow 
cytometry using a standard PI and Annexin V staining.  PI- Annexin V+ cells represent 
the apoptotic population.  E) shControl and shVprBP cell lines were transfected with an 
HA-Vpr-expressing plasmid or a control plasmid.  Two days after transfection, cell 
cycle profiles were determined by flow cytometry and PI staining.  Western blot 
analysis was performed on the transfected cells to monitor levels of HA-Vpr. 
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SUPPLEMENTAL FIGURE 3. K48- or K63-linked polyubiquitination is not 
required for UV-induced H2AX phosophorylation. 
HeLa cells were transiently transfected with a plasmid expressing HA-Ub (K48R) (A) or 
HA-Ub (K63R) (B). Seventy-two hours after transfection, cells were irradiated or not 
with 25 J/m2 ultraviolet light at 254 nm.  Four hours after irradiation cells were fixed, 
permeabilized and stained with antibodies against γ-H2AX (red) and HA (blue). 
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CHAPTER 3: FORMATION OF CHROMATIN-ASSOCIATED 
NUCLEAR FOCI CONTAINING HIV-1 VPR AND VPRBP IS 
CRITICAL FOR THE INDUCTION OF G2 CELL CYCLE ARREST  
 
 
RÉSUMÉ 
 
La protéine Vpr (Viral protein R) du VIH-1 induit un arrêt de cycle cellulaire en 
phase G2/M en activant le senseur de dommage à l’ADN ATR.  Certaines recherches 
incluant les nôtres ont récemment démontré que Vpr remplissait cette fonction en 
recrutant la E3 ubiquitine ligase DDB1-CUL4A (VprBP).  Cependant, le compartiment 
subcellulaire où le complexe se forme et où il agit demeurent inconnus.  En utilisant des 
techniques d’immunofluorescence et de microscopie confocale nous avons démontré 
que Vpr forme des foyers nucléaires dans plusieurs types cellulaires incluant des cellules 
HeLa et des lymphocytes T CD4+ primaires.  Nous avons découvert que ces foyers 
nucléaires co-localisaient avec VprBP ainsi qu’avec des facteurs de réparation d’ADN 
tels que 53BP1 et RPA32.  Des traitements avec de la caféine, un inhibiteur non-
spécifique d’ATR, ou avec des ARN d’interférence ciblant VprBP n’ont eu aucun effet 
sur la formation de ces foyers.  En revanche, des mutations dans le domaine C-terminal 
de Vpr ainsi que la séquestration cytoplasmique de Vpr induite par la surexpression de 
Gag-Pol ont inhibé la formation des foyers et l’induction de l’arrêt de cycle.  En accord 
avec ces résultats, nous avons aussi observé que la protéine Vpr du singe mangabé 
enfumé pouvait former ces foyers mais pas son paralogue Vpx, incapable d’induire un 
arrêt de cycle.  Ainsi, ces résultats suggèrent que la formation de ces foyers de Vpr 
constitue un événement précoce important pour l’induction d’un arrêt de cycle en G2.  
En outre, nous avons découvert que Vpr pouvait s’associer à la chromatine via son 
domaine C-terminal et qu’il pouvait y former un complexe avec VprBP.  Globalement, 
nos résultats suggèrent que Vpr induirait l’ubiquitination d’un substrat cellulaire associé 
à la chromatine, menant à la génération de stresses au niveau de la réplication de l’ADN, 
à l’activation d’ATR et finalement à un arrêt de cycle en phase G2.
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ABSTRACT 
 
HIV-1 Viral protein R (Vpr) induces a cell cycle arrest at the G2/M phase by 
activating the ATR DNA damage/stress checkpoint.  Recently, we and several other 
groups showed that Vpr performs this activity by recruiting the DDB1-CUL4A (VprBP) 
E3 ubiquitin ligase.  While recruitment of this E3 ubiquitin ligase complex has been 
shown to be required for G2 arrest, the subcellular compartment where this complex 
forms and functionally acts is unknown.  Herein, using immunofluorescence and 
confocal microscopy, we show that Vpr forms nuclear foci in several cell types 
including HeLa cells and primary CD4+ T-lymphocytes.   These nuclear foci were 
found to co-localize with VprBP and the DNA repair factors 53BP1 and RPA32. While 
treatment with the non-specific ATR inhibitor caffeine or depletion of VprBP by siRNA 
did not inhibit formation of these foci, mutations in the C-terminal domain of Vpr and 
cytoplasmic sequestration of Vpr by overexpression of Gag-Pol resulted in impaired 
formation of these nuclear foci and defective G2 arrest. Consistently, we observed that 
G2 arrest-competent sooty mangabey Vpr could form these foci but not its G2 arrest-
defective paralog Vpx, suggesting that formation of these foci represents a critical early 
event in the induction of G2 arrest.  Indeed, we found that Vpr could associate to 
chromatin via its C-terminal domain and that it could form a complex with VprBP on 
chromatin.  Overall, our results suggest that Vpr would target a chromatin-bound 
cellular substrate for ubiquitination in order to induce DNA damage/replication stress, 
ultimately leading to ATR activation and G2 cell cycle arrest.    
 
INTRODUCTION 
 
 HIV-1 encodes several proteins termed accessory that have been implicated in 
the modulation of host cell environment to promote efficient viral replication and to 
impair innate and acquired immunity [1].  One of these accessory proteins, viral protein 
R (Vpr), is a small amphipathic protein of 96 amino acids. In addition to being 
expressed in infected cells, Vpr is packaged into virions through an interaction with the 
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p6 domain of the Gag polyprotein precursor [2-4]. The molecular structure of Vpr was 
recently resolved and found to consist of a hydrophobic core comprising three 
interacting alpha helices flanked by N- and C-terminal flexible domains [5].   Of note, 
the third alpha helix includes a leucine-rich region essential for the stability of the core 
and the flexible C-terminus comprises a functionally important stretch of positively 
charged arginine residues [6].  Several biological functions have been attributed to Vpr 
including transactivation of the viral long terminal repeat (LTR), enhancement of 
infection in macrophages, induction of apoptosis, and promotion of a cell cycle arrest at 
the G2/M phase [7].   
 
 Vpr-mediated G2 arrest likely plays an important role in vivo for viral 
replication or pathogenesis given that this activity is highly conserved among primate 
lentiviruses [8,9] and since abnormal accumulation of cells in G2/M can be observed in 
HIV-infected individuals [10]. Indeed, recent studies reported that Vpr upregulated the 
expression of ligands for the activating NKG2D receptor and promoted natural killer 
(NK) cell-mediated killing by a process that relied on Vpr ability to induce a G2 arrest, 
thus suggesting an immunomodulatory role for Vpr that may not only contribute to 
HIV-1-induced CD4+ T-lymphocyte depletion but may also take part in HIV-1-induced 
NK cell dysfunction [11,12].  Several investigators have reported that Vpr-induced cell 
cycle arrest involves the activation of the ATR (ataxia telangiectasia-mutated and Rad3-
related)-mediated G2/M checkpoint [10,13,14].   ATR is a kinase of the 
phosphatidylinositol 3 kinase-like family and is involved in the activation of the G2/M 
checkpoint and in the coordination of DNA repair following the occurrence of DNA 
damages or DNA replication stress.  Activation of ATR by exogenous DNA damaging 
agents such as UV leads to phosphorylation of several effector molecules, including 
Chk1 and H2AX (histone 2A, variant X), inducing the formation of DNA repair foci 
containing γ-H2AX (phosphorylated H2AX), MDC1 (mediator of DNA damage 
checkpoint 1), 53BP1 (p53 binding protein 1), BRCA1 (breast cancer 1), as well as the 
RPA (replication protein A), 9-1-1 (Rad9-Hus1-Rad1), and Rad17 complexes on the 
sites of DNA damage [15,16].  Activation of ATR by Vpr similarly leads to 
phosphorylation of Chk1 and to the formation of DNA repair foci containing γ-H2AX, 
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53BP1, RPA, Hus1, Rad17, and BRCA1 [13,14,17,18].  The immediate cause of the 
activation of ATR following Vpr expression has remained elusive but implicates in part 
the recruitment by Vpr of the host DDB1 (damage DNA binding protein 1)-CUL4A 
(cullin 4A) E3 ubiquitin ligase complex via a direct binding to the substrate specificity 
receptor VprBP (Vpr-binding protein, also known as DCAF1) [19-25].  Specifically, 
RNA interference-mediated depletion of VprBP or mutations in the hydrophobic 
leucine-rich core domain of Vpr impaired association to the E3 ligase complex and 
induction of G2 arrest.  In contrast, G2 arrest-defective mutants of Vpr in the C-terminal 
arginine-rich domain, which maintained their association to the E3 ligase, nevertheless 
failed to induce G2 arrest [19-25].  These results indicate that association of Vpr to the 
E3 ligase complex is required but not sufficient to induce G2 arrest, thus supporting a 
model in which Vpr would act as a connector between a ubiquitin ligase complex and a 
yet-unknown cellular protein.  We recently provided evidence that Vpr-induced K48-
polyubiquitination and proteasomal degradation of this protein(s) would lead to DNA 
damage/stress, activation of ATR, and ultimately G2 cell cycle arrest [26].  HIV-2 and 
some species of simian immunodeficiency virus (SIV) encode a paralog of Vpr, called 
Vpx, which does not induce G2/M arrest but instead counteracts a putative restriction 
factor expressed in macrophages and dendritic cells that affects infection at a post-entry 
step [1].  Interestingly, Vpx also interacts with DDB1-CUL4A (VprBP) via its 
hydrophobic leucine-rich core domain.  This association is required for the inactivation 
of the restriction factor and probably leads to its proteasomal degradation [27-29]. 
 
The subcellular localization of Vpr and its importance for the induction of G2 
arrest has remained a source of controversy.  Several investigators reported that Vpr 
expressed in absence of any other viral proteins primarily localized to the nucleus in a 
diffuse pattern [30-36] while others observed a significant accumulation at the nuclear 
envelope [37-42].  Of note, Sherman et al. showed that Vpr shuttles between the 
cytoplasm and nucleoplasm [43].  Moreover, Vpr has been shown to form punctuate 
structures in the nucleus [17] as well as to induce and co-localize with nuclear 
membrane herniations [44].  C-terminal mutations impairing G2 arrest did not alter 
localization of Vpr whereas other mutations, predominantly in the first alpha-helix, 
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impaired both nuclear import and G2 arrest, implying that nuclear/nuclear-envelope 
localization of Vpr would be required but not sufficient for this activity [33,38].  In 
agreement with this model, Lai et al showed that nuclear punctuate structures formed by 
Vpr were associated to chromatin and partially co-localized with γ-H2AX, suggesting 
that Vpr might target host cell DNA and interfere with DNA replication [17].  In 
contrast, the F34I, V57L, R62P, L68S, and I70S mutations in Vpr caused a re-
localization of the protein to the cytoplasm without significantly affecting the induction 
of G2 arrest [30,36,37,41].  Although inconsistent results were also obtained for some of 
these mutants [38], these data would suggest instead that Vpr does not induce G2 arrest 
from the nucleus but from an extra-nuclear compartment.  
 
 Therefore, the spatial prerequisites for the induction of Vpr-mediated G2 arrest 
remain unclear.   Additionally, while recruitment of the DDB1-CUL4A (VprBP) E3 
ubiquitin ligase complex has been shown to be critical for G2 arrest, the subcellular 
compartment where this association occurs is still unknown.  We thus sought to locate 
the Vpr-VprBP interaction and to determine the relevance of this localization for the 
induction of G2 arrest with the goal of furthering our understanding of the mechanism 
underlying Vpr activation of ATR and providing important information on the potential 
substrate targeted by Vpr.  Herein, we show that Vpr forms foci that co-localizes with 
VprBP and the DNA repair proteins RPA32 and 53BP1 in the nucleus of cells.   
Moreover, we provide evidence that formation of these Vpr nuclear foci constitute a 
critical early event in the induction of G2 arrest.  We also show that Vpr associates to 
chromatin via its C-terminal domain and that it binds VprBP on chromatin, suggesting 
that the Vpr-DDB1-CUL4A (VprBP) E3 ubiquitin ligase complex might target a 
chromatin-bound substrate in order to activate ATR and induce G2 arrest. 
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RESULTS 
 
HIV-1 Vpr forms nuclear foci containing VprBP  
The interaction between Vpr and VprBP was previously revealed to be required 
for the induction of a G2 cell cycle arrest [19-25].  However, the subcellular localization 
where this event might take place still remains to be determined.  To this end, we 
performed laser-scanning confocal fluorescence immunohistochemistry to identify the 
respective subcellular localization and potential co-localization of Vpr and VprBP.  
HeLa cells were transduced with a lentiviral vector co-expressing HA-tagged Vpr (HA-
Vpr) and GFP or a control lentiviral vector expressing GFP alone.  Forty-eight hours 
after transduction, cells were fixed, permeabilized and stained with antibodies against 
HA, VprBP, and nucleoporin.  The localization of HA-Vpr was mostly diffuse in the 
nucleus at standard amplification gain (data not shown).  However, when the gain was 
reduced, we could observe that HA-Vpr formed small circular nuclear structures of 
variable relative sizes that we refer to thereafter as Vpr nuclear foci (VNF) (Fig 1A).  
The number of Vpr nuclear foci varied from cell to cell and from experiment to 
experiment but generally averaged 35 foci (SD ± 10) per cell.  Formation of these foci 
was not due to the HA tag because we observed that native Vpr could also form nuclear 
foci (Fig S1A).  Endogenous VprBP was found to be mostly localized to the nucleus in a 
punctuate pattern (Fig 1A).  We observed that HA-Vpr colocalized with endogenous 
VprBP in the nucleus.  Strikingly, a significant fraction but not all of Vpr nuclear foci 
co-localized with VprBP foci, suggesting that Vpr might be able to recruit the E3 
ubiquitin ligase complex to these discreet structures.   Although the localization of 
endogenous VprBP was found to vary greatly between the different cell lines tested 
(HeLa, HEK293T, and HEK293) or different clones of the same cell line (HeLa), 
ranging from completely nuclear to mostly cytoplasmic, co-localization with Vpr was 
always observed in these nuclear foci (data not shown).  Of note, in presence of Vpr, we 
also observed some nuclear membrane perturbations reminiscent of the previously 
described Vpr-induced membrane herniations [44].  Importantly, transduction of 
activated primary CD4+ T-lymphocytes with a lentiviral vector expressing HA-Vpr also 
resulted in the formation of Vpr nuclear foci that co-localized with VprBP (Fig 1B), 
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indicating that these foci are not solely the result of overexpression of Vpr in 
transformed cell lines but that their formation also occurs in a physiological cellular host 
of HIV.  Infection of HeLa cells with a VSV-G- pseudotyped virus expressing HA-Vpr 
(HxBru HA-Vpr) also resulted in the formation of Vpr nuclear foci in a minor fraction 
of cells (Fig S1B).  However, the majority of cells displayed a relocalization of HA-Vpr 
to cytoplasmic compartments (Fig S1B), suggesting that formation of these foci would 
be a dynamic process, regulated over time during the infection cycle.  
 
Vpr nuclear foci co-localize with DNA repair proteins 
To investigate the nature and composition of these Vpr nulear foci we first 
evaluated whether these would correspond to known well-defined nuclear micro-
domains with similar sizes and numbers.  We did not however find any significant co-
localization with the canonical nuclear speckle marker SC35 (also known as SFRS2) or 
with PML (promyelocytic leukemia) bodies (data not shown).   Lai et al. previously 
reported formation and partial co-localization of Vpr nuclear foci with the DNA repair 
protein γ-H2AX [17].  We thus evaluated if the Vpr nuclear foci described herein where 
the same foci that Lai et al reported.  Interestingly, we observed a co-localization 
between a significant fraction of HA-Vpr nuclear foci and 53BP1 (Fig 2A).  Indeed, 
expression of HA-Vpr induced the re-localization of 53BP1 from its sites of residence in 
the nucleus to HA-Vpr-containing foci.  We also observed a co-localization between 
some HA-Vpr nuclear foci and phosphorylated RPA32 (replication protein A2, 32kDa) 
(Fig 2B).  Interestingly, in foci where co-localization was observed, the Vpr signal 
overlapped with 53BP1 foci while it generally concurred with RPA32 foci.  Finally, 
even though we could detect a significant increase in γ-H2AX foci in response to Vpr 
expression [26], only a weak co-localization was observed between Vpr and 
phosphorylated H2AX (data not shown).  
 
Formation of Vpr nuclear foci represents a critical early event in Vpr-mediated G2 
arrest 
Co-localization of Vpr with DNA repair factors suggest that formation of these 
foci by Vpr might represent an early event in the induction of G2 arrest that would be 
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responsible for the generation of DNA replication stress or DNA damage.  Conversely, 
those might simply reflect the re-organization of the nuclear compartment following the 
activation of the ATR checkpoint by Vpr.  To distinguish between these two 
possibilities, we transduced HeLa cells with a lentiviral vector expressing HA-Vpr and 
concomitantly treated the cells with caffeine, a non-specific inhibitor of ATR and ATM 
(ataxia telangiectasia mutated).  In these conditions, the addition of caffeine inhibited 
Vpr-induced cell cycle arrest (Fig S2).  However, we did not detect significant changes 
in the number of Vpr nuclear foci (Fig 3A, 33±10 for non-treated cells vs 32±9 for 
caffeine-treated cells), suggesting that formation of these foci would take place 
independently of the activation of ATR.  Moreover, consistent with the observation that 
not all Vpr nuclear foci co-localized with VprBP (Fig 1A), depletion of VprBP by 
siRNA in HeLa cells (Fig 3B) did not significantly alter the number of foci (36±10 for 
control siRNA vs 33±8 for VprBP siRNA), indicating that VprBP is dispensable for the 
formation of Vpr nuclear foci.  Similar results (data not shown) were obtained in a 
HEK293T monoclonal cell line stably depleted of VprBP [26].  These results indicate 
that Vpr forms these foci prior to activation of ATR and G2 arrest and suggest that it is 
Vpr that recruits VprBP to these foci and not the inverse.   
 
To evaluate the potential role of these Vpr nuclear foci in the induction of G2 
arrest, we monitored the capacity of several G2 arrest-defective Vpr mutants to form 
these foci.  HeLa cells were transfected with plasmids expressing HA-tagged Vpr 
mutants and formation of nuclear foci was evaluated by fluorescence 
immunohistochemistry and confocal microscopy (Fig 4).  We found that Vpr (R80A), 
which still interacts with the E3 ligase but is strongly attenuated for the induction of G2 
arrest, was defective for the formation of nuclear foci (2.4±1.1).  Deletion of the C-
terminus of Vpr (Vpr 1-78), which also maintains the association with the E3 ligase [22] 
but impairs the induction of G2 arrest [45], similarly resulted in a defect in the formation 
of nuclear foci (Fig 4).  Similar results were also obtained with the C-terminal mutants 
Vpr (S79A) and Vpr (1-86) (data not shown).  Vpr (Q65R), which is unable to associate 
with the E3 ligase and is consequently defective for G2 arrest, was found to be defective 
for the formation of nuclear foci and also accumulated in cytoplasmic aggregates.  The 
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results obtained with the Q65R mutation are in contrast with the siRNA-mediated 
depletion of VprBP which did not block the formation of Vpr nuclear foci, suggesting 
that this mutant protein might have additional defects besides an impaired interaction 
with VprBP.  These results thus suggest that the putative C-terminal substrate-
interacting domain of Vpr, which is required for the induction of G2 arrest, is also 
critical for the formation of Vpr nuclear foci.   
 
 The observation that C-terminal, G2 arrest-defective mutants of Vpr are 
compromised in their capacity to form nuclear foci suggest that these nuclear foci might 
constitute an important early event in the induction of G2 arrest by Vpr.  To directly 
address this possibility, we first evaluated the functional effect of artificially 
sequestering Vpr in the cytoplasm by overexpression of Gag-Pol.  Co-transfection of 
HeLa cells with HA-Vpr- and Gag-Pol-expressing plasmids produced a re-localization 
of HA-Vpr from the nucleus to p24-positive cytoplasmic compartments (Fig 5A).  This 
relocalization abrogated Vpr nuclear foci formation (Fig 5A).  Similar results were 
obtained in HEK293T cells (data not shown).  To evaluate the functional effect of this 
cytoplasmic sequestration of Vpr, HEK293T cells were co-transfected with plasmids 
expressing HA-Vpr and Gag-Pol or with adequate empty plasmid controls.  Two days 
later, the cell cycle profile of transfected cells was evaluated by flow cytometry (Fig 5B 
and 5C).  Expression of HA-Vpr alone produced an accumulation of cells in G2/M 
(G2+M:G1=1.81 vs 0.66 for mock-transfected cells).  Interestingly, expression of Gag-
Pol completely abrogated HA-Vpr-induced G2 arrest (G2+M:G1=0.67) in absence of 
any significant effect on the cell cycle when expressed alone (G2+M:G1=0.77).  
Although overexpression of Gag-Pol led to a reduction of the affinity between HA-Vpr 
and endogenous VprBP, the overall increase in the expression of HA-Vpr resulted in an 
increase in the levels of Vpr-bound VprBP (Fig 5D), excluding the possibility that 
overexpression of Gag-Pol inhibited G2 arrest by preventing the Vpr-VprBP interaction.  
These results thus imply that nuclear localization of Vpr and possibly the formation of 
nuclear foci would be required for the induction of G2 arrest. These data also suggest 
that the stability of Vpr may be increased when in complex with Gag. 
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To further show that the formation of these Vpr nuclear foci is critical for the 
induction of G2 arrest, we evaluated the capacity of SIV Vpr and its paralog Vpx to 
form these foci.  Both of these proteins are able to associate with the E3 ligase complex 
but in contrast to Vpr, Vpx does not induce G2 arrest but counteract a putative 
restriction factor in macrophages and dentritic cells [27-29].  HeLa cells were 
transfected with plasmids expressing either HA-tagged sooty mangabey Vpr (HA-Vpr 
sm) or Vpx (HA-Vpx sm).  Two days after transfection, cells were fixed, permeabilized, 
and stained with antibodies against HA, nucleoporin and VprBP (Fig 6).   Consistent 
with its ability to induce G2 arrest (data not shown and [9]), we found that Vpr sm could 
accumulate into nuclear foci (16±4 foci per cell) in contrast to the G2-arrest incompetent 
Vpx that did not form any foci despite being present in the nucleus (Fig 6). Overall, 
these results indicate that formation of Vpr nuclear foci is an early event that is required 
to induce G2 arrest.  These results also indicate that nuclear localization of Vpr is not 
sufficient to induce formation of foci. 
 
Vpr oligomerization is not sufficient to induce foci formation 
Given that these foci constitute an early event in the induction of G2 arrest, we 
sought to determine how they would form.  These foci are likely the results of a local 
observable accumulation of Vpr either through oligomerization of the protein or 
following its recruitment by a locally abundant tethering factor.  To distinguish between 
these two possibilities, we first monitored the dimerization efficiency of the Vpr mutants 
Q65R and R80A, which are defective for foci formation.   HEK293T cells were co-
transfected with plasmids expressing enhanced yellow fluorescence protein (eYFP) 
fused to the N-terminus of wild type Vpr and renilla luciferase (Rluc) fused to the N-
terminus of wild type Vpr and mutants.  Two days after transfection, self-affinity was 
assessed by bioluminescence resonance energy transfer (BRET). Figure 7A reveals that 
all Vpr fusion proteins were efficiently expressed.  In this system, we observed a 
specific energy transfer between eYFP-Vpr (WT) and Rluc-Vpr (WT) (Fig 7B).  The 
maximum energy transfer at saturation (BRETmax) was 0.983 and the concentration of 
acceptor at 50% of BRETmax (BRET50) was 0.397.  In contrast, co-expression of eYFP 
and Rluc-Vpr did not lead to any significant energy transfer, demonstrating the 
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specificity of the eYFP-Vpr/Rluc-Vpr interaction.  The Q65R mutant, showed a 
significant decrease in its affinity for wild type eYFP-Vpr (BRET50 = 0.791, 50% self-
affinity) as well as a drastic decrease in BRETmax (0.314 for Q65R vs 0.983 for wild 
type Vpr), suggesting that in addition to a reduction in dimerization efficiency, 
formation of higher-order complexes (multimerization) would also be synergistically 
decreased.  In contrast, the R80A mutant displayed an affinity for wild type Rluc-Vpr 
that was at least comparable to wild type Vpr (BRET50 = 0.326, 121% self-affinity 
relative to wild type).  Similar results were obtained when eYFP-Vpr R80A and Rluc-
Vpr R80A were co-expressed (data not shown).  Thus, these results suggest that the 
ability of Vpr to oligomerize does not directly correlate with nuclear foci formation and 
does not explain the defect in foci formation observed in the context of C-terminal 
mutants. 
 
Association of Vpr to chromatin correlates with formation of nuclear foci 
Since oligomerization does not fully account for the ability of Vpr to form foci, 
Vpr could thus be tethered to specific sites by a cellular factor.  Co-localization of Vpr 
nuclear foci with chromatin-bound DNA repair factors suggests that this tethering factor 
could be a chromatin-bound protein or DNA itself.  To assess this possibility, HeLa cells 
were first transiently transfected with an empty plasmid or a plasmid expressing HA-
Vpr and cells were lysed with 0.5% Triton X-100, resulting in the release of soluble 
proteins.  Treatment of Triton-insoluble cellular material, including chromatin, with 
microccocal nuclease resulted in the solubilization of chromatin-bound cellular proteins 
including RPA70 (replication protein A1, 70 kDa) (data not shown) and histone 3 (Fig 
8A).  These proteins were not detected when cell extracts were incubated in buffer 
without microccocal nuclease.  Importantly, chromatin extracts were not contaminated 
with cytoplasmic proteins as revealed by the absence of GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) (Fig 8A).  Using this system, we found that a fraction of HA-
Vpr was released in extracts treated by microccocal nuclease but not with buffer alone, 
indicating that Vpr associates with chromatin directly or indirectly via other proteins 
(Fig 8A).  A specific association of a fraction of endogenous VprBP with chromatin was 
also observed in presence and in absence of Vpr (Fig 8A).  To determine whether the 
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defects of foci formation observed with C-terminal mutants of Vpr would correlate with 
a defect in chromatin association, we analyzed the capacity of several Vpr mutants to 
associate to chromatin in HeLa cells.  Interestingly, both Vpr (R80A) and a C-terminal 
deletion mutant (Vpr 1-78) showed a drastic reduction in their association to chromatin 
(Fig 8B).  Of note, Vpr (Q65R) also failed to associate with chromatin (Fig 8B), 
possibly explaining its unexpected incapacity to form foci.  Therefore, the ability of Vpr 
to form foci correlates with its ability to associate with chromatin.   
 
Vpr and VprBP interact on chromatin 
Co-localization of Vpr nuclear foci with VprBP and the association of both 
proteins to chromatin suggest that they might interact on chromatin.  To evaluate this 
possibility, we transfected HeLa cells with an empty plasmid or a plasmid expressing 
HA-Vpr and performed anti-HA immunoprecipitations on proteins released from 
chromatin by microccocal nuclease (Fig 9).  Interestingly, we could detect co-
immunoprecipitation of endogenous VprBP specifically in cells extracts containing HA-
Vpr, in the soluble fraction as well as in the chromatin fraction (Fig 9).  These data 
suggest that Vpr interacts with VprBP on chromatin.  Importantly, histone 3 did not co-
immunoprecipitate with HA-Vpr in the chromatin fraction, thus excluding the 
possibility that the observed Vpr-VprBP interaction was mediated by incompletely 
digested chromatin fragments.  Overall, our results suggest that Vpr would bind to 
chromatin via its C-terminus where it would contact a yet-unknown cellular factor, 
triggering accumulation of Vpr and formation of nuclear foci.  These would serve as a 
scaffold to recruit the DDB1-CUL4A (VprBP) E3 ubiquitin ligase to induce the 
ubiquitination and degradation of a chromatin-bound substrate, resulting in DNA 
damage or replication stress. 
 
DISCUSSION 
 
Our results show that Vpr mainly localizes to the nucleus in transformed 
epithelial cells, such as HeLa and HEK293T cells, as well as in primary CD4+ T-
lymphocytes (Fig 1 and data not shown).  We noticed that the localization of Vpr in 
157 
 
HeLa cells closely resembles that observed in primary CD4+ T-lymphocytes, prompting 
us to select this cellular model for most of our study.  Moreover, we found that both 
ectopically and virally expressed HA-tagged Vpr had a subcellular localization similar 
to that of the native protein (Fig S1).  Our localization data show that Vpr can form 
nuclear punctuate structure that we termed Vpr nuclear foci (Fig 1), as was reported 
previously by Lai and colleagues [17].  It is noteworthy that these foci are not readily 
apparent and require careful calibration of gain to be observed (data not shown).  
Importantly, we observed a strong co-localization of Vpr with VprBP in the nucleus, 
particularly in these foci, suggesting that Vpr might interact with the E3 ubiquitin ligase 
at the levels of these punctuate structures.  In contrast to the observations of other 
investigators [37-42], we did not observe a significant accumulation of Vpr at the 
nuclear membrane in these cell types.  Several technical reasons might explain these 
discrepancies, including cell types, levels of expression, fixation and permeabilization 
conditions, or the tag used.  We did however observe some enrichment at the nuclear 
membrane in another clone of HeLa cells (data not shown).  Given that this phenotype is 
not generally observed in primary CD4+ T-cells, it is probably not physiologically 
relevant for the induction of G2 arrest.  
 
 We obtained several lines of evidence demonstrating that Vpr nuclear foci are 
involved in Vpr-mediated G2 arrest.  First, we observed a partial colocalization between 
these foci and DNA repair factors such as RPA32, 53BP1 and γ-H2AX (Fig 2 and data 
not shown).  Similar results were obtained by Lai and colleagues in the case of γ-H2AX 
[17].  Secondly, C-terminal mutants of Vpr defective for G2 arrest failed to induce 
formation of Vpr foci despite their nuclear localization (Fig 4).   Thirdly, cytoplasmic 
sequestration of Vpr by overexpression of Gag inhibited G2 arrest as well as foci 
formation (Fig 5).  Fourthly, only Vpr from sooty mangabey SIV but not its G2 arrest-
defective paralog Vpx was able to form these foci (Fig 6).  Lastly, the reduced number 
of foci formed by sooty mangabey Vpr in comparison to HIV-1 Vpr correlated with 
reduced G2 arrest activity in human cells (data not shown and [9]).  All these results 
suggest that formation of foci is linked to G2 arrest.  Moreover, these results also 
suggest that nuclear localization of Vpr is required but not sufficient to induce formation 
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of these foci.  Our results and conclusions are in contrast with previous reports, 
including one of ours, describing cytoplasmic mutants of Vpr that retain their G2 arrest 
activity [30,36,37,41].  We had reported over a decade ago that the V57L and R62P 
mutations induced the relocalization of Vpr to the cytoplasm, while these mutants were 
still able to induce G2 arrest [36].  However, careful re-examination of the localization 
of these mutants showed that both mutants could localize to the nucleus to some degree.  
While, the V57L mutant had a reduced capacity to form foci, the R62P mutant was 
completely defective for foci formation (Fig S3A).  The reduced capacity of V57L 
mutant and the defect of the R62P mutant in foci formation correlated, respectively, 
with attenuation and abrogation of G2 arrest (Fig S3B).   These differences between our 
present localization data and our previously published results can probably be explained 
by improved imaging sensitivity, whereas the discrepancies in G2 arrest activity are 
unclear.  Nevertheless, these results highlight an important technical limitation in these 
types of localization experiments: lack of detection in a subcellular compartment does 
not necessarily indicate an absence of protein.  
 
Correlation between G2 arrest and formation of Vpr nuclear foci implies that the 
formation of these foci could either be an early event leading to G2 arrest or could be a 
consequence of this G2 arrest.  We observed that treatment with the ATR/ATM inhibitor 
caffeine (Fig 3A) did not abrogate formation of Vpr foci, thus indicating that these foci 
likely constitute an early event in the induction of G2 arrest by Vpr.  In fact, formation 
of Vpr foci were not affected by knockdown of VprBP indicating that their formation is 
independent of the recruitment of the E3 ligase complex and would therefore precede 
ubiquitination and degradation of the putative G2 arrest substrate (Fig 3B).  In contrast, 
we found that the Q65R mutant of Vpr was unable to form foci.  In addition to a reduced 
affinity for VprBP [19,20,22], this mutation also leads to other defects including 
accumulation of Vpr in the cytoplasm (Fig 4), reduced dimerization efficiency (Fig 7), 
and absence of binding to chromatin (Fig 8B), indicating that the Q65R mutation has 
pleitropic effects on the functions of Vpr.  Cautions should thus be used when 
interpreting results obtained with this mutant.    
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 Given that Vpr foci containing VprBP co-localize with chromatin-bound protein 
such as RPA32 and that Vpr associates with DNA in vitro [46] and in vivo (Fig 8A and 
[17]), we propose that Vpr might be able to target a chromatin-bound cellular factor.  In 
support of this hypothesis, Lai et al. showed that in situ nuclease treatment of Vpr-
expressing cells eliminates Vpr nuclear foci [17], suggesting that Vpr nuclear foci are 
anchored to chromatin.  Deletion of the putative substrate-interacting C-terminal domain 
of Vpr drastically reduced foci formation (Fig 4) and its chromatin association (Fig 8B).  
Similar results were obtained by Lai and colleagues [17] .  Moreover, mutation of the 
arginine at position 80 did not affect direct binding to nucleic acids in vitro [46] but 
nevertheless impaired association to chromatin in vivo (Fig 8B), implying that a cellular 
factor rather than a direct binding to DNA would be implicated in association to 
chromatin.  Importantly, we also observed protein-protein interaction between Vpr and 
VprBP on chromatin (Fig 9), suggesting that Vpr would be able to recruit the E3 ligase 
DDB1-CUL4A (VprBP) onto chromatin.  Therefore, Vpr could bind to its cognate 
chromatin-bound substrate via its C-terminus.  This event would induce the local 
accumulation of Vpr (formation of Vpr nuclear foci) because of large amount of the 
putative substrate on these genomic loci and would trigger the recruitment of DDB1-
CUL4A (VprBP).  Although possible, it is however unlikely that Vpr multimerization 
(Fig 7)[30,40] would play a role in this process given that the I70S mutation was 
previously shown to block dimerization without affecting the induction of G2 arrest 
[30].   It also remains unclear whether VprBP would bind Vpr pre- or post-foci 
formation, particularly when considering the important level of interaction observed in 
the Triton-soluble fraction (Fig 9).  Finally, as was recently documented, the substrate 
would be covalently modified with classical K48-linked polyubiquitin chains in a 
DDB1-CUL4A (VRPBP)-dependent manner and degraded by the proteasome [26].  
This model would imply that, although Vpr would initially require binding to the 
substrate to form foci, once formed, these structures would be sufficiently stable to 
outlast the degradation of the substrate.  Alternatively, Vpr could interact with a 
chromatin-bound cellular cofactor via its C-terminal domain.  This first event would 
then allow Vpr to contact a chromatin-bound substrate via a yet-undefined domain and 
target it for degradation.  Nonetheless, our results also imply that Vpr might not target 
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the overall pool of substrate for degradation but only locally in these foci.  Partial rather 
than complete co-localization of Vpr nuclear foci with the DNA repair factors 53BP1 
(Fig 2A), RPA32 (Fig 2B), and γ-H2AX [17] further suggest that ubiquitination and 
degradation of this unknown cellular factor would induce a generalized genomic 
instability, affecting sites other than that of Vpr nuclear foci.  However, given that Vpr 
nuclear foci might be dynamic structures, we cannot completely exclude the possibility 
that Vpr could induce DNA damage or replication stress in situ and that the absence of 
co-localization would be due to the disappearance of Vpr nuclear foci.    
.   
Overall, our results show that Vpr forms nuclear foci that co-localizes with 
VprBP and demonstrate that formation of these foci constitutes a critical early event in 
the induction of DNA damage/stress and G2 arrest.  Our results further suggest that the 
putative G2 arrest substrate targeted by Vpr in these foci is likely to be a chromatin-
associated protein. 
 
MATERIALS AND METHODS 
 
Cells, antibodies, and other reagents 
HeLa and HEK293T cells were cultured as previously described [47].  Primary 
CD4+ T-lymphocytes were isolated and cultured as previously described [26].  Caffeine 
was purchased from Sigma-Aldrich (St. Louis, MO, USA).  SiRNA targeting VprBP 
(siGenome SMARTpool M-021119-00) and scrambled control siRNA (non-targeting 
siRNA #2) were obtained from Dharmacon (Chicago, IL, USA).  The anti-HA (clone 
12CA5) and anti-p24 (catalog no. HB9725) monoclonal antibodies were produced from 
hybridomas obtained from the American Type Culture Collection (Manassas, VA, 
USA).  Mouse anti-nucleoporin, mouse anti-RPA70, rabbit anti-53BP1, rabbit anti-
GAPDH, and rabbit anti-H3 antibodies were purchased from Abcam (Cambridge, MA, 
USA), whereas the rabbit anti-phospho RPA32 (S4/S8) antibody was obtained from 
Bethyl Laboratories (Montgomery, TX, USA).  The rabbit polyclonal antibody against 
VprBP and actin were respectively obtained from Accurate Chemical and Scientific 
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Corporation (Westbury, NY, USA) and Sigma-Aldrich (St. Louis, MO, USA).  The 
monoclonal antibody against Vpr (clone 8D1) was a kind gift of   Y. Ishizaka 
(International Medical Center of Japan, Tokyo, Japan) [48].  All fluorochrome-
conjugated secondary antibodies were obtained from Molecular Probes (Invitrogen, San 
Diego, CA, USA). 
 
Plasmid construction 
SVCMV-HA-Vpr (WT), SVCMV-HA-Vpr (V57L), SVCMV-HA-Vpr (R62P), 
SVCMV-HA-Vpr (Q65R), SVCMV-HA-Vpr (R80A), SVCMV-HA-Vpr (S79A), 
SVCMV-HA-Vpr (1-86), and SVCMV-HA-Vpr (1-78) were constructed by PCR as 
previously described [19,45].   Plasmids pCDNA3.1_eYFP-MCS(MB) and 
pCDNA3.1_Rluc-MCS(MB) for the expression of eYFP and renilla luciferease (Rluc) 
N-terminal fusion proteins were kind gifts of M. Baril and D. Lamarre [49].  Wild type 
Vpr was amplified by PCR from SVCMV-HA-Vpr (WT) and subcloned into 
pCDNA3.1_eYFP-MCS(MB) and pCDNA3.1_Rluc-MCS(MB) to generate respectively 
pCDNA3.1-eYFP-Vpr(WT) and pCDNA3.1-Rluc-Vpr (WT).  Vpr (R80A) and Vpr 
(Q65R) were subcloned into pCDNA3.1_Rluc-MCS(MB) to generate pCDNA3.1-Rluc-
Vpr (R80A) and pCDNA3.1-Rluc-Vpr (Q65R) using the same strategy.  The lentiviral 
vector pWPI as well as the packaging plasmid psPAX2 were obtained from D. Trono 
(School of Life Sciences, Swiss Institute of Technology, Lausanne, Switzerland). The 
lentiviral vector pWPI-HA-Vpr (WT) tranducing HA-tagged Vpr and GFP was 
generated from the parental vector pWPI using a strategy described previously [19].  
The plasmids expressing sooty mangabey HA-tagged Vpr and Vpx were obtained from 
S. Benichou (Institut Cochin, Paris, France) [4].  The infectious molecular clones HxBru 
(Vpr-) and HxBru (HA-Vpr) were described previously [26,50]   
 
Production and titration of viruses and lentiviral vectors 
The production and titration of VSV-G-pseudotyped HIV particles and lentiviral 
vectors were performed as described previously [19,45]. 
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Transfection, transduction and infection 
HeLa cells were transfected using the Lipofectamine 2000 reagent (Invitrogen 
Canada, Burlington, Ontario, Canada) according to the manufacturer’s instructions.  
HEK293T cells were transfected by a standard calcium phosphate precipitation protocol.  
SiRNA were transfected using Oligofectamine (Invitrogen Canada, Burlington, Ontario, 
Canada), according to the manufacturer’s instructions and as previously published [19].   
HeLa cells were transduced with the lentiviral vectors WPI and WPI-HA-Vpr in 
presence of 8µg/ml polybrene at a multiplicity of infection of 0.5 or 2.5, as indicated for 
each experiment.  Primary CD4+ T-lymphocytes were transduced by spinoculation at a 
multiplicity of infection of 1.   Briefly, cells were mixed with lentiviral vector particles 
in presence of 8µg/ml polybrene and centrifuged for 2 hours at 1200g.  HeLa cells were 
infected with VSV-G-pseudotyped viruses at a concentration of 100 cpm/cell in 
presence of 8 µg/ml polybrene. For all experiments, cells were harvested two days after 
transfection, transduction or infection.  
 
Fluorescence immunohistochemistry 
Fifty thousand HeLa cells were seeded on cover slips in 24-well plates.  Cells 
were transfected, transduced, or infected as indicated for each experiment.  Two days 
later, cells were processed for immunohistochemistry and laser-scanning confocal 
microscopy as previously described [51].  For analysis of CD4+ primary T-
lymphocytes, 5X105 cells were first adhered on poly-Lysine-treated coverslips for two 
hours in PBS and then processed as described [51].   Quantification of Vpr nuclear foci 
was performed in at least 30 randomly selected cells by manual counting.   
 
Cell cycle analysis 
Cell cycle analysis was performed using propidium iodide staining and flow 
cytometry as previously described [19]. 
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Immunoprecipitation and westen blot 
Immunoprecipitations using anti-HA-conjugated agarose beads were performed 
as previously described [26]. Analysis of proteins by western blot was performed as 
previously described [26]. 
 
Bioluminescence resonance energy transfer (BRET) assays     
HEK293T cells were transfected in 24-well plates with 10 ng of the BRET donor 
plasmids pCDNA3.1_Rluc-MCS(MB), pCDNA3.1-Rluc-Vpr (WT), pCDNA3.1-Rluc-
Vpr (R80A) or pCDNA3.1-Rluc-Vpr (Q65R) and increasing concentration (0 to 500 ng) 
of the BRET acceptor plasmids pCDNA3.1_eYFP-MCS(MB) or pCDNA3.1-eYFP-Vpr 
(WT) using Lipofectamine 2000.  Two days after transfection, cells were harvested, 
washed twice in PBS, and aliquoted in two wells of a 96-well plate (Costar 3917).  Total 
eYFP fluorescence was measured with an excitation wavelength of 485 nm and an 
emission wavelength at 520±10 nm.  BRET was initiated by adding 5µM of the renilla 
luciferase substrate coelenterazine H (Prolume Ltd., Lakeside, AZ, USA).  
Luminescence was then measured 10 minutes later at 475±15 nm and BRET 
fluorescence was measured at 535±15 nm.  All measurements were performed on a 
PheraStar microplate reader (BMG Labtech, Cary, NC, USA).  BRET ratios were 
calculated using this formula: (emission at 535 nm/emission at 475 nm)-(background 
emission at 535nm/background emission at 475 nm), as previously described [52].   
 
Chromatin binding assays 
Cells were lysed in triton lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% 
Triton X-100, and complete protease inhibitors cocktail (Roche) for 15 minutes.  
Insoluble cell debris, including chromatin, was pelleted by centrifugation (2500g for 10 
minutes).  The supernatant was harvested and represented the soluble input control.  
Pellets were washed once with nuclease buffer (50 mM Tris pH 8.0, 5 mM CaCl2, and 
100 µg/ml BSA), split in two, and resuspended in nuclease buffer alone or nuclease 
buffer containing 200 U/ml microccocal nuclease (New England Biolabs, Ipswich, MA, 
USA).  Pellets were incubated for 30 minutes on ice and then centrifuged at 12000g for 
10 minutes.  The supernatant was harvested and represented the chromatin-bound 
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fraction.  The corresponding supernatant obtained in absence of nuclease was used to 
control for non-specific release.  
 
ACKNOWLEDGMENTS 
 
We thank Julien Briffotaux, Jonathan Richard, and Nicole Rougeau for technical 
assistance.  We also wish to thank Didier Trono for the lentiviral vector WPI and the 
packaging plasmid psPAX2, Serge Benichou for the plasmids expressing sooty 
mangabey Vpr and Vpx, and Yukihito Ishizaka for the monoclonal anti-Vpr antibody   
Finally, we also thank Daniel Lamarre, Martin Baril, and Laurent Chatel-Chaix for 
reagents and advice with the BRET assay as well as François Robert, Alain Bataille, and 
Simon Drouin for helpful discussions regarding isolation of chromatin-bound proteins.  
This work was performed by JPB in partial fulfillment of his doctoral thesis. 
 
REFERENCES 
 
1. Malim MH, Emerman M (2008) HIV-1 accessory proteins--ensuring viral survival in 
a hostile environment. Cell Host Microbe 3: 388-398. 
2. Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA (1999) Incorporation of Vpr 
into human immunodeficiency virus type 1 requires a direct interaction with the p6 
domain of the p55 gag precursor. J Biol Chem 274: 9083-9091. 
3. Lu YL, Bennett RP, Wills JW, Gorelick R, Ratner L (1995) A leucine triplet repeat 
sequence (LXX)4 in p6gag is important for Vpr incorporation into human 
immunodeficiency virus type 1 particles. J Virol 69: 6873-6879. 
4. Selig L, Pages JC, Tanchou V, Preveral S, Berlioz-Torrent C, et al. (1999) Interaction 
with the p6 domain of the gag precursor mediates incorporation into virions of Vpr 
and Vpx proteins from primate lentiviruses. J Virol 73: 592-600. 
165 
 
5. Morellet N, Bouaziz S, Petitjean P, Roques BP (2003) NMR structure of the HIV-1 
regulatory protein VPR. J Mol Biol 327: 215-227. 
6. Morellet N, Roques BP, Bouaziz S (2009) Structure-function relationship of Vpr: 
biological implications. Curr HIV Res 7: 184-210. 
7. Le Rouzic E, Benichou S (2005) The Vpr protein from HIV-1: distinct roles along the 
viral life cycle. Retrovirology 2: 11. 
8. Planelles V, Jowett JB, Li QX, Xie Y, Hahn B, et al. (1996) Vpr-induced cell cycle 
arrest is conserved among primate lentiviruses. J Virol 70: 2516-2524. 
9. Stivahtis GL, Soares MA, Vodicka MA, Hahn BH, Emerman M (1997) Conservation 
and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in 
primate lentivirus evolution and biology. J Virol 71: 4331-4338. 
10. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, et al. (2006) 
Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro 
and in vivo. J Virol 80: 10407-10418. 
11. Richard J, Sindhu S, Pham TN, Belzile JP, Cohen EA (2009) HIV-1 Vpr upregulates 
expression of ligands for the activating NKG2D receptor and promotes NK cell-
mediated killing. Blood. 
12. Ward J, Davis Z, DeHart J, Zimmerman E, Bosque A, et al. (2009) HIV-1 Vpr 
triggers natural killer cell-mediated lysis of infected cells through activation of the 
ATR-mediated DNA damage response. PLoS Pathog 5: e1000613. 
13. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V (2003) Activation of the ATR-
mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 278: 
25879-25886. 
166 
 
14. Zimmerman ES, Chen J, Andersen JL, Ardon O, Dehart JL, et al. (2004) Human 
immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and 
induces nuclear BRCA1 and gamma-H2AX focus formation. Mol Cell Biol 24: 9286-
9294. 
15. Cimprich KA, Cortez D (2008) ATR: an essential regulator of genome integrity. Nat 
Rev Mol Cell Biol 9: 616-627. 
16. McGowan CH, Russell P (2004) The DNA damage response: sensing and signaling. 
Curr Opin Cell Biol 16: 629-633. 
17. Lai M, Zimmerman ES, Planelles V, Chen J (2005) Activation of the ATR pathway 
by human immunodeficiency virus type 1 Vpr involves its direct binding to 
chromatin in vivo. J Virol 79: 15443-15451. 
18. Andersen JL, Zimmerman ES, DeHart JL, Murala S, Ardon O, et al. (2005) ATR 
and GADD45alpha mediate HIV-1 Vpr-induced apoptosis. Cell Death Differ 12: 
326-334. 
19. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, et al. (2007) HIV-1 Vpr-
Mediated G2 Arrest Involves the DDB1-CUL4A(VPRBP) E3 Ubiquitin Ligase. 
PLoS Pathog 3: e85. 
20. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, et al. 
(2007) HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin 
proteasome system. Virol J 4: 57. 
21. Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, et al. 
(2007) Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate 
cell cycle. Proc Natl Acad Sci U S A 104: 11778-11783. 
167 
 
22. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, et al. (2007) HIV1 Vpr 
arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 
ubiquitin ligase. Cell Cycle 6: 182-188. 
23. Schrofelbauer B, Hakata Y, Landau NR (2007) HIV-1 Vpr function is mediated by 
interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad 
Sci U S A 104: 4130-4135. 
24. Tan L, Ehrlich E, Yu XF (2007) DDB1 and Cul4A are required for human 
immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol 81: 10822-10830. 
25. Wen X, Duus KM, Friedrich TD, de Noronha CM (2007) The HIV1 protein Vpr acts 
to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing 
ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem 282: 
27046-27057. 
26. Belzile JP, Richard J, Rougeau N, Xiao Y, Cohen EA HIV-1 Vpr Induces the K48-
Linked Polyubiquitination and Proteasomal Degradation of Target Cellular Proteins 
to Activate ATR and Promote G2 Arrest. J Virol. 
27. Srivastava S, Swanson SK, Manel N, Florens L, Washburn MP, et al. (2008) 
Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 
E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog 4: e1000059. 
28. Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, et al. (2008) Primate lentiviral 
Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog 4: 
e1000057. 
29. Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, et al. (2009) The 
human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 
DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. J 
Virol 83: 4854-4860. 
168 
 
30. Bolton DL, Lenardo MJ (2007) Vpr cytopathicity independent of G2/M cell cycle 
arrest in human immunodeficiency virus type 1-infected CD4+ T cells. J Virol 81: 
8878-8890. 
31. Depienne C, Roques P, Creminon C, Fritsch L, Casseron R, et al. (2000) Cellular 
distribution and karyophilic properties of matrix, integrase, and Vpr proteins from the 
human and simian immunodeficiency viruses. Exp Cell Res 260: 387-395. 
32. Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, et al. (1995) 
Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted 
N-terminal alpha-helical structure in Vpr nuclear localization and virion 
incorporation. J Virol 69: 7032-7044. 
33. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR (1995) Mutational 
analysis of cell cycle arrest, nuclear localization and virion packaging of human 
immunodeficiency virus type 1 Vpr. J Virol 69: 7909-7916. 
34. Lu YL, Spearman P, Ratner L (1993) Human immunodeficiency virus type 1 viral 
protein R localization in infected cells and virions. J Virol 67: 6542-6550. 
35. Zhao LJ, Mukherjee S, Narayan O (1994) Biochemical mechanism of HIV-I Vpr 
function. Specific interaction with a cellular protein. J Biol Chem 269: 15577-15582. 
36. Subbramanian RA, Yao XJ, Dilhuydy H, Rougeau N, Bergeron D, et al. (1998) 
Human immunodeficiency virus type 1 Vpr localization: nuclear transport of a viral 
protein modulated by a putative amphipathic helical structure and its relevance to 
biological activity. J Mol Biol 278: 13-30. 
37. Vodicka MA, Koepp DM, Silver PA, Emerman M (1998) HIV-1 Vpr interacts with 
the nuclear transport pathway to promote macrophage infection. Genes Dev 12: 175-
185. 
169 
 
38. Jacquot G, Le Rouzic E, David A, Mazzolini J, Bouchet J, et al. (2007) Localization 
of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication 
in macrophages. Retrovirology 4: 84. 
39. Kamata M, Aida Y (2000) Two putative alpha-helical domains of human 
immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two 
mechanisms. J Virol 74: 7179-7186. 
40. Fritz JV, Didier P, Clamme JP, Schaub E, Muriaux D, et al. (2008) Direct Vpr-Vpr 
interaction in cells monitored by two photon fluorescence correlation spectroscopy 
and fluorescence lifetime imaging. Retrovirology 5: 87. 
41. Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Weiner DB (1997) Nuclear 
import, virion incorporation, and cell cycle arrest/differentiation are mediated by 
distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol 71: 
6339-6347. 
42. Mahalingam S, Collman RG, Patel M, Monken CE, Srinivasan A (1995) Functional 
analysis of HIV-1 Vpr: identification of determinants essential for subcellular 
localization. Virology 212: 331-339. 
43. Sherman MP, de Noronha CM, Heusch MI, Greene S, Greene WC (2001) 
Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J Virol 
75: 1522-1532. 
44. de Noronha CM, Sherman MP, Lin HW, Cavrois MV, Moir RD, et al. (2001) 
Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 
Vpr. Science 294: 1105-1108. 
45. Xiao Y, Chen G, Richard J, Rougeau N, Li H, et al. (2008) Cell-surface processing 
of extracellular human immunodeficiency virus type 1 Vpr by proprotein 
convertases. Virology 372: 384-397. 
170 
 
46. Zhang S, Pointer D, Singer G, Feng Y, Park K, et al. (1998) Direct binding to 
nucleic acids by Vpr of human immunodeficiency virus type 1. Gene 212: 157-166. 
47. Yao XJ, Mouland AJ, Subbramanian RA, Forget J, Rougeau N, et al. (1998) Vpr 
stimulates viral expression and induces cell killing in human immunodeficiency virus 
type 1-infected dividing Jurkat T cells. J Virol 72: 4686-4693. 
48. Hoshino S, Sun B, Konishi M, Shimura M, Segawa T, et al. (2007) Vpr in plasma of 
HIV type 1-positive patients is correlated with the HIV type 1 RNA titers. AIDS Res 
Hum Retroviruses 23: 391-397. 
49. Baril M, Racine ME, Penin F, Lamarre D (2009) MAVS dimer is a crucial signaling 
component of innate immunity and the target of hepatitis C virus NS3/4A protease. J 
Virol 83: 1299-1311. 
50. Lavallee C, Yao XJ, Ladha A, Gottlinger H, Haseltine WA, et al. (1994) 
Requirement of the Pr55gag precursor for incorporation of the Vpr product into 
human immunodeficiency virus type 1 viral particles. J Virol 68: 1926-1934. 
51. Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, et al. (2009) Suppression 
of Tetherin-Restricting Activity on HIV-1 Particle Release Correlates with 
Localization of Vpu in the trans-Golgi Network. J Virol. 
52. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, et al. (2006) Molecular architecture 
and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443: 590-593. 
 
171 
 
FIGURES 
 
Figure 1.  HIV-1 Vpr forms nuclear foci containing VprBP.   
A) HeLa cells were transduced with lentiviral vectors expressing GFP (WPI) or co-
expressing GFP and HA-tagged Vpr (WPI-HA-Vpr) at a multiplicity of infection of 0.5.  
B) Primary activated CD4+ T-lymphocytes were transduced by spinoculation with WPI 
or WPI-HA-Vpr at a multiplicity of infection of 2.5.  For both panels, two days after 
transduction, cells were fixed, permeabilized, and stained with antibodies against HA 
(red), nucleoporin (blue) and VprBP (green).  Images were acquired by confocal 
microscopy with a 63X objective.  Images shown are representative of multiple fields.  
Enlarged (3X) images are shown below panels.  Yellow arrows highlight examples of 
punctuate co-localization.  
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Figure 2. Vpr nuclear foci co-localizes partially with DNA repair foci.   
HeLa cells were transduced with lentiviral vectors expressing GFP (WPI) or co-
expressing GFP and HA-tagged Vpr (WPI-HA-Vpr) at a multiplicity of infection of 0.5.  
Two days after transduction, cells were fixed, permeabilized, and stained with 
antibodies against HA (red) and with either rabbit polyclonal antibodies against 53BP1 
(green) (A) or phospho-RPA32 (green) (B).  Images were acquired by confocal 
microscopy.  Images shown are representative of multiple fields.  Enlarged (3X) images 
are shown below panels.  Yellow arrows highlight examples of punctuate co-
localization.    
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Figure 3.  Formation of Vpr nuclear foci is independent of ATR activation and of 
the recruitment of VprBP.   
A) HeLa cells were pre-treated with 2.5 mM caffeine for 1 hour and then transduced 
with lentiviral vectors co-expressing GFP and HA-Vpr (WPI-HA-Vpr) or expressing 
GFP alone (WPI).  B) HeLa cells were transfected with control scrambled siRNA or 
siRNA targeting VprBP.  Twenty-four hours after transfection, cells were transduced 
with lentiviral vectors co-expressing GFP and HA-Vpr (WPI-HA-Vpr) or expressing 
GFP alone (WPI).  Two days after transduction, cells were fixed, permeabilized, and 
stained with antibodies against HA (red), nucleoporin (blue) and VprBP (green).  
Images were acquired by confocal microscopy.  Images shown are representative of 
multiple fields.  Averages of the number of Vpr nuclear foci (VNF) per cell and 
corresponding standard deviations are shown.  
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Figure 4.  Analysis of the capacity of Vpr mutants to form nuclear foci.   
HeLa cells were transfected with plasmids expressing HA-tagged Vpr (WT), Vpr 
(Q65R), Vpr (R80A), and Vpr (1-78).  Forty-eight hours after transfection, cells were 
fixed, permeabilized, and stained with antibodies against HA (red), nucleoporin (blue) 
and VprBP (green).  Images were acquired by confocal microscopy.  Images shown are 
representative of multiple fields.  Averages of the number of Vpr nuclear foci (VNF) per 
cell and corresponding standard deviations are shown. 
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Figure 5. Cytoplasmic sequestration of Vpr abrogates foci formation and G2 
arrest.   
A) HeLa cells were co-transfected with the packaging plasmid psPAX2 encoding Gag-
Pol, Tat, and Rev and with an HA-Vpr-expressing plasmid or appropriate empty plasmid 
control.  Two days after transfection, cells were fixed, permeabilized, and stained with 
antibodies against HA (red), nucleoporin (blue) and p24 (green).  Images were acquired 
by confocal microscopy.  Images shown are representative of multiple fields.  B) 
HEK293T cells were cotransfected with plasmids expressing GFP, HA-Vpr and Gag-
Pol (psPAX2) or with an empty plasmid control as indicated.  Forty-eight hours after 
transfection, cell cycle analysis was performed by flow cytometry using propidium 
iodide staining.  Percentages of G1 and G2/M cell populations were determined using 
the ModFit software. C) Expression of HA-Vpr and p24 was monitored by western blot 
using specific antibodies.  HA-Vpr and p24 were detected using specific monoclonal 
antibodies.  Actin was detected using a rabbit polyclonal antibody.  D) HEK293T cells 
were transfected as in B).  Two days after transfection, cells were lysed and subjected to 
anti-HA immunoprecipitation as described in Materials and Methods. HA-Vpr, p24 or 
VprBP levels were evaluated in cell lysates and immunocomplexes. HA-Vpr and p24 
were detected using specific monoclonal antibodies.  VprBP was detected using a rabbit 
polyclonal antibody. 
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Figure 6.  Sooty mangabey Vpr but not Vpx forms nuclear foci.   
HeLa cells were transfected with plasmids expressing sooty mangabey HA-tagged Vpr 
(HA-Vpr sm) or Vpx (HA-Vpx sm).  Two days after transfection, cells were fixed, 
permeabilized, and stained with antibodies against HA (red), nucleoporin (blue) and 
VprBP (green).  Images were acquired by confocal microscopy.  Images shown are 
representative of multiple fields.  Averages of the number of Vpr nuclear foci (VNF) per 
cell and corresponding standard deviations are shown. 
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Figure 7. Analysis of the self-affinity of wild type Vpr and mutants.   
A) HEK293T cells were co-transfected with plasmids expressing Rluc-Vpr (WT), Rluc-
Vpr (Q65R), Rluc-Vpr (R80A), eYFP-Vpr (WT) and eYFP fusion proteins.  Two days 
later, cell lysates were resolved by SDS-PAGE and protein expression was determined 
by western blot using a rabbit polyclonal antibodies directed against Vpr and GFP. A 
non-specific band, depicted by the asterisk, was used as loading control.  B) BRET 
saturation assays were performed with live HEK293T cells. A plasmid expressing Rluc-
Vpr (WT), Rluc-Vpr (Q65R) or Rluc-Vpr (R80A) (BRET donor) was co-transfected 
with increasing concentration of a plasmid expressing eYFP-Vpr (BRET acceptor) or 
eYFP (non-specific control). Forty-eight hours post-transfection, energy transfer was 
initiated by addition of the cell-permeable renilla luciferase substrate coelenterazine H. 
Donor saturation curves were obtained by measuring BRET in presence of a fixed 
quantity of donor and increasing amounts of acceptor. The x-axis shows the ratio 
between the fluorescence (520 nm) of the acceptor (YFP-YFP0, where YFP0 is the 
fluorescence value in cells expressing the BRET donor alone) and the luminescence 
(475 nm) of the donor. BRET ratios (y-axis) were calculated as described in Materials 
and Methods.  BRETmax is the maximal BRET signal reached at saturation.  BRET50 , 
which represent the concentration (fluorescence/ luminescence) of acceptor giving 50% 
of BRETmax, is a measure of the relative affinity of each fusion protein.  Self- affinities 
relative to wild type are depicted in the graph.  Curves shown represent the means ± 
standard deviations of results from one representative experiment performed in 
duplicate. The curves were generated by non-linear regression, in which a single binding 
site was assumed using the Sigma Plot software v.10. 
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Figure 8. Association of Vpr to Chromatin correlates with the formation of nuclear 
foci.  
A) HeLa cells were transfected with plasmids expressing HA-tagged Vpr (WT) or an 
empty plasmid used as negative control.  Forty-eight hours after transfection, cells were 
harvested and lysed with 0.5% Triton X-100.  The soluble fraction was used as input 
control (Sol.input).  Insoluble debris containing chromatin was treated with microccocal 
nuclease (+MNase) or with buffer alone (-MNase).  The resulting solubilized fractions 
and input controls were resolved by SDS-PAGE and analyzed by western blot.  Specific 
monoclonal antibodies were used to detect GAPDH (cytoplasmic marker) and HA-Vpr.  
Histone 3 (chromatin marker) and VprBP were detected using rabbit polyclonal 
antibodies.  * Denotes a non-specific band detected with the anti-HA antibody.  B) HeLa 
cells were transfected with plasmids expressing HA-tagged Vpr (WT), Vpr (Q65R), Vpr 
(R80A), and Vpr (1-78).  Cell extracts were processed and analysed as in A).  
 
186 
 
 
 
 
 
 
 
 
187 
 
Figure 9. Vpr and VprBP associate on chromatin.   
HeLa cells were transfected with a plasmid expressing HA-tagged Vpr (WT) or an 
empty plasmid used as negative control.  Soluble and chromatin-bound fractions were 
isolated as before and were subjected to anti-HA immunoprecipitation as described in 
Materials and Methods.  Input controls and immunoprecipitates were resolved by SDS-
PAGE and analyzed by western blot. Specific monoclonal antibodies were used to 
detect GAPDH (cytoplasmic marker) and HA-Vpr.  Histone 3 (chromatin marker) and 
VprBP were detected using rabbit polyclonal antibodies.  * Denotes a non-specific band 
detected with the anti-HA antibody.   
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SUPPLEMENTAL MATERIAL 
 
Figure S1. Native Vpr and virally encoded Vpr form nuclear foci.   
A) HeLa cells were transfected with plasmids expressing native Vpr.  Two days after 
transfection, cells were fixed, permeabilized, and stained with monoclonal antibodies 
against Vpr (clone 8D1) and analyzed by confocal microscopy.  B) HeLa cells were 
infected with VSV-G-pseudotyped viruses defective for Vpr expression (HxBru Vpr-) or 
expressing HA-tagged Vpr (HxBru HA-Vpr) at 100 cpm/cell.  Two days after infection, 
cells were fixed, permeabilized, and stained with antibodies against HA (red), 
nucleoporin (blue) and VprBP (green).  Images were acquired by confocal microscopy.  
Images shown are representative of multiple fields that encompass minor and major 
phenotypes. 
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Figure S2. Caffeine inhibits the induction of G2 arrest by HA-Vpr.   
HeLa cells were transduced with lentiviral vectors expressing HA-Vpr or with control 
lentiviral vectors.  Cells were concomitantly treated or not with 2.5mM caffeine for the 
duration of the experiment.  Twenty-four hours after transduction, cells were harvested, 
stained with propidium iodide and their cell cycle profile was monitored by flow 
cytometry.  Percentages of cells in G1 and G2/M were determined using the ModFit 
software. 
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Figure S3. Localization and G2 arrest activity of the Vpr mutants V57L and R62P.  
A) HeLa cells were transfected with plasmids expressing HA-tagged Vpr (V57L) and 
Vpr (R62P).  Forty-eight hours after transfection, cells were fixed, permeabilized, and 
stained with antibodies against HA (red) and nucleoporin (blue).  Images were acquired 
by confocal microscopy.  Images shown are representative of multiple fields.  60% of 
cells expressing HA-Vpr (V57L) could form nuclear foci while the remaining 40% 
displayed perinuclear accumulation with reduced or absence of nucleoporin staining.  
20% of cells expressing HA-Vpr (R62P) displayed an exclusive nuclear localization 
while the remaining 80% of cells showed accumulation of Vpr in the cytoplasm.  In all 
cases, HA-Vpr (R62P) did not form nuclear foci.  B) HEK293T cells were co-
transfected with a plasmid expressing GFP and a plasmid expressing HA-Vpr (WT), 
HA-Vpr (V57L), or HA-Vpr (R62P).  An empty plasmid was used as negative control 
(mock).  Forty-eight hours after transfection, cell cycle analysis was performed by flow 
cytometry using propidium iodide staining.  Percentages of G1 and G2/M cell 
populations were determined using the ModFit software. 
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DISCUSSION 
 
1. HIV-1 VPR HIJACKS A CELLULAR CULLIN-RING E3 UBIQUITIN 
LIGASE 
 
The work presented in this thesis identifies the cellular E3 ubiquitin ligase 
CRL4A(VprBP) as an essential cellular partner of HIV-1 Vpr for the activation of ATR 
and induction of G2/M cell cycle arrest.  Importantly, the involvement of 
CRL4A(VprBP) in Vpr-induced G2 arrest was corroborated by several other studies 
[332,553-556].  This interaction with CRL4A(VprBP) and its role in Vpr-induced G2 
arrest is also conserved in other lentiviral lineages, including HIV-2 and SIVmac 
[553,554,556].  Vpx, a simian paralog of Vpr, also functionally interacts with 
CRL4A(VprBP)[557-560].  Vpx is present in the SIVmac/SIVsm/HIV-2 lentiviral 
lineage and probably arose as a result of a gene duplication event.  In contrast to Vpr, 
Vpx does not induce G2 arrest but instead counteracts a putative restriction factor acting 
in the early steps of the infection of cells of the monocytic lineage.  All these 
observations points towards an important role of the Vpr-CRL4A(VprBP) interaction in 
viral replication and dissemination throughout lentiviral evolution.   
 
Vpr is the third HIV-1 protein known to hijack a CRL complex.  Vpu and Vif 
respectively recruit CRL1(β-TrCP) and CRL5 to perform their functions [561].  Vpr and 
Vpx engage the CRL4A ubiquitin ligase similarly to the way Vpu interacts with CRL1.  
All three proteins interact directly with a substrate receptor: β-TrCP for Vpu and VprBP 
for Vpr and Vpx.  In contrast, Vif does not need a substrate receptor and appears to itself 
act as a substrate receptor by interacting directly with cullin 5 and the heterodimeric 
adaptor Elongin B-C.  HIV-1 is not the only virus to encode proteins usurping the 
functions of CRLs.  HBV and parainfluenza viruses such SV5 hijack CRL4A via direct 
interactions between viral proteins (HBx and SV5 V) and DDB1.  [562-564].  Other 
notable examples include the Epstein-Barr virus and adenovirus.  The Epstein-Barr 
nuclear antigen 3C (EBNA3C) engages CRL1(SKP2) to induce the ubiquitination and 
proteasomal degradation of the tumor suppressor Rb [565].  The adenoviral proteins 
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E4orf6 and E1B55K functionally interact and form a complex with a cullin 5-based 
ligase to ubiquitinate and degrade several cellular proteins including p53, MRN 
components and DNA ligase IV (reviewed in [566].   Our results therefore add Vpr to a 
long list of viral proteins hijacking CRLs, suggesting that it is a very common strategy 
used by viruses. 
 
Our study and the ones of other investigators [332,553-556] have highlighted the 
existence of at least two functional domains in Vpr.  The first one is involved in 
engaging VprBP and was mapped to the third alpha helix.  The second one is located at 
the C-terminus.  The C-terminus of Vpr is not involved in engaging CRL4A(VprBP) but 
is nevertheless essential for the induction of G2 arrest.  The simplest model to explain 
these results is that Vpr would recruit a cellular substrate via its C-terminus to forcibly 
induce its ubiquitination by the CRL4A(VprBP) complex (Figure 9, p.197).  Our results 
presented in Chapter 2 provide direct evidence for this model.  Indeed, we showed that 
Vpr could induce the K48-linked polyubiquitination and proteasomal degradation of 
interacting cellular proteins.  Vpr-mediated K48-polyubiquitination and proteasomal 
degradation of these substrates was found to be necessary for the activation of ATR and 
for G2 arrest.  Moreover, in Chapter 3, we demonstrate that this substrate is probably a 
chromatin-bound cellular protein.  Specifically, we found that Vpr could associate to 
chromatin via its C-terminus and could form structures that we called Vpr nuclear foci.  
It is still unclear whether Vpr contacts its substrates directly on chromatin or via a 
potential cellular cofactor (Figure 9, p.197).  The latter situation would explain why Vpr 
still associates with chromatin and why Vpr nuclear foci are still present in G2, when the 
substrate is supposedly degraded.  The use of a chromatin-bound cofactor in Vpr might 
involve additional functional domains in the protein but not necessarily.  Indeed, Vpr 
could interact with its chromatin-associated cofactor, which would be in proximity or 
even physically interacting with the substrate.  This would allow Vpr to position the E2 
in proximity to its substrate and would induce efficient transfer of ubiquitin.  Similar 
mechanisms are used by SV5 V and by CRL4A(DDB2).   SV5 V acts  
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Figure 9. Proposed model for the mechanism of induction of G2 arrest by Vpr. 
Vpr associates directly or via an unknown cofactor with a putative chromatin-bound cellular 
substrate X (1), triggering accumulation of Vpr via oligomerization of the protein or increased 
association to the substrate or cofactor (2).  Vpr then recruits the CRL4A(VprBP) E3 ubiquitin 
ligase through an interaction with the substrate receptor VprBP (3) and induces the K48-linked 
polyubiquitination of the substrate X (4).  Degradation of the ubiquitinated substrate by the 
proteasome (5) stalls DNA replication or induces other types of DNA damages (6).  These 
genotoxic stresses are recognized by DNA damage sensors including RPA (7) and leads to the 
activation of the ATR-mediated DNA damage checkpoint, ultimately resulting in G2 arrest (8).         
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as a connector between DDB1 and STAT2, inducing the ubiquitination of STAT2-
bound STAT1 [567].  Binding of DDB2 to UV-induced bulky adducts orients the E2 in 
a way that it can transfer its ubiquitin to nearby histones [568].  Conversely, Vpr could 
interact simultaneously with a cofactor and its substrate, both of which would be 
associated to chromatin.  Such a mode of action is exemplified by CRL4A(Cdt2).  
CRL4A(Cdt2) needs to bind simultaneously to chromatin-bound PCNA and Cdt1 in 
order to induce Cdt1 ubiquitination [569].  Finally, because of a lack of knowledge on 
the normal functions of VprBP, we have not been able to determine whether Vpr 
induces ubiquitination of its own substrates or whether it forcibly increases the 
ubiquitination of the natural substrates of VprBP.  It is noteworthy that most CRL4A 
complexes are spatially regulated, particularly at the level of chromatin [438].  Vpr 
could therefore bypass this regulation by binding to a cofactor on chromatin, thereby 
recruiting CRL4A(VRPBP) in proximity of its substrates.  Constructing chimeras 
between Vpr and the G2-arrest-incompetent Vpx might address some of these 
possibilities by identifying additional functional domains in Vpr necessary for 
association to chromatin, formation of nuclear foci and induction of G2 arrest.  A similar 
strategy has been used recently and identified the N-terminus of Vpx as an essential 
domain to facilitate infection of macrophages [570].  However, a complete 
comprehension of the mechanism by which Vpr uses CRL4A(VprBP) to induce G2 
arrest will require the identification of the cellular proteins targeted by Vpr and VprBP. 
 
2. IDENTIFICATION OF VPR’S G2 ARREST SUBSTRATE 
 
  The most important unresolved aspect of the mechanisms by which Vpr induces 
G2 arrest is of course the identity of the chromatin-bound cellular proteins targeted by 
Vpr.  There are several approaches that can be pursued to identify these proteins.  
Ideally, these approaches should encompass both mechanistic possibilities: Vpr targets 
its own substrates or Vpr induces the ubiquitination of VprBP’s substrates.  
Identification of the substrate by tandem affinity purification and mass spectrometry 
represents the most direct approach.  This is the technique that we used in chapter 1 to 
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identify VprBP and DDB1 as cellular partners of Vpr.  Because the substrate is 
degraded and because enzyme-substrate interactions are generally transient, special care 
has to be taken to stabilize the interaction between Vpr and its potential substrates 
[571,572].  As presented in Chapter 2, we have already optimized conditions to detect 
the interaction between Vpr and its ubiquitinated substrates.  To further enrich Vpr-
interacting ubiquitinated proteins, we improved the approach described in chapter 2 by 
adding an additional purification step (data not shown).  The new procedure called 
TSAP-Ub (three-step affinity purification of ubiquitinated substrates) involves 
denaturation of purified TAP-Vpr complexes and isolation of Myc-Ub-conjugated 
proteins using anti-myc agarose.  This procedure has to date yielded several interesting 
candidates.  Since Vpr has a tendency to be a promiscuous binding protein [320], non-
porous magnetic beads and short post-lysis incubation time could be used to decrease 
non-specific interactions and limit the number of candidates.  Alternatively, the 
HEK293T cell line stably depleted of VprBP (chapter 2) can be used as an experimental 
system to block ubiquitination and degradation of Vpr’s substrates.  The caveat of this 
last approach is that it will only identify Vpr’s own substrates and not VprBP’s.   
 
Moreover, strategies other than proteomic approaches can be used, not to 
directly identify the substrate, but to improve our knowledge of its cellular roles and 
functional interactions.  In chapter 3, we described the formation of chromatin-
associated Vpr nuclear foci and suggest that Vpr would contact its substrates on 
chromatin, either directly or indirectly.  These discreet foci also imply that Vpr could 
associate to specific regions of chromatin.  Identification of the sequence of these 
regions of chromatin might therefore yield important information about the processes 
targeted by Vpr and might even allow the identification of the substrate.  We can 
therefore perform ChIP-chip or ChIP-seq experiments to determine if Vpr binds to 
chromatin on consensus sequences and to identify these sequences.  Comprehensive 
work by the Planelles’ laboratory described the activation by Vpr of the canonical ATR-
mediated DNA damage checkpoint, suggesting that Vpr would induce the formation of 
RPA-coated ssDNA intermediates [285,286,289,290].  Our results (Chapters 2 and 3) 
support these conclusions and further demonstrate that Vpr nuclear foci partially co-
200 
 
localize with these RPA-coated ssDNA intermediates.  Extensive knowledge is now 
available on the different DNA damage repair mechanisms.  Co-localization between 
Vpr-induced RPA foci and markers of BER (base excision repair), NER (nucleotide 
excision repair), DSBs (DNA double-strand breaks), stalled replication fork, and 
delayed origin firing could potentially identify what genotoxic stresses and which repair 
processes are induced by Vpr.  Most proteins involved in DNA replication associate to 
chromatin in a cell cycle-dependent manner.  Careful analysis of the timing of Vpr 
nuclear foci and association of Vpr to chromatin in synchronized cells would determine 
at what phase of the cell cycle the cofactor/substrate associate to chromatin.  Similarly, 
temporal monitoring of H2AX phosphorylation in response to Vpr will determine if Vpr 
causes direct DNA damages (phosphorylation of H2AX in G1) or whether it interferes 
directly with origin firing or DNA replication fork progression (phosphorylation of 
H2AX in S-phase).  These experiments would unlikely identify the substrate but would 
indicate in what cellular pathways it is involved.  These data would be very useful to 
restrict the number of candidates identified by other means such as mass spectrometry.  
A pre-characterization of the restriction factor counteracted by Vpu has similarly 
contributed to the later identification of Tetherin [155].  Indeed, the initial observations 
by Neil and colleagues that the restriction factor was endogenously expressed in some 
cell lines, that it could be up-regulated by IFN-alpha and that it was acting at the cell 
surface greatly helped to restrict the number of candidates that had to be individually 
tested [152-154].  
3. ROLE OF G2/M ARREST DURING INFECTION 
 
The identification of the substrates of Vpr will likely be necessary to our 
understanding of the function of ATR activation and G2 arrest in viral replication and 
pathogenesis.  Activation of the G2/M checkpoint could be an end in itself or could be 
the unavoidable consequence of the inhibition of a cellular restriction factor.  In support 
of the former, expression from the HIV-1 LTR is modestly up-regulated (2 to 4 folds) 
when cells are in G2, leading to increased viral production [321].   Recent evidences 
show that UV-induced G2 arrest abolishes the requirement for P-TEFb and SKIP to 
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overcome a restriction on transcriptional elongation from the LTR [573].  It is 
reasonable to assume that Vpr could function in a similar manner.  Other potential 
benefits of a G2/M arrest include increased proviral integration [574] and active 
translation from the HIV-1 IRES [575].  Many viruses induce cell cycle perturbation to 
optimize viral replication [468-470].  However, they unusually curb checkpoint 
responses [576].  For instance, adenoviruses and HSV-1 induce a pseudo-S-phase to 
increase viral DNA replication but inhibit ATR and ATM activation by respectively 
sequestering the MRN complex and by inhibiting RNF8 and RNF168 [577,578].  The 
fact that HIV-1 does not inhibit ATR activity points to potential roles of the checkpoint 
response during infection.  These could include immunomodulatory functions important 
for viral persistence in vivo and for pathogenesis.  Our group and others have recently 
shown that Vpr-induced activation of ATR leads to the up-regulation at the cell surface 
of ligands of the activating NK cell receptor NKG2D and results in increased NK cell 
cytolytic activity [340,341].  This up-regulation could act at the level of T-cell depletion 
but could also be involved in NK cell exhaustion.  Interestingly, recent studies show that 
HBV-induced NKG2D ligand up-regulation in hepatocytes is causing extensive liver 
damage by producing an acute immune response mediated by NK and NKT cells [579-
581].  Moreover, preliminary data show that MCMV mutants defective for NKG2D 
ligands down-modulation, although initially attenuated in replication, were ultimately 
causing a persistent infection lasting longer than wild type viruses [582].  A precise 
regulation of NKG2D ligands expression might therefore be required for 
immunosurveillance.  Vpr could contribute to viral pathogenesis and persistence by 
upsetting this balanced NKG2D response.  A reassessment of the role of Vpr in the 
pathogenic lentiviral infection of simian models, particularly at the level of immune 
function, would probably be required to confirm this hypothesis.         
 
4. IMPLICATION OF CRL4A(VprBP) IN OTHER FUNCTIONS OF VPR  
 
In this thesis, we have mostly studied the involvement of CRL4A(VprBP) in 
Vpr-induced G2 arrest.  As mention in the introduction, Vpr also performs other 
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functions in the viral replication cycle: it facilitates infection of macrophages, induces 
apoptosis, and perturbs immunomodulatory functions.  Moreover, as mentioned above, 
the simian paralog of Vpr, Vpx, also usurps CRL4A(VprBP) to block a restriction factor 
in cells of the monocytic lineage [557-560].  This conserved functional interaction 
suggest that, besides G2 arrest, CRL4A(VprBP) could be involved in other functions of 
Vpr.  Like Vpx, Vpr has been implicated in facilitating infection of non-dividing cells, 
notably macrophages.  However, Vpr and Vpx probably target different processes since 
Vpx can drastically increase the infection of HIV-1, even in presence of Vpr [557,560].  
It is therefore possible, even probable, that Vpr could hijack CRL4A(VprBP) to 
inactivate a distinct cellular restriction factor.  Interestingly, the C-terminus of Vpr 
appears to be important for both G2 arrest and infection of macrophages, suggesting that 
Vpr could be targeting the same substrate responsible for G2 arrest to somehow 
facilitate infection of macrophages.  Moreover, Vpr has been shown to induce apoptosis 
independently of G2 arrest by interacting with ANT [302,326,327].  Is Vpr somehow 
inducing the ubiquitination and degradation of ANT or other anti-apoptotic factors by 
recruiting CRL4A (VprBP)?  A likely role of Vpr in viral pathogenesis is to modulate 
the activity of the immune system.  In vitro, several mechanisms have already been 
proposed, including defects in DC and NK cell activity [336].  Some of these functions, 
such as up-regulation of NKG2D ligands, require activation of ATR and therefore 
involves the recruitment of CRL4A(VprBP) [340,341].  However, the 
immunomodulatory role of Vpr has also been correlated to its expression in non-
dividing cells such as macrophages and dendritic cells.  Is Vpr using the same E3 ligase 
complex to target modulator of immune functions in these cell types?  Thorough 
analyses of the involvement of CRL4A(VprBP) in the other functions of Vpr would 
therefore be very informative and would help resolves the paradox of how such a small 
protein can perform so may different functions. 
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5. ARCHITECTURE AND COMPOSITION OF THE E3 LIGASE COMPLEX 
RECRUITED BY VPR 
 
Several questions also arise in respect to the composition and architecture of the 
E3 ubiquitin ligase complex recruited by Vpr.  First, our observation that Q65R, the 
bona fide mutant of Vpr defective for the interaction VprBP, also displays aberrations in 
its localization and defects in oligomerization, raise the question as to whether the 3rd 
alpha-helix of Vpr is the domain of interaction or whether lack of binding merely 
reflects misfolding of the compact hydrophobic ternary structure of Vpr.  Given that 
most mutations in the third alpha helix of Vpr have pleiotropic effects [257], it is 
unlikely that a mutagenesis approach will convincingly characterize its VprBP 
interaction domain.  The most appropriate way to map the VprBP-interaction domain 
would by obtaining the crystal structure of the Vpr-VprBP heterodimer.  Another 
interesting question is the functional implication of the C-terminus of Vpr, specifically 
the role of phosphorylation at position S79 [272].  Why does Vpr need to be 
phosphorylated in order to perform its functions?  In the case of Vpu, its 
phosphorylation mimics a phosphodegron, the recognition domain of Cullin 1-Skp1-
associated F-Box substrate receptors [561].  In the case of Vpr, phosphorylation is not 
involved in the interaction with the E3 ubiquitin ligase (Chapter 1).  Is phosphorylation 
necessary to interact with phospho-specific cellular factors such as those involved in 
DNA replication and DNA repair signalling or does it induce a change in formation in 
Vpr allowing the proper positioning of the E3 ligase?        
 
The domain of VprBP involved in the interaction with Vpr is also unclear.  The 
minimal binding domain was mapped to a large C-terminal fragment of the protein 
[553].  This region comprises the dual WDxR motifs characteristic of the DDB1 
substrate receptor family and is thought to form a seven-bladed β-propeller.  This β-
propeller was originally thought to constitute the binding interface for DDB1 [583-585].  
However the recently characterized crystal structure of the DDB2-DDB1 heterodimer in 
complex with damaged DNA shows that it is rather involved in binding to DNA [568].  
A protruding alpha-helix in DDB2 is contacting the hydrophobic groove formed 
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between beta-propellers A (BPA) and C (BPC) in DDB1.  The same binding interface is 
used by alpha-helices in SV5 V and HBx to interact with DDB1 [568,583,586], 
suggesting that it is the way WDxR substrate receptors interact with DDB1.  
Intriguingly, mutating the WDxR motifs of VprBP abrogated both its interaction with 
Vpr and with DDB1 [553].  In DDB2, the WDxR motif is not directly involved in either 
binding to DNA or DDB1.   Instead, it is presumed to be involved in the proper folding 
of the β-propeller [568].  Therefore, we can assume that the interaction domains of both 
DDB1 and Vpr on VprBP reside in the β-propeller or in its close vicinity.  However, the 
exact residues involved remain to be identified.  Does VprBP possess a protruding 
alpha-helix involved in its interaction with DDB1?  Is the β-propeller in VprBP involved 
in its binding to chromatin?  Is Vpr somehow mimicking the recognition structure of the 
VprBP β-propeller to forcibly recruit it to Vpr nuclear foci?  Again, a mutagenesis 
approach might give some clues on these interaction domains and their functions, but 
given the highly organized architecture of these proteins, the full characterization of the 
structure of the Vpr-VprBP-DDB1 complex is likely to be necessary to understand its 
architecture.    
 
The composition of the E3 ubiquitin ligase complex recruited by Vpr is also 
unknown.  The functional involvement of VprBP, DDB1, CUL4A, ROC1, and DDA1 
has been previously described (Chapter 1 and [332,553-556]).  However, although 
DDB1, VprBP, and DDA1 could be readily identified by mass spectrometry as Vpr-
associated factors, CUL4A and ROC1 were never detected by these large-scale 
approaches.  Moreover, only very limited amount of CUL4A could be co-
immunopurified with Vpr when using western blot as a detection method (Chapter 1).  
These data suggest that the interaction between the Vpr-VprBP-DDB1 subcomplex and 
the rest of the E3 machinery is very transient or is spatially restricted to a minor fraction 
of these complexes.  Moreover, studies by Hrecka and colleagues showed that, in 
absence of Vpr, VprBP could form complexes, ranging from 250 kDa to over 1MDa, 
with presumably other cellular proteins [554].  Subunits of the signalosome (CSN) could 
also be co-immunopurified with VprBP complexes.  As mentioned in the introduction to 
this thesis, the CSN complex appears to sequesters in its inactive form subsets of 
205 
 
CRL4A ligases, including CRL4A(VprBP) [461].  In presence of Vpr however, CSN 
subunits did not associate anymore with CRL4A(VprBP) [554], suggesting that Vpr 
would activate CRL4A(VprBP) by uncoupling CSN.  A similar mechanism was 
described for CRL4A(DDB2).  Upon UV irradiation, CSN dissociates from CRL4A 
(DDB2), allowing the E3 ligase to bind damaged DNA and induce ubiquitination of its 
substrates [462].  There are other functional implications to the uncoupling of CSN from 
CRLs.  The absence of CSN would likely limit the activity of CRL4A(VprBP) to one 
cycle of substrate recognition and ubiquitination by preventing deneddylation of Cullin 
4A.  In support of this, increased neddylation of CRL4A(VprBP) has been observed in 
presence of Vpr [554].  Another implication of uncoupling of CSN would be the 
possible autoubiquitination and degradation of Vpr and VprBP.  Results by our group 
and others have shown that interfering with the recruitment or activity of 
CRL4A(VprBP), either by using mutants or small interfering RNA, results in an 
increased levels of Vpr (Chapter 2 and [556]) .  If Vpr truly dissociates CSN from the 
ubiquitin ligase, it is therefore paradoxical that the molecular weights of 
CRL4A(VprBP) complexes associated with Vpr are higher in molecular weights than 
their native counterparts [554].  This implies that the interaction of Vpr with 
CRL4A(VprBP) would induce a change of complex architecture such as formation of a 
dimer or would recruit additional cellular factors.  The latter might be constituents of the 
chromatin-associated foci formed by Vpr (Chapter 3 and [290]).  Large-scale proteomic 
approaches using milder extraction conditions would probably be necessary to identify 
these factors.   
 
6. INTERACTIONS BETWEEN VPR AND OTHER COMPONENTS OF UPS 
 
The association between Vpr and CRL4A(VprBP) is not the first instance of an 
interaction between Vpr and the ubiquitin-proteasome system (UPS).  Indeed, two other 
cellular proteins implicated in UPS, Mov34/hVIP/CSN6 [296] and hHR23A (human 
homologue of Rad23) [297,298], have been previously reported to interact with Vpr.  
Although the interaction between Vpr and CSN6 has been to date primarily implicated 
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in glucocorticoid signalling [587], the function of CSN6 suggests other potential roles in 
Vpr functions.  Indeed, CSN6 is a core subunit of the signalosome (CSN).  It contains a 
non-catalytic metalloenzyme JAMM domain involved in maintaining the structural 
integrity of the whole CSN complex [588].  CSN6 interacts directly with ROC1 and 
likely assists in the docking of the CSN complex to CRLs [589,590].  Could it be that 
Vpr needs first to dissociate CSN6 from CRL4A(VprBP) in order to activate the ligase?  
Could it account for the apparent lack of association between CRL4A(VprBP) and CSN 
subunits in presence of Vpr?  Could it result in increased neddylation of CUL4A?  The 
hHR23A protein represents an interesting functional paradox.  It has a role in NER 
repair via its interaction with the damage sensor XPC but it is also one of the ubiquitin 
receptors on the regulatory subunit of the proteasome [591].  Vpr interacts directly with 
an hydrophobic loop region within the ubiquitin-binding domain of hHR23A [592,593].  
This interaction was first implicated in Vpr-mediated G2 arrest [297,298], but a later 
mutagenesis study using the yeast two-hybrid system showed that binding to hHR23A 
was neither required nor sufficient to induce G2 arrest [301].  The Vpr mutants defective 
for the interaction with hHR23A spanned all three helices and showed additional defects 
in UNG2 and Gag interactions.  Surprisingly, they were nevertheless active for G2 arrest 
[301].  In spite of these negative results, it is tempting to speculate that recruitment of 
the proteasome to the site of ubiquitination of its substrates could allow Vpr to 
efficiently induce their degradation by evading the regulatory activity of cellular 
deubiquitinases.  It is possible that Vpr would form foci containing multiple units of Vpr 
to coordinate the activation of the E3 ligase, the polyubiquitination of substrates and the 
efficient proteasomal degradation of these substrates.  Alternatively, given the role of 
hHR23A in NER, perhaps Vpr targets it to inactivate damage recognition by NER.  
During infection, inactivation of NER leads to a modest but significant increase in 2-
LTR circle formation, in integrated provirus, and in viral replication [594].  These 
phenotypes are very similar to the effect of Vpr on nuclear import of the pre-integration 
complex and on viral replication [236,270,314,317].  Therefore, the binding of Vpr to 
CSN6 and to hHR23A should probably be revisited to reassess their potential 
involvement in the functions of Vpr using modern tools such as RNA interference.  A 
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confocal analysis to monitor the presence or absence of hHR23A and CSN6 in Vpr 
nuclear foci would also be informative. 
7. DEVELOPMENT OF DRUGS TARGETING THE VPR-VprBP BINDING 
INTERFACE  
 
The Vpr-VprBP interaction represents an interesting target for the development 
of protein-protein interaction inhibitors.  Targeting Vpr activity is unlikely to generate 
much commercial or therapeutic interest given the non-essential role of the protein in 
viral replication.  However, such an inhibitor would constitute a very interesting tool to 
study the functional involvement of CRL4A(VprBP) in the functions of Vpr other than 
G2 arrest and would likely help in the characterization of the substrates of Vpr.  In 
addition, this inhibitor could be used to characterize the function of Vpr in pathogenesis 
by blocking Vpr’s activity at different stages of infection in rhesus macaques.  The 
development of small molecule inhibitors targeting protein-protein interaction has not 
been intensively pursued by the pharmaceutical industry, particularly in regard to HIV-1 
treatment.  Notable exceptions include a series of entry inhibitors targeting gp41 fusion 
intermediates, the gp120-CD4 interaction, and the gp120-CCR5 interaction [595]. 
However, recent work by Debyser’s group and collaborators describes the identification 
of a small inhibitor disrupting the integrase-LEDGFp75 interaction [596].  De Luca and 
colleagues used software-assisted modeling to design a pharmacophore that would block 
this interaction.  Virtual screening of chemical database and further optimization of the 
candidates led to the discovery of a potent inhibitor able to interfere with the integrase-
LEDGF/p75 interaction at micromolar concentration.  The lack of structural information 
about the Vpr-VprBP interaction interface precludes the use of computer-assisted 
rational design.  However, BRET- or FRET-based high-throughput in vitro screening of 
chemical libraries constitutes an interesting alternative.  This strategy has been used 
successfully to develop inhibitors targeting IL-2, Bcl-XL, MDM2, TNF, and human 
papillomavirus E2 [597].  The development of small inhibitor targeting the Vpr-VprBP 
interaction will likely contribute to a better understanding of the functions of Vpr in 
pathogenesis.   
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CONCLUSION 
 
The mechanism by which the HIV-1 accessory protein Vpr induces G2 arrest is a 
complex one.  A first aspect of it was solved a few years ago by the discovery that Vpr 
activates the canonical ATR-mediated DNA damage checkpoint.  The studies presented 
in this thesis resolve another piece of the puzzle by identifying CRL4A(VprBP) as an 
essential cellular partner of Vpr.  However, much work remains to fully understand how 
Vpr induces G2 arrest and its functional implications for viral replication and 
pathogenesis. 
 
 
In summary, the major scientific contributions of this thesis are: 
 
1- Vpr engages the cellular E3 ubiquitin ligase complex CRL4A(VprBP) 
through an interaction with the substrate receptor VprBP. 
2- The interaction between Vpr and CRL4A(VprBP) is required but not 
sufficient for the induction of G2 arrest. 
3- Vpr hijacks CRL4A(VprBP) to induce the K48-linked polyubiquitination 
and proteasomal degradation of as-yet-unknown cellular proteins. 
4- Vpr-mediated K48-polyubiquitination is necessary for ATR activation. 
5- Vpr forms chromatin-associated foci that co-localize with VprBP and DNA 
repair factors. 
6- Formation of Vpr nuclear foci represents a critical early event in the 
induction of G2 arrest. 
7- Vpr associates with chromatin via its C-terminal putative substrate 
recognition domain and interacts with VprBP on chromatin. 
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